

ONKOLOŠKI
INŠTITUT
LJUBLJANA



INSTITUTE
OF ONCOLOGY
LJUBLJANA

EPIDEMIOLOGIJA IN REGISTER RAKA
EPIDEMIOLOGY AND CANCER REGISTRY

Rak v Sloveniji

2012

Cancer in Slovenia



Rak
v Sloveniji

2012

Cancer
in Slovenia

Naslov / Title

Rak v Sloveniji 2012 / Cancer in Slovenia 2012

Uredniški odbor / Editorial Board

Maja Primic Žakelj, glavna urednica / editor-in-chief
Matej Bračko, Marko Hočevar, Katja Jarm,
Vera Pompe-Kirn, Primož Strojan, Vesna Zadnik,
Branko Zakotnik in Tina Žagar

Računalniška obdelava / EDP analysis

Katja Jarm in Tina Žagar

Oblikovanje in priprava za tisk / Design & Typesetting

Studio N, studio za oblikovanje in grafično pripravo

Tisk / Printing

Medium d.o.o., Žirovnica

Izdajatelj / Published by

Onkološki inštitut Ljubljana / Institute of Oncology Ljubljana, Slovenia
Epidemiologija in register raka / Epidemiology and Cancer Registry
Register raka Republike Slovenije / Cancer Registry of Republic of Slovenia

Naklada / Published in

500 izvodov / 500 copies

Nasvet za citiranje / Recommended reference

Rak v Sloveniji 2012. Ljubljana: Onkološki inštitut Ljubljana, Epidemiologija in register raka, Register raka Republike Slovenije, 2015.

Cancer in Slovenia 2012. Ljubljana: Institute of Oncology Ljubljana, Epidemiology and Cancer Registry, Cancer Registry of Republic of Slovenia, 2015.

Osebe Registra raka Republike Slovenije / Staff of the Cancer Registry of Republic of Slovenia

Maja Primic Žakelj, vodja / head
Barbara Babuder, Andrej Kirn, Andrej Krašovec, Gaber Plavc, Polona Škulj, Darja Strle,
Fani Škrlec, Nataša Šturm in Tina Žagar

Naslov / Correspondence to

Register raka Republike Slovenije / Cancer Registry of Republic of Slovenia
Onkološki inštitut Ljubljana / Institute of Oncology Ljubljana
Zaloška c. 2, 1001 Ljubljana, p.p. 2217, Slovenija
Telefon / Phone: + 386 1 5879 450
E-pošta / E-mail: register@onko-i.si
Spletna stran / Web site:

<http://www.onko-i.si/rrs/>
<http://www.onko-i.si/crs/>

<http://www.slora.si/>
<http://www.slora.si/en/>

Uvod	7
Viri podatkov in metode registracije	9
Viri in nabor podatkov	9
Priprava podatkov za računalniško obdelavo	10
Kakovost podatkov RRRS in popolnost registracije	11
Statistične metode	12
Incidenca in umrljivost	12
Grobe in starostno specifične stopnje	12
Starostno standardizirane stopnje	12
Kumulativne incidenčne stopnje in kumulativno tveganje	13
Prevalenca	13
Relativno preživetje	14
Prebivalstvo Slovenije	15
Rak v Sloveniji 2012	16
Zahvala	19
Introduction	21
Data sources and methods of registration	23
Data sources and the list of data collected	23
Preparation of data for computer processing	24
Data quality and completeness of registration	25
Statistical methods	26
Incidence and mortality	26
Crude and age-specific rates	26
Age-standardised rates	26
Cumulative incidence rate and cumulative risk	27
Prevalence	27
Relative survival	28
Population of Slovenia	29
Cancer in Slovenia 2012	30
Acknowledgment	33
Reference / References	34

Slike / Figures

Slika 1:	Breme raka, Slovenija 2012.	36
Figure 1:	Cancer burden, Slovenia 2012.	
Slika 2:	Odstotni delež vseh rakov po starostnih skupinah in spolu, Slovenija 2012.	36
Figure 2:	Percentage distribution of all cancer sites by age group and by sex, Slovenia 2012.	
Slika 3:	Najpogostejše lokacije raka in njihov odstotni delež po spolu in pri obeh spolih skupaj, Slovenija 2012.	37
Figure 3:	The leading cancer sites with percentage distribution by sex and for both sexes together, Slovenia 2012.	
Slika 4:	Groba in kumulativna letna incidenčna in umrljivostna stopnja vseh rakov po spolu s povprečno letno spremembo za zadnjih 10 let, Slovenija 1950–2012.	38
Figure 4:	Crude and cumulative annual incidence and mortality rates for all cancer sites by sex with average annual change in last 10 years, Slovenia 1950–2012.	
Slika 5:	Groba letna incidenčna stopnja izbranih rakov po spolu s povprečno letno spremembo za zadnjih 10 let, Slovenija 1950–2012.	39
Figure 5:	Crude annual incidence rates of selected primary cancer sites by sex with average annual change in last 10 years, Slovenia 1950–2012.	
Slika 6:	Petletno relativno preživetje (s 95 % intervalom zaupanja) bolnikov, zbolelih za izbranimi raki v letih 2003–2007 in 2008–2012 po spolu.	40
Figure 6:	Five-year relative survival (with 95% confidence interval) of patients diagnosed with selected cancers in periods 2003–2007 and 2008–2012 by sex.	
Slika 7:	Povprečni letni delež spremembe grobe in starostno standardizirane (SSS; po svetovni standardni populaciji) incidenčne stopnje desetih najpogostejših rakov po spolu, Slovenija 2003–2012.	43
Figure 7:	Average annual percentage change in crude and age standardized (ASR; according to World standard population) incidence rates for ten leading cancer sites by sex, Slovenia 2003–2012.	
Slika 8:	Odstotni deleži napogostejših rakov po starostnih skupinah in spolu, Slovenija 2008–2012.	44
Figure 8:	Percentage distribution of leading cancer sites by age group and by sex, Slovenia 2008–2012.	

Podatki v tabelah / Data in tables

Tabela 1:	Opazovana in ocenjena incidenca raka, Slovenija 2003–2012 in 2015.	46
Table 1:	Observed and estimated cancer incidence, Slovenia 2003–2012 and 2015.	
Tabela 2:	Incidenca, groba incidenčna stopnja in po svetovni, evropski ter slovenski standardni populaciji standardizirane incidenčne stopnje raka, Slovenija 2012.	47
Table 2:	Incidence, crude incidence rate and according to World, European and Slovenian standard population standardized cancer incidence rates, Slovenia 2012.	
Tabela 3:	Incidenca raka glede na način postavitve diagnoze po lokaciji in spolu, Slovenija 2012.	48
Table 3:	Cancer incidence according to basis of diagnosis by site and by sex, Slovenia 2012.	
Tabela 4:	Incidenca raka po lokaciji, spolu in starosti, Slovenija 2012.	52
Table 4:	Cancer incidence by site, by sex and by age, Slovenia 2012.	
Tabela 5:	Groba in starostno specifična incidenčna stopnja na 100.000 prebivalcev ter kumulativna stopnja (KS) po lokaciji in spolu, Slovenija 2012.	56
Table 5:	Crude and age specific cancer incidence rate per 100,000 and cumulative rate (CR) by site and by sex, Slovenia 2012.	

Tabela 6a:	Incidenca najpogostejših lokacij raka po statističnih regijah in spolu, Slovenija 2012.	62
Table 6a:	Incidence of most frequent cancer sites by statistical regions and by sex, Slovenia 2012.	
Tabela 6b:	Starostno standardizirana incidenčna stopnja najpogostejših lokacij raka po statističnih regijah in spolu, Slovenija 2012.	63
Table 6b:	Age standardised incidence rate of most frequent cancer sites by statistical regions and by sex, Slovenia 2012.	
Tabela 7:	Incidenca histološko (H) in citološko (C) potrjenih primerov raka po histološki vrsti in lokaciji, Slovenija 2012.	64
Table 7:	Incidence of histologically (H) and cytologically (C) confirmed cancer cases by histological type and by site, Slovenia 2012.	
Tabela 8:	Incidenca raka (brez primerov registriranih samo iz zdravniških poročil o vzroku smrti) po stadiju, lokaciji in spolu, Slovenija 2012.	73
Table 8:	Cancer incidence (without cases registered from death certificates only) by stage, by site and by sex, Slovenia 2012.	
Tabela 9:	Incidenca ne-Hodgkinovih limfomov po lokaciji, spolu in starosti, Slovenija 2012.	76
Table 9:	Incidence of non-Hodgkin's malignant lymphomas by site, by sex and by age, Slovenia 2012.	
Tabela 10:	Incidenca malignih neoplazem limfatičnega tkiva v skladu s klasifikacijo Svetovne zdravstvene organizacije iz leta 2008, po spolu in starosti, Slovenija 2012.	77
Table 10:	Incidence of malignant neoplasms of lymphoid tissue according to 2008 version of Classification of Tumours of Haematopoietic and Lymphoid Tissues (published by World Health Organization), by sex and by age, Slovenia 2012.	
Tabela 11a:	Število in deleži bolnikov (brez primerov registriranih samo iz zdravniških poročil o vzroku smrti), v Sloveniji zbolelih leta 2012, ki so bili v okviru prvega zdravljenja operirani, zdravljeni s sistemskim zdravljenjem ali obsevani.	79
Table 11a:	Number of patients (without cases registered from death certificates only) diagnosed in Slovenia in 2012, that were treated by surgery, systemic therapy or radiotherapy during their first treatment.	
Tabela 11b:	Število bolnikov (brez primerov registriranih samo iz zdravniških poročil o vzroku smrti), v Sloveniji zbolelih leta 2012, ki so bili v okviru prvega zdravljenja operirani, po lokaciji raka in bolnici posega.	80
Table 11b:	Number of patients (without cases registered from death certificates only) diagnosed in Slovenia in 2012, that were treated by surgery during their first treatment by primary site and treatment institution.	
Tabela 11c:	Število bolnikov (brez primerov registriranih samo iz zdravniških poročil o vzroku smrti), v Sloveniji zbolelih leta 2012, ki so v okviru prvega zdravljenja prejeli sistemsko zdravljenje, po lokacijah raka in bolnici posega.	81
Table 11c:	Number of patients (without cases registered from death certificates only) diagnosed in Slovenia in 2012, that were treated by systemic therapy during their first treatment by primary site and treatment institution.	
Tabela 12:	Prevalenca po spolu in izbrani primarni lokaciji raka, Slovenija, 31. 12. 2012.	82
Table 12:	Prevalence of cancer patients by sex and by selected primary cancer site, Slovenia, December 31, 2012.	
Tabela 13:	Umrljivost za rakom po lokaciji, spolu in starosti, Slovenija 2012.	83
Table 13:	Cancer mortality by site, by sex and by age, Slovenia 2012.	

Izbor publikacij / Selected publications	86
--	----

Register raka Republike Slovenije (RRRS) je eden najstarejših populacijskih registrov raka v Evropi. Leta 1950 ga je na Onkološkem inštitutu Ljubljana (OI) ustanovila in do leta 1975 vodila pokojna profesorica dr. Božena Ravnihar. Njeno delo je prevzela profesorica dr. Vera Pompe Kirn, ki je do upokojitve leta 2003 skrbela za nadaljnje uveljavljanje RRRS v domačem in mednarodnem merilu. Od leta 2003 je RRRS z Enoto za epidemiologijo posebna služba OI, ki se imenuje Epidemiologija in register raka. V njej delujejo še *bolnišnični register OI*, ki omogoča podrobnejši pregled nad bolniki, zdravljenimi na OI (ne glede na to, kje imajo stalno prebivališče), in RRRS oskrbuje z velikim delom podatkov, *državni register za vodenje in spremljanje organiziranega presejalnega programa za raka materničnega vratu* (Register ZORA) in od leta 2007 *informacijski sistem za vabljenje žensk in epidemiološko spremljanje organiziranega presejalnega programa za raka dojk* (Register DORA).

Podatki o novih primerih raka, incidenci, preživetju in prevalenci, ki se zbirajo v RRRS, so skupaj s podatki o umrljivosti, ki jih zbira in obdeluje Nacionalni inštitut za javno zdravje RS, osnova za ocenjevanje bremena rakavih bolezni v državi. Pomembni so za načrtovanje in ocenjevanje državnega programa obvladovanja raka (DPOR) na področju primarne in sekundarne preventive, diagnostike, zdravljenja in rehabilitacije, za načrtovanje zmogljivosti in sredstev, ki so potrebni za obvladovanje rakavih bolezni (osebje, medicinska oprema, posteljne zmogljivosti); dragoceni so tudi za klinične in epidemiološke raziskave v Sloveniji in v širših mednarodnih raziskavah ter za vrednotenje učinkovitosti presejalnih programov.

Redna letna poročila RRRS so namenjena neposrednemu seznanjanju strokovne javnosti in drugih zainteresiranih z obdelanimi podatki RRRS. Ker nas omejuje tehnologija zbiranja podatkov, saj je njihovih virov več, je za dokončanje letne zbirke podatkov, njihovo analizo in objavo rezultatov potreben čas, ki je pri nas in v drugih državah podoben, običajno 2 leti do 3. V poročilih pa zadnja leta objavimo tudi pričakovano incidenco raka v letu, ko je poročilo izdano (v tokratnem poročilu za leto 2014); izračunana je s posebno statistično metodo za napovedovanje incidence raka.

RRRS je prva letna poročila izdal v letih 1953–1957 za leta 1951–1955. Prva analiza podatkov za leto 1950 je bila objavljena v *Zdravstvenem vestniku leta 1951*. Podatki za leta 1957–1971 so bili objavljeni v periodičnih publikacijah Svetovne zdravstvene organizacije *Epidemiological and Vital Statistics* in v *World Health Statistics Report*. Od leta 1965 so bili podatki spet redno objavljani v posebnih letnih poročilih z naslovom *Rak v Sloveniji* (1965–1977) in *Incidenca raka v Sloveniji* (1978–2006), in sicer v slovenskem in angleškem jeziku. Poleg letnih poročil so objavljene tudi 4 monografije: *Zemljevidi incidence raka v Sloveniji 1978–1987*, *Preživetje bolnikov z rakom v Sloveniji 1963–1990*, *Preživetje bolnikov z rakom v Sloveniji 1983–1997* in *Preživetje bolnikov z rakom, zbolelih v letih 1991–2005 v Sloveniji*. Seznam drugih pomembnejših del, objavljenih v zadnjih petih letih, je v dodatku na koncu poročila.

Podatki RRRS so vključeni v številne mednarodne podatkovne zbirke in projekte. Objavljeni so v vseh devetih zvezkih in v deseti elektronski verziji knjige *Rak na petih kontinentih* (*Cancer Incidence in Five Continents*), ki jo izdaja Mednarodna

agencija za raziskovanje raka, in v podatkovnih zbirkah *ECO*, *GLOBOCAN* in *ACCIS*. Preživetje slovenskih bolnikov je obdelano v mednarodnih raziskavah *EUROCARE-2*, *EUROCARE-3*, *EUROCARE-4*, *EUROCARE-5*, *EUROCARE-6*, *RARECARE* in *EUNICE*.

Leta 2010 smo v celoti prenovili računalniško bazo in posodobili obdelavo podatkov v RRRS. Od takrat deluje tudi *interaktivni spletni portal*, ki smo ga poimenovali *SLORA* po začetnih črkah besed »Slovenija in rak«. Dostopen je na elektronskem naslovu www.slora.si. Omogoča preprost in hiter dostop do večine podatkov o raku v Sloveniji, ki jih zbirata RRRS do zaključenega leta obdelave, trenutno 2012 (incidenca, prevalenca in preživetje), in Nacionalni inštitut za javno zdravje RS (umrljivost). S hitrim dostopom do tujih baz omogoča tudi primerjavo bremena raka v Sloveniji z drugimi državami v Evropi in v svetu. Dodane so tudi obširne strokovne razlage, ki pojasnjujejo podatke in seznanjajo uporabnike z nevarnostnimi dejavniki raka, možnostmi zgodnjega odkrivanja in uspešnostjo zdravljenja raka.

Viri in nabor podatkov

Prijavljanje raka je v Republiki Sloveniji obvezno in zakonsko predpisano že od ustanovitve RRRS (Ur. l. SRS št. 10/50, št. 29/50, št. 14/65, št. 1/80, št. 45/82, št. 42/85; Ur. l. RS št. 9/92 in št. 65/00). Osnovni vir podatkov so *prijavnice rakave bolezni*. Registru jih pošiljajo iz vseh bolnišnic in diagnostičnih centrov v Sloveniji, iz ordinacij osnovnega zdravstvenega varstva pa le izjemoma, če bolnik ni napoten na nadaljnje preiskave in/ali zdravljenje.

S prijavicami zbiramo osebne podatke, podatke o vrsti bolezni (anatomsko mesto raka, histološka oz. citološka diagnoza, stadij po TNM ali drugi klinični klasifikaciji) in o vrsti zdravljenja. Dodatni vir podatkov so zdravniška poročila o vzroku smrti, ki nam jih pošilja Nacionalni inštitut za javno zdravje RS. Veliko časa porabimo za poizvedbe o bolnikih, za katere nimamo popolnih podatkov ali pa dobimo o njih prvo informacijo šele ob smrti.

Za izračun preživetja bolnikov potrebujemo podatek, ki se imenuje *vitalno stanje* (ali je oseba živa, mrtva ali izgubljena iz registra prebivalstva). Podatek dobimo iz Centralnega registra prebivalstva (CRP), in sicer za vse osebe iz RRRS. Od leta 2010 smo po prenovi računalniške baze s posebej varovano spletno tehnologijo neposredno povezani s CRP, zato ta podatek dobimo dnevno. Pri izgubljenih osebah upoštevamo kot datum izgube datum zadnje prijave oz. datum izgube, kot velja v CRP, odvisno od tega, kateri datum je kasnejši. Od leta 1985, odkar RRRS prejema od CRP enotno matično številko občana (EMŠO), je v RRRS odstotni delež izgubljenih manjši od 1 %; pri bolnikih, registriranih v zadnjem desetletju, je znašal le 0,1 %.

Pri analizi prostorske razporeditve raka upoštevamo Uredbo o standardni klasifikaciji teritorialnih enot – SKTE (2000), ki predpisuje delitev slovenskega ozemlja na 11 ravni. Točno opredeljevanje stalnih naslovov bolnikov z rakom nam omogoča redna povezava z Registrom prostorskih enot Geodetske uprave RS. V Tabeli 6 smo do Letnega poročila 2002 prikazovali podatke po 9 zdravstvenih regijah, v skladu z omenjeno uredbo pa smo potem prešli na raven SKTE-3, na 12 statističnih regij.

Slovenske statistične regije



Priprava podatkov za računalniško obdelavo

Podatke, prispele v RRRS na prijavnica, posebej usposobljene medicinske sestre najprej kodirajo v skladu z mednarodnimi in v RRRS dogovorjenimi pravili.

Za razvrščanje neoplazem po primarni lokaciji je od leta 1997 v veljavi deseta revizija Mednarodne klasifikacije bolezni in sorodnih zdravstvenih problemov za statistične namene (MKB-10), pred tem pa smo uporabljali osmo.

Pri uvrščanju med maligne bolezni je treba opozoriti še na klasifikacijo morfologije neoplazem, za katero uporabljamo morfološki del Mednarodne klasifikacije bolezni za onkologijo. Od leta 2012 uporabljamo njeno tretjo izdajo z dopolnitvami leta 2011. V tej izdaji je nekaj novosti, med drugimi navedba, katere histološke vrste sodijo med maligne, in nekaj novih histoloških vrst, ki do tedaj niso bile obravnavane posebej. Tako npr. gastrointestinalne stromalne tumorje (GIST) uvrščamo med posebne histološke vrste šele od leta 2001. V skladu z novimi pravili mejno malignih tumorjev jajčnikov ne uvrščamo več v kategorijo C56, pač pa v D39.1. Po tretji reviziji so med maligne uvrščene kronične mieloproliferativne bolezni in mielodisplastični sindromi (sedaj v topografski šifri C96.7) in policitemije, ki jih od 2001 uvrščamo v skupino C94.

Z razvojem molekularne in genske tehnologije je mogoče natančneje opredeliti vrsto celičnih sprememb, ki nastanejo pri malignomih krvotvornega in limfatičnega tkiva, in jih zato bolj usmerjeno zdraviti. S tem se večja tudi število različnih vrst bolezni, njihovo razvrščanje pa se vedno bolj izpopolnjuje. Svetovna zdravstvena organizacija je leta 2001 objavila posebno klasifikacijo, ki opredeljuje malignome krvotvornega in limfatičnega tkiva glede na imunofenotip, genetske spremembe in klinično sliko. Leta 2008 je bila ta klasifikacija posodobljena in v kliniki zamenjuje številne dodatne klasifikacije malignomov krvotvornega in limfatičnega tkiva. Povzema jo tudi Mednarodna klasifikacija bolezni za onkologijo (3. izdaja, dopolnitev 2011). V letošnjem poročilu v Tabeli 10 razvrščamo neoplazme limfatičnega tkiva tudi v skladu z verzijo 2008 klasifikacije Svetovne zdravstvene organizacije iz leta 2008.

Od leta 1993 je obvezno prijavljanje sprememb materničnega vratu, označenih kot CIN III (šifra 219 po 8. reviziji MKB), dotlej pa so se registrirale le spremembe, označene s šifro 234.0 (carcinoma in situ). Primerjava s podatki za obdobje 1961–1992 tako ni možna. Po 10. reviziji MKB so vse intraepitelijske spremembe materničnega vratu uvrščene v šifro D06. Od leta 1987 registriramo tudi prijavljene intraepitelijske karcinome dojke (šifra D05), od leta 1995 pa intraepitelijske karcinome mehurja (šifra D09.0) in kožne melanome Clark I (šifra D03).

Za prikaz porazdelitve bolezni po stadiju ob diagnozi v letnih poročilih uporabljamo poenostavljeno razvrščanje v eno od treh skupin: omejena bolezen, regionalno razširjena bolezen in oddaljeno razširjena bolezen. Primer opredelimo na osnovi ugotovitev katere koli zapisane preiskave – od popisa operacije do obdukcije, če bolnik poprej ni bil zdravljen. Poenostavljena opredelitev stadijev pri solidnih tumorjih praviloma sledi klasifikaciji TNM. V omejen stadij je tako praviloma uvrščen primer bolezni, pri katerem je tumor označen s T1 ali T2. Pri dojki, kožnem

melanomu in ščitnici so v omejen stadij vključeni tudi tumorji T3; pri materničnem vratu, materničnem telesu in sarkomih, ter pri jajčniku, jajcevodu in trofoblastnih tumorjih v omejen stadij sodijo le tumorji T1. Pri omejeni bolezni seveda niso prizadete področne bezgavke in ni zasevkov v oddaljenih organih (N0, M0). V stadiju regionalne razširitve je primer, pri katerem je tumor opredeljen kot T3 in T4 (razen v omenjenih izjemah) in/ali so prizadete tudi področne bezgavke (N1), zasevkov v oddaljenih bezgavkah in organih pa ni (M0). V skupino oddaljeno razširjene bolezni pa uvrščamo primere, pri katerih je zapisano, da so bili zasevki že v oddaljenih bezgavkah ali organih (M1). V bazi RRRS hranimo tudi podatek o stadiju bolezni po klasifikaciji TNM ali drugih klasifikacijah, če je bil tako opredeljen na prijavnici oz. je bilo na njej vsaj dovolj podatkov za njegovo naknadno opredelitev. Maligni limfomi so opredeljeni po klasifikaciji Ann-Arbor.

Kakovost podatkov RRRS in popolnost registracije

Kakovost podatkov registrov raka opredeljujejo naslednji kazalniki: odstotni delež mikroskopsko (histološko ali citološko) potrjenih primerov in odstotni delež primerov, registriranih samo iz zdravniških poročil o vzroku smrti. Vrednosti teh kazalcev so prikazane v Tabeli 3.

Popolnost registracije kaže delež vseh novih primerov raka na področju, ki ga pokriva register in ki so vključeni v podatkovno zbirko registra. Neposredno jo je mogoče meriti samo s posebnimi raziskavami, namenjenimi oceni popolnosti, npr. s ponovnim pregledom odpustnih diagnoz in popisov bolezni v bolnišnicah ali ambulantah na določenem območju. V Sloveniji takih raziskav zaenkrat še nismo delali, veliko pa nam k popolnosti zajema pomagajo kolegi kliniki, ki jih zanima, kakšno je preživetje bolnikov, zdravljenih pri njih; ko nam pošljejo podatke o svojih skupinah bolnikov, v njih velikokrat najdemo take, ki jih v podatkovni zbirki RRRS še ni.

Na splošno velja, da je popolnost podatkov večja tam, kjer ima register dostop do zdravniških poročil o vzroku smrti. Za tiste, ki so umrli za rakom, pa (še) niso zapisani v registru, RRRS tako išče dodatne podatke. Na ta način se izboljša popolnost registracije rakov s slabo napovedjo izida, ne pa manj usodnih. Domnevamo, da je v Sloveniji – in tudi v drugih evropskih populacijskih registrih raka – manj popolna registracija nemelanomskega kožnega raka in tistih malignomov, ki se zdravijo samo ambulantno.

Incidenca in umrljivost

Incidenca in *umrljivost* pomenita absolutno število vseh na novo ugotovljenih primerov kake bolezni oz. število vseh umrlih za to boleznijo v točno določeni populaciji v enem koledarskem letu. V incidenco raka ne štejemo novih primarnih rakov parnega organa iste lokacije, če je bila histološka vrsta obeh rakov, npr. leve in desne dojke, enaka. Prav tako v incidenco ne štejemo novega pojava raka iste histološke vrste na istem organu, npr. multiple lezije v debelem črevesu. V incidenco so vključeni primeri bolezni bolnikov s stalnim bivališčem na območju Republike Slovenije ne glede na to, kje so bili bolniki zdravljeni.

Za *oceno incidence* v letu 2015 (prikazano v Tabeli 1) je uporabljena metoda po Dybi in Hakulinenu, ki je primerna za napoved incidence v krajšem časovnem obdobju, saj upošteva samo obdobje diagnoze in starost; pri dolgoročnejših napovedih je treba upoštevati tudi vpliv rojstne kohorte.

Pri časovnih trendih smo ocenjevali delež letne spremembe z Joinpoint regresijsko analizo. Uporabili smo program Joinpoint Regression Program (Version 4.1.1 – August 2014), ki je narejen na podlagi metodologije, ki so jo razvili Kim s sodelavci.

Grobe in starostno specifične stopnje

Groba incidenčna stopnja je število novih primerov bolezni, preračunano na 100.000 oseb opazovane populacije, *groba umrljivostna stopnja* pa število vseh umrlih na 100.000 oseb opazovane populacije. Natančneje sta stopnji definirani kot število novih primerov bolezni (oz. število umrlih) v določenem časovnem obdobju, praviloma enem letu (= incidenca oz. umrljivost), deljeno s številom oseb, ki so na začetku tega obdobja izpostavljene tveganju, da zbolijo oz. umrejo zaradi določene bolezni; izražamo jo na 100.000 oseb-let. *Starostno specifična stopnja* pove to relativno število (incidenčno oz. umrljivostno stopnjo) v posamezni petletni starostni skupini.

Starostno standardizirane stopnje

Če analiziramo incidenco (ali umrljivost) v daljšem časovnem obdobju, v katerem se lahko starostna struktura prebivalstva v času spreminja, ali če primerjamo incidenco (ali umrljivost) med populacijami z različno starostno strukturo, je treba uporabiti eno od metod starostne standardizacije. Starostno standardizirana stopnja je teoretična incidenčna (oz. umrljivostna) stopnja, pri kateri predpostavimo, da je starostna struktura opazovane populacije taka kot v standardni populaciji. V Tabeli 2 prikazujemo poleg grobe incidenčne stopnje rakavih bolezni v Sloveniji, še starostno standardizirane stopnje na svetovno, evropsko in slovensko standardno populacijo z metodo *neposredne standardizacije*. Starostno standardizirane umrljivostne stopnje so dostopne na spletišču SLORA. V Tabeli 6b je za primerjavo incidenčnih stopenj med slovenskimi statističnimi

regijami uporabljen slovenski standard, starostna struktura prebivalcev Slovenije ob popisu leta 2002. Uporabljena standardna populacija je vedno enaka za oba spola, kar v posameznih primerih lahko privede do nepričakovanih rezultatov, ko so standardizirane stopnje pri enem spolu (ponavadi pri moških, ki so v povprečju mlajši) večje od grobih stopenj, pri drugem spolu pa manjše.

Kumulativne stopnje in kumulativno tveganje

Kumulativna incidenčna (ali umrljivostna) stopnja (KS) (prikazana v zadnjem stolpiču Tabele 5) je petkratna vsota starostno specifičnih incidenčnih (ali umrljivostnih) stopenj po petletnih starostnih skupinah do 74. leta starosti, preračunana na 100 prebivalcev. Je poseben primer neposredne starostne standardizacije, kjer je standardna populacija v vseh starostnih skupinah enaka in zato vrednost ni odvisna od izbora standarda. Kumulativno stopnjo smo uporabili za prikaz časovnega trenda incidence in umrljivosti v spodnjem delu Slike 4.

Kumulativno tveganje (KT) je verjetnost posameznika, da zbolí za rakom v izbranem starostnem obdobju, npr. do 74. leta starosti, če ne umre prej zaradi drugih vzrokov. Kumulativno tveganje izražamo v odstotkih. Če je KS manjša kot 10/100, jo lahko uporabimo za približek kumulativnemu tveganju. Pri večjih kumulativnih stopnjah pa kumulativno tveganje izračunamo iz kumulativne stopnje po obrazcu: $KT = 100 (1 - e^{-KS/100})$.

Kumulativno incidenčno stopnjo raka dojk pri ženskah 8,0/100 tako lahko uporabimo za oceno kumulativnega tveganja raka dojk, ki je v tem primeru 8,0-odstotno. To pomeni, da bo 8,0 % deklic (ali približno ena od 13), rojenih leta 2012, do 74. leta starosti verjetno zbolelo za rakom dojk.

Prevalenca

Prevalenca je število vseh bolnikov z rakom, ki so bili živi na izbrani datum, ne glede na to, kdaj so zboleli. Celotna prevalenca obsega vse bolnike, ne glede na to, kako dolgo pred datumom izračuna so zboleli, medtem ko delna prevalenca šteje samo bolnike, ki so zboleli v določenem obdobju, npr. 1, 5 ali 10 let pred datumom, na katerega to mero računamo. Pri raku so ta obdobja še zlasti pomembna, saj odsevajo število bolnikov v različnih fazah poteka bolezni, npr. enoletna vključuje bolnike v času prvega zdravljenja, triletna bolnike v obdobju rednih kontrolnih kliničnih pregledov, petletna in zlasti še desetletna pa vključuje bolnike, za katere vsaj pri večini rakavih bolezni menimo, da so ozdravljeni.

Nekateri bolniki zbolijo za več kot eno rakavo boleznijo, zato je vsota prevalenc bolnikov po posameznih vrstah raka večja kot skupna prevalenca, pri kateri štejemo samo bolnike ne glede na število posameznih rakavih bolezni.

Relativno preživetje

Relativno preživetje je približek preživetja bolnikov v primeru, da bi kot vzrok smrti upoštevali samo izbranega raka. Izračuna se kot razmerje med opazovanim preživetjem proučevane skupine bolnikov in preživetjem, ki ga glede na spol in starost v določenem obdobju pričakujemo v celotni populaciji, iz katere prihajajo bolniki. Pričakovano preživetje se izračuna na podlagi podatkov o splošni umrljivosti, ki se v obliki tablic umrljivosti za posamezno državo rutinsko objavljajo v okviru demografske statistike; za naše izračune so uporabljene slovenske letne popolne momentne tablice umrljivosti. Izračunano je s knjižnjico *relsurv* v programskem paketu R.

Opozarjamo še, da metoda, uporabljena za izračun relativnega preživetja, prikazanega v tem poročilu, ni enaka tisti, s katero je mogoče prikazati relativno preživetje na spletnem portalu SLORA. Za izračun relativnega preživetja na spletišču SLORA je uporabljena t.i. Hakulinenova ali popolna metoda izračuna relativnega preživetja. Po tej metodi prispevajo bolniki, ki jim zaradi predhodnega zaključka opazovanja ne sledimo polni čas, k relativnemu preživetju samo leta, za katera so dejanski podatki na voljo. Tako skupina zbolelih tri leta pred zaključkom opazovanja prispeva k eno- in triletnemu relativnemu preživetju, k petletnemu pa ne.

Podatki o številu prebivalcev in o starostni strukturi so pomembni pri izračunavanju in interpretiranju večine kazalnikov bremena raka. Za Slovenijo je točno število in starostna struktura prebivalcev na voljo za popisna leta že ves čas registracije raka. Nacionalni popis prebivalstva je bil napravljen približno na vsakih deset let. Podatkov za vmesna obdobja do leta 1985 ni, zato smo pri izračunu kazalnikov predpostavili, da je bila med dvema popisnima letoma struktura enaka. Od sredine osemdesetih let, odkar število prebivalstva v Sloveniji spremlja Centralni register prebivalstva, je mogoče dobiti ažuren podatek o številu in starostni strukturi prebivalcev. V letnih poročilih uporabljamo podatek o prebivalcih na datum 30. junij posameznega leta, kot ga dobimo na podatkovnem portalu SI-STAT Statističnega urada RS. Podatki o prebivalstvu po spolu in petletnih starostnih skupinah za celotno Slovenijo za leto 2012 so v spodnji tabeli.

Starostna skupina	Skupaj	Moški	Ženske
0–4	110.294	56.696	53.598
5–9	93.558	48.031	45.527
10–14	91.681	47.335	44.346
15–19	99.550	51.147	48.403
20–24	120.144	62.073	58.071
25–29	139.655	72.858	66.797
30–34	156.881	82.481	74.400
35–39	153.781	80.264	73.517
40–44	146.735	75.718	71.017
45–49	157.171	79.934	77.237
50–54	152.376	77.379	74.997
55–59	153.920	78.426	75.494
60–64	131.836	65.414	66.422
65–69	95.569	44.664	50.905
70–74	89.001	39.411	49.590
75–79	73.399	28.885	44.514
80+	90.711	26.698	64.013
Skupaj	2.056.262	1.017.414	1.038.848

Prebivalci Slovenije po starosti in spolu na dan 1. 7. 2012.

Pri razporeditvi prebivalcev v posamezne statistične regije (spodnja tabela) je uporabljen le podatek o stalnem naslovu oseb in ne tudi začasnem, kot je upoštevan v pripravi števila prebivalcev po klasični »statistični« definiciji.

Statistična regija	Skupaj	Moški	Ženske
Pomurska	118.573	57.916	60.657
Podravska	323.026	159.525	163.501
Koroška	72.267	36.255	36.012
Savinjska	260.545	129.969	130.576
Zasavska	43.775	21.431	22.344
Spodnjeposavska	70.818	35.550	35.268
JV Slovenija	142.146	71.485	70.661
Osrednjeslovenska	537.712	262.946	274.766
Gorenjska	204.170	100.875	103.295
Notranjsko-Kraška	52.423	26.432	25.991
Goriška	119.230	59.459	59.771
Obalno-Kraška	111.577	55.571	56.006
Slovenija	2.056.262	1.017.414	1.038.848

Prebivalci Slovenije po statističnih regijah in spolu na dan 1. 7. 2012.

Leta 2012 je v Sloveniji za rakom zbolelo 13.277 ljudi, 7.240 moških in 6.037 žensk. (*Slika 1*), umrlo pa 5.821 ljudi, 3.264 moških in 2.557 žensk. Od rojenih leta 2012 bosta do 75. leta starosti predvidoma za rakom zbolela eden od dveh moških in ena od treh žensk (*Tabela 5*).

Konec decembra 2012 je živel 89.788 ljudi (39.335 moških in 50.453 žensk), ki so kadar koli od ustanovitve RRRS zboleli za rakom (*Slika 1*). Ocenjujemo, da je leta 2015 za rakom zbolelo približno 14.600 prebivalcev Slovenije, približno 8.200 moških in 6.400 žensk. Ocene incidence za posamezne lokacije raka so prikazane v *Tabeli 1* skupaj s povprečnimi petletnimi vrednostmi za zadnje 10-letno obdobje.


Ogroženost z rakom se zmerno veča in je največja v starejših letih; od vseh bolnikov z rakom je leta 2012 kar 60 % moških in 57 % žensk zbolelo po 65. letu starosti. Pri otrocih in mladostnikih (do 20. leta) obsegajo rakave bolezni manj kot 1 % vseh primerov raka (*Slika 2*). Ker se slovensko prebivalstvo stara, je samo zaradi vedno večjega deleža starejših pričakovati, da se bo število novih primerov raka še večalo.

Ker na incidenco raka najbolj vpliva starostna struktura prebivalstva, so za verodostojnejšo primerjavo z drugimi državami z različno starostno strukturo v *Tabeli 2* poleg grobih stopenj izračunane tudi starostno standardizirane. Glede na to, da so v uporabi različni standardi, smo uporabili tri standardne populacije svetovno, evropsko in slovensko.

Pet najpogostejših vrst raka pri nas – kožni (razen melanoma), rak debelega črevesa in danke, prostate, dojke in pljuč – obsega 59 % vseh novih primerov rakavih bolezni (*Slika 3*). Raki teh organov so povezani z nezdravim življenjskim slogom, čezmernim sončenjem, nepravilno prehrano, kajenjem in čezmernim pitjem alkoholnih pijač, zato je ogroženost z njimi treba zmanjšati z ukrepi primarne preventive. Pri moških je bil z 19,7 % vseh novih primerov na prvem mestu rak prostate. Pri ženskah je bil na prvem mestu rak dojk, ki je predstavljal petino primerov vseh rakov pri ženskah (21,5 %) (*Slika 3*).

Od leta 1950 se je groba incidenčna stopnja raka v Sloveniji zvečala za skoraj 600 % pri moških in za 350 % pri ženskah; v zadnjih 10 letih se je pri moških večala povprečno za 3,1 % letno, pri ženskah pa za 1,6 %. Groba umrljivostna stopnja se je v zadnjih 10-ih letih večala pri moških povprečno za 1,5 % letno, pri ženskah pa za 1,7 % (*Slika 4*). Več kot polovica zvečanja incidence gre na račun staranja prebivalstva. Kumulativna incidenčna stopnja se je v zadnjih 10-ih letih pri moških večala v povprečju le za 1,4 % letno, pri ženskah pa za 0,4 %. Kumulativna umrljivostna stopnja se od leta 1985 pri obeh spolih manjša (*Slika 4*), pri moških za 1,7 % letno, pri ženskah pa za 1,2 %. Manjšanje verjetnosti smrti za rakom ob večanju incidence kaže, da je zdravljenje uspešnejše in da vse več bolnikov ozdravi in/ali živi z rakom, medtem ko jih je prej več umrlo zaradi rakave bolezni. Vse povprečne letne spremembe, razen pri kumulativni incidenci pri ženskah, so statistično značilne pri stopnji tveganja 0,05.

Časovni trend pogostejših rakov pri moških kaže, da se je incidenčna stopnja pljučnega raka večala vse do začetka devetdesetih let prejšnjega stoletja, ko se je ustalila pri vrednosti okoli 83/100.000, v zadnjih desetih letih se postopno manjša



(za 1,4 % povprečno letno), strmo pa pljučnega raka prehitvajo rak prostate (povečanje za 8,1 % povprečno letno), koža, razen melanoma (povečanje za 4,7 % povprečno letno) ter rak debelega črevesa in danke (povečanje za 4,0 % povprečno letno). Izjemno povečanje incidence raka prostate v zadnjem desetletju ni posledica kakega novega nevarnostnega dejavnika, pač pa predvsem vse širše rabe testa za določanje za prostato specifičnega antigena (PSA) pri zdravih moških in odkrivanja velikega števila primerov, ki bi drugače ostali vse življenje prikriti. V zadnjem desetletju se skoraj ne spreminja incidenčna stopnja raka glave in vratu. Pri ženskah se večajo incidenčne stopnje raka dojke (za 1,3 % povprečno letno), koža, razen melanoma (povečanje za 3,4 % povprečno letno), pljučnega raka (za 3,5 % povprečno letno). V zadnjem desetletju se skoraj ne spreminja incidenčna stopnja raka materničnega telesa, medtem ko se incidenčna stopnja raka materničnega vratu od leta 2003 počasi manjša (za -5,9 % povprečno letno). Pri obeh spolih se večja pogostost raka debelega črevesa in danke, malignega melanoma in drugih kožnih rakov, podobno kot drugod v svetu pa je želodčnega raka pri obeh spolih vse manj; povprečne letne odstotne spremembe so prikazane pri krivuljah na *Sliki 5*.

Slika 6 prikazuje petletno relativno preživetje bolnikov z vsemi (razen kožnega) in izbranimi raki, zbolelih v letih 2008–2012 po spolu in za oba spola skupaj. Za primerjavo je prikazano tudi relativno preživetje bolnikov, zbolelih v predhodnem petletnem obdobju (2003–2007). Pri moških se je skupno preživetje povečalo za 7 odstotnih točk, predvsem zaradi večjega odkrivanja in boljšega prijavljanja raka prostate nižjih stadijev, ki so povezani z boljšo prognozo, saj je preživetje bolnikov, zbolelih v zadnjem obdobju, večje za skoraj 7 odstotnih točk. Ker se 95 % intervala zaupanja ne prekrivata, lahko zaključimo, da je razlika statistično značilna. Preživetje bolnic, zbolelih v obeh petletnih obdobjih, je skoraj enako (59 %); večje preživetje so imele bolnice z rakom debelega črevesa in danke, z rakom ščitnice in s kožnim melanomom.

Slika 7 kaže, kako sta se v zadnjem desetletju spreminjali groba in starostno standardizirana incidenčna stopnja vseh in najpogostejših rakavih bolezni. Pri vseh raki skupaj sta se pri moških groba in starostno standardizirana stopnja večali bolj kot pri ženskah, tudi če ne upoštevamo kožnega nemelanomskega raka. Pri obeh spolih skupaj pa večji porast grobe kot starostno standardizirane stopnje kaže, da se povprečna letna stopnja večja predvsem na račun staranja prebivalstva, manj na račun širjenja drugih nevarnostnih dejavnikov. Spodbudno pa je, da se pri moških manjša (starostno standardizirana) incidenca rakov mehurja, glave in vratu, želodca in pljuč; torej predvsem s kajenjem povezanih rakov. Pri ženskah pa se manjša (starostno standardizirana) incidenca rakov materničnega telesa, želodca in jajčnikov.

Najpogostejši raki so v raznih življenjskih obdobjih različni. Pri otrocih in mladostnikih do 20. leta je rak zelo redka bolezen, v zadnjih letih (2008–2012) je v povprečju letno zbolelo 34 dečkov in 30 deklic. Najpogostejše pri dečkih so bile levkemije (28,0 %), sledili so jim tumorji centralnega in avtonomnega živčnega sistema (17,3 %) in rak mod (10,7 %). Pri deklicah pa so bile na prvem mestu tudi levkemije (24,7 %), drugo mesto pa so si delili tumorji centralnega in avtonomnega živčnega in Hodgkinova bolezen (po 13,3 %). Mlajših odraslih moških (starih 20–34 let) je zbolelo v povprečju 126 letno; med njimi je skoraj polovica primerov raka mod (40,1 %), drugo mesto pa si delijo nemelanomski kožni raki in kožni melanom (po 10,0 %). Pri mlajših

ženskah (v povprečju je bilo letno 151 novih primerov) pa sta bila na prvem mestu rak dojke in kožni melanom (po 17,1 %), sledil je rak ščitnice (13,1 %) (*Slika 8*).

Pri večini bolnikov je diagnoza bolezni potrjena mikroskopsko. Iz *Tabele 3* je razvidno, da je bila leta 2012 pri 94,1 % od 13.277 na novo registriranih primerov raka diagnoza potrjena mikroskopsko (histološko ali citološko), pri 5,7 % z drugimi preiskavami, le 0,2 % primerov pa je bilo v RRRS vpisanih samo na osnovi zdravniškega poročila o vzroku smrti. Ta zadnja odstotna vrednost, ki je že več let podobna, odseva število bolnikov, ki verjetno zaradi starosti ali napredovale bolezni niso bili zdravljeni v bolnišnici. Iz *Tabele 3* je poleg načina postavitve diagnoze razvidno tudi število vseh novih primerov po posameznih mestih raka, v *Tabeli 4* je prikazano razporejanje teh primerov po 5-letnih starostnih skupinah, v *Tabeli 5* pa so te vrednosti preračunane v starostno specifične stopnje na 100.000 prebivalcev.

V *Tabeli 6a* je število novih primerov vseh in izbranih rakov prikazano po statističnih regijah. Ta števila so pomembna za načrtovanje zdravstvenih zmogljivosti. Starostno standardizirane vrednosti v *Tabeli 6b* pa kažejo razlike v ogroženosti z rakom v posameznih regijah, saj te niso posledica razlik v starostni strukturi prebivalcev.

Kakšna je bila morfološka slika malignomov pri 12.498 primerih, pri katerih je bila diagnoza potrjena mikroskopsko, kaže *Tabela 7*. V njej so posebej prikazani primeri, ki so potrjeni histološko (95 %), in tisti, ki so bili potrjeni samo citološko (5 %).

Tabela 8 prikazuje porazdelitev bolnikov po stadiju, v katerem je bila bolezen odkrita. Uporabljena je poenostavljena opredelitev stadijev, ki upošteva vse preiskovalne metode, vključno z operacijo in tudi obdukcijo, če bolnik ni bil poprej zdravljen.

Tabela 9 kaže starostno porazdelitev ektranodalnih in nodalnih lokacij ne-Hodgkinovih malignih limfomov. Ker je število ektranodalnih lokacij majhno, so prikazane le absolutne številke.

V *Tabeli 10* je prikazana starostna porazdelitev neoplazem limfatičnega tkiva v skladu s klasifikacijo Svetovne zdravstvene organizacije iz leta 2008, ki jo uporabljajo kliniki in patologi.

Tabela 11 prikazuje osnovne podatke o zdravljenju bolnikov. Ker je veliko bolnikov zdravljenih na več načinov, je vsota bolnikov po vrsti zdravljenja večja od števila novih primerov. Iz *Tabele 11a* je razvidno, kako so bili bolniki zdravljeni, v *Tabelah 11b* in *11c* pa, v katerih zdravstvenih ustanovah so bili bolniki v okviru prvega zdravljenja operirani in/ali zdravljeni s sistemskimi zdravili; z obsevanjem se z redkimi izjemami (tujina) zdravijo samo na Onkološkem inštitutu Ljubljana.

Tabela 12 prikazuje prevalenco vseh in pogostejših rakov na dan 31. 12. 2012. Poleg celotne prikazujemo tudi delno, to je 1-, 3-, 5- in 10-letno prevalenco.

V *Tabeli 13* so uradni podatki o umrljivosti za rakom v letu 2012; zbira jih Nacionalni inštitut za javno zdravje RS. Grobe in starostno standardizirane stopnje so na voljo na spletišču Slora.

Zdravniki, medicinske sestre in administrativno osebje iz slovenskih bolnišnic in drugih zdravstvenih ustanov so RRRS dokaj vestno pošiljali prijavnice s podatki o novih primerih raka, o poteku bolezni in usodi bolnikov. Dopolnili so nam tudi morebitne pomanjkljive prijave. Podatke, ki so za RRRS nujni, a jih ni bilo mogoče najti v bolnišnicah, so nam z zavzetim delom priskrbeli družinski in splošni zdravniki.

Vsaj polovico podatkov, obdelanih v tem poročilu, sta prispevali sodelavki Bolnišničnega registra Onkološkega inštituta Ljubljana, Maruška Ferjančič in Polona Škulj. Patologinja dr. Gorana Gašljević nam je pomagala opredeliti histološke izvide malignomov limfatičnega tkiva.

Poročila bi skorajda ne mogli napraviti, njegovi podatki pa bi bili bistveno manj verodostojni, ko bi ne imeli naklonjenega sodelovanja Centralnega registra prebivalstva RS, Nacionalnega inštituta za javno zdravje RS in Statističnega urada RS.

Vsem imenovanim in tudi drugim, ki so kakorkoli prispevali k temu poročilu, se najlepše zahvaljujemo.

Uredniški odbor

Cancer Registry of the Republic of Slovenia (CRRS) is one of the oldest population based cancer registries in Europe. It was founded at the Institute of Oncology Ljubljana (IO) in 1950 by the late Professor Božena Ravnihar, who headed it till 1975. She was succeeded by Professor Vera Pompe-Kirn, who contributed a lot to the further development of the CRRS as well as its recognition at the national and international level all until her retirement in 2003. Since 2003, the CRRS has been merged with the Unit of Epidemiology into a single Epidemiology and Cancer Registry service. Besides the CRRS, the new service also comprises the *hospital-based Cancer Registry* of the IO, which contributes a considerable part of information to the CRRS and facilitates a more detailed overview of patients treated at the IO, irrespective of their permanent residence. In the last decade, a new *national registry in charge of coordinating and monitoring the organised cervical cancer screening programme* (Registry ZORA) has been established, while an *information system to support organized breast screening program* has been established in 2007 (Registry DORA).

The data on cancer collected by the CRRS, incidence, survival and prevalence, serve together with mortality data collected by the National Institute of Public Health of RS as the basis for assessing the cancer burden in the country. They are important for planning and evaluation of the National Cancer Control Plan (NCCP), in the field of primary and secondary prevention, diagnosis, treatment and rehabilitation, for planning facilities and funding needed for cancer control (personnel, equipment and hospital capacities) as well as for clinical and epidemiological research in Slovenia and in international multicentre studies and for evaluation of effectiveness of cancer screening programs.

The Annual Reports of the CRRS are one of the regular ways of disseminating information on cancer among professionals and other interested groups. As we are limited by the technology of data collection from a variety of sources, data collection, their linking and publication is rather time consuming (with us and elsewhere) and usually takes two to three years. Over the last few years the estimated numbers and rates for the expected incidence in the year the Annual Report is published (in this report for the year 2014) are presented; they are calculated by a special statistical method.

The first annual reports of the CRRS for the period 1951–1955 were issued during the years 1953–1957. The first data analysis for the year 1950 was published in *Zdravstveni vestnik* in 1951. The data for the period 1957–1971 were appearing in the periodicals *Epidemiological and Vital Statistics Report* and *World Health Statistics Report*, both edited by the World Health Organization. From 1965 onwards, the data have been appearing regularly in special bi-lingual (Slovene-English) annual reports, first entitled *Cancer in Slovenia* (1965–1977), and then *Cancer Incidence in Slovenia* (1978–2006). Besides Annual Reports, four special publications have been published: *Atlas of Cancer Incidence in Slovenia 1978–1987*, *Cancer Patients' Survival in Slovenia 1963–1990*, *Cancer Patients' Survival in Slovenia 1983–1997* and *Survival of Cancer Patients, diagnosed in 1991–2005 in Slovenia*. The list of other relevant publications in last five years is at the end of this report.

Data of the CRRS are included in several international databases and projects. They have been published in all nine volumes and the tenth electronic version of the *Cancer Incidence in Five Continents* issued by the International Agency for Research on Cancer. The data are included in international databases *ECO*, *GLOBOCAN* and *ACCIS*. The survival of Slovenian cancer patients is analysed in the international studies *EUROCARE-2*, *EUROCARE-3*, *EUROCARE-4*, *EUROCARE-5*, *EUROCARE-6*, *RARECARE* and *EUNICE*.

In 2010, the CRRS's database has been upgraded and data processing modernized. At the same time an interactive web portal named SLORA was launched as well. The name comes from the first letters of the sentence in Slovenian language: "SLOvenia and RAk/cancer". It is available at www.slora.si. It enables a simple access to data on cancer in Slovenia collected by the CRRS (incidence, prevalence and survival; currently till 2012) and the National Institute of Public Health of Republic of Slovenia (RS) (mortality) and comparison with other countries in the European Union and in the world. It describes the data and offers its users professional explanations of cancer risk factors, screening and early detection and treatment outcomes.

Data sources and the list of data collected

Notification of cancer has been compulsory in Slovenia since the foundation of the CRRS and prescribed by law (Official Gazette of SRS, No 10/50, 29/50, 14/65, 1/80, 45/82 and 42/85; Official Gazette of RS, No 9/92 and 65/00). The main sources of data are *notifications of cancer*, gathered from all hospitals and diagnostic centres in Slovenia, exceptionally also from primary health care centres in case the patient has not been referred for further diagnostic investigations and/or treatment.

The data gathered with notifications are identification data, data on the cancer disease (anatomic cancer site, histological or cytological diagnosis and stage by TNM or other clinical classification) and basic data on treatment. Additional sources of information are death certificates that we get from National Institute of Public Health of RS. Where patients' data are incomplete or the only information about their disease is acquired from the death certificate, time consuming queries about patients must be performed by the CRRS's staff.

Calculation of patient survival requires the patient's *vital status* (a person may be alive, dead or lost to follow-up). This data is obtained from the Central Population Registry for all persons registered in the CRRS data base as alive. Since 2010, together with the upgrade of CRRS's database, an on-line connection with the Central Population Registry has been established using a specially secured web technology. This enables an on-line connection and up-to-date vital status of all registered patients. In persons lost to follow-up the date of last notification or the date of loss obtained from the Central Population Registry, whichever first, is considered as the date of loss to follow-up. From 1985, since the uniform personal ID number has been used in Slovenia, the percentage of the lost to follow-up in CRRS is below 1%, furthermore, in patients registered in the last decade being only 0.1%.

When analysing the spatial distribution of cancer, the Decree on the standard classification of territorial units from the year 2000 that introduced the system of division of Slovenian territory at eleven levels is followed. Our regular connection with the Registry of Spatial Units of the Surveying and Mapping Authority enables us to perform the exact mapping of patients' permanent address. Till the Annual Report 2002 the data have been presented by 9 health regions in Table 6 and in accordance with aforementioned decree 12 statistical regions are used to present the data since then.

Statistical regions of Slovenia



Preparation of data for computer processing

In CRRS specially trained nurses code the data retrieved from notifications of cancer in accordance with the international and internal CRRS guidelines.

Since 1997, cancer sites are coded according to the 10th revision of the International Statistical Classification of Diseases and Related Health Problems (ICD-10); before, the 8th revision was used (ICD-8).

When classifying tumours as malignant, the behaviour digit of the morphology code of the third edition of International Classification of Diseases for Oncology has been used since the report for 2001. In this edition some changes were introduced in terms of morphology and behaviour code and some new morphology codes were added for tumours that till 2001 have not been coded separately. For example, gastrointestinal stromal tumours (GIST) are a distinct entity since 2001. According to the new rules, ovarian tumours of borderline malignancy are currently coded as D39.1 (and not C56). According to the third edition, chronic myeloproliferative disorders and myelodysplastic syndromes as well as polycythaemia are classified as malignant, the former two being assigned to C96.7 and the polycythaemia is classified under the topography code C94 from year 2001 on. From year 2012 on, the third edition with 2011 updates is used.

Development of molecular and genetic technologies enabled more detailed classification of the type of cellular changes, found in neoplasms of the lymphoid and haematopoietic tissues. Better and more detailed identification enables targeted treatment. All this correspond to greater number of disease types and its classification is constantly updating. In 2001, the World Health Organization published special classification of the lymphoid and haematopoietic tissue based on immunophenotype, genetic changes and clinical picture. The classification was updated in 2008 and replaced several other classifications of the lymphoid and haematopoietic tissue in clinical use. Furthermore, the International Classification of Diseases for Oncology (third revision, 2011 update) follows this classification. In this report, malignant neoplasms, stated or presumed to be primary, of lymphoid, haematopoietic and related tissue are systemized in Table 10 according to 2008 version of the classification of the World Health Organization from year 2008.

In 1993, compulsory registration of all cervical intraepithelial dysplasia classified as CIN III was introduced (code 219 according to ICD-8). Till then, only carcinoma in situ (code 234.0) was registered. Thus, the comparison with the data for the period 1961–1992 is not possible. According to ICD-10, all cervical intraepithelial neoplasms (in situ and CIN III) are coded as D06. Since 1987, the number of all reported intraepithelial carcinomas of breast (D05) and since 1995, all reported intraepithelial carcinomas of the bladder (D09.0) and all malignant melanomas Clark I (D03) have been registered as well.

For stage description, a simplified definition of stages at diagnosis is used, classifying them into localized, regional and remote stage of disease. The simplified definition is based on all investigation methods, including surgery. In case the patient was not treated before death, the autopsy record is considered as well. In



solid tumors, the simplified stage definition generally follows the TNM classification. Localized stage includes all cancers where the tumor has been classified as T1 and T2. In breast cancer, skin melanoma and thyroid cancer T3 tumor is also included in localized stage. In uterine cervix, corpus and sarcomas, ovarian cancer, tube and trophoblastic tumors only T1 tumor is included in localized stage. In all of these cases neither regional lymph node involvement nor distant metastases are found (N0, M0). The regional stage includes tumors classified as T3 and T4 (with aforementioned exceptions) and/or regional lymph node metastases (N1), without presence of metastases in distant lymph nodes or organs (M0). The disease with metastases in distant lymph nodes or organs is classified as the remote stage (M1). Stage according to TNM or any other appropriate classification is also stored in the CRRS database, if available. Malignant lymphomas are classified according to Ann-Arbor System.

Data quality and completeness of registration

The quality of information can be assessed by the following parameters: the percentage of microscopically (histologically or cytologically) confirmed cases and the percentage of cancer cases registered on the basis of death certificates only. The values of these parameters are presented in Table 3.

The completeness of registration shows the proportion of all new cancer cases in the region covered by the registry that are included in the registry's data base. It can be measured directly only by means of special surveys for the evaluation of completeness, e.g. by reviewing patients' records in the hospitals or outpatient clinics in a particular region. In Slovenia, no such surveys have been carried out so far. However, a considerable contribution towards the completeness of registration is made by our colleagues – clinicians, who send us the data on their groups of patients in order to provide us with information about their vital status and among them we often find cases that have not been entered into the CRRS database yet.

In general, the registration is more complete where the registries have access to death certificates. This enables the registry to send out additional inquiries where disease for the deceased has not been entered into the database yet. This improves the completeness of registration of cancers with poor prognosis, but not also of less fatal ones. It is presumed that in Slovenia – as well as in other European population based cancer registries – registration is less complete in non-melanoma skin cancer and in malignomas that are treated on the out-patient basis only.

Incidence and mortality

Incidence and mortality are absolute numbers of all newly diagnosed cases of any disease or number of deceased from this disease in a defined population in one calendar year. New primary cancers of the same histology in paired organs, e. g. in the left and right breast, are not comprised in the incidence figures, neither are any new cancers of the same histology appearing in the same organ, e.g. multiple lesions of the colon. The incidence registered by CRRS includes only the data on patients with permanent residence in Slovenia, regardless of the country where they have been treated.

The method by Dyba and Hakulinen was used for estimation of incidence in 2015 (presented in Table 1). This method is suitable for predictions in shorter time period, taking into account the period of diagnosis and age structure of population. For long-term predictions the cohort effect should be included also.

For assessing time trends, the average annual change was calculated with joinpoint regression analysis by Joinpoint Regression Program (Version 4.1.1 - August 2014), which follows the models developed by Kim et al.

Crude and age specific rates

Crude incidence rate is the number of new cases per 100,000 population, while crude mortality rate is the number of deaths per 100,000 population. More precisely it is defined as number of new cases (or number of deaths) in a specified time interval, usually one calendar year (= incidence or mortality), divided by the number of persons at risk of disease (or death) at the beginning of time interval; it is expressed per 100,000 person-years. The *age specific rate* expresses incidence or mortality rate in an individual five-year age group.

Age standardized rates

When analysing the incidence (or mortality) rate within longer time period (if the age structure of population changes) or comparing the incidence (or mortality) between populations with different age structure, age standardization is needed to adjust the rate for the effect of age. The age-standardized rate is a theoretical incidence (or mortality) rate assuming that the age structure in the observed population is the same as in the standard population. In Table 2, besides crude cancer incidence rates, age standardized rates by direct method are presented, using World, European and Slovenian standard population. Age standardized mortality rates are also available at SLORA web-portal. In Table 6b the incidence rates in different statistical regions in Slovenia are compared using the Slovenian standard, which is the age structure of Slovenian 2002 census population. Because the standard population is always the same for both sexes, there are some situations where standardized rate is bigger than crude rate in one sex, usually in males who are on average younger, and smaller in the other.

Cumulative incidence rate and cumulative risk

The cumulative incidence (or mortality) rate (cumulative incidence rate is presented in the last column of Table 5) is five times the sum of the age-specific incidence (or mortality) rates over five-year age groups up to the age of 74 years, calculated per 100 population. The cumulative rate can be interpreted as a form of direct age-standardization with the same standard population size in each age group. Thus, it avoids the arbitrary choice of standard population. The cumulative incidence rate was also used to present the incidence time trend in the lower part of the Figure 4.

The cumulative risk (CR) is the risk an individual would have of developing the disease in question during a certain age period, e.g. up to the age of 74, if no other causes of death were in operation. The cumulative risk is expressed per 100 (per cent). If cumulative rate is lower than 10/100, its value is practically equal to that of the cumulative risk. When cumulative rate is greater than 10/100, it should be calculated from cumulative risk according to the following formula: $CR = 100 (1 - e^{-CR/100})$.

Cumulative incidence rate of breast cancer in females 8.0/100 can be used to estimate cumulative risk of breast cancer that is in this case 8.0%. This means that 8.0% of women born in 2012 (approximately one out of 13) are expected to develop breast cancer by their age of 74 in the absence of any other cause of death.

Prevalence

Prevalence is the number of all cancer patients that are alive on a given date, regardless of when they were diagnosed with cancer. Lifetime cancer prevalence is defined as all persons living and ever diagnosed with cancer, while partial prevalence counts only those patients, diagnosed with cancer within a defined period of time e. g. 1, 5 or 10 years before the date on which prevalence is calculated. In cancer these periods are important, as they reflect the number of cancer cases in different course of disease, e. g. the one-year prevalence includes patients during their primary treatment, 1–4 years prevalence those requiring regular follow-up, while 5–9 and especially 10 and more years prevalence includes predominantly those considered cured from cancer.

Some patients have more than one cancer, hence the sum of prevalence of cancer patients by individual cancer site is bigger than the prevalence of all cancer patients, as patients are counted only once regardless of the number of cancer diseases.

Relative survival

Relative survival is an approximation of patients' survival in the case where the observed cancer would be considered as the only cause of death. Relative survival is a ratio between the observed and the expected survival, i.e. the survival expected with respect to gender and age in certain time period in the whole population the patients come from. The expected survival is calculated from general mortality data published routinely in the form of mortality tables for an individual country within the framework of its vital statistics. The relative survival for the needs of this report was calculated using the Slovenian annual complete yearly life tables using package *relsurv* in statistical software R.

It should be noted that the method used for survival calculation in this report is different from the one used to present survival at web-portal SLORA where the relative survival is computed by complete or Hakulinen's method. In this method the patients followed up for a shorter period of time are considered in the calculation only for the time when they were actually followed. Thus, a group diagnosed three years before the completion of study contributes to one- and three-year complete relative survival but not also to five-year survival.

Population of Slovenia

Population data, especially the number and age structure, are important for calculation and interpretation of most indicators of cancer burden. Census population data are available for the whole time period since the beginning of cancer registration. Census has been performed nearly every 10 years, but till 1985 no data were available for intermediate years, so for this time period it was assumed that the population structure between two censuses was the same. Since the middle of the eighties, the population data are available for any particular date from the Central Population Registry. In CRRS Annual Reports the population data on June 30 of a particular year are used, which are obtained from Statistical Office of Republic of Slovenia. In the following table, numbers of inhabitants of Slovenia in 2012 by age and by sex are presented.

Age	Total	Males	Females
0–4	110.294	56.696	53.598
5–9	93.558	48.031	45.527
10–14	91.681	47.335	44.346
15–19	99.550	51.147	48.403
20–24	120.144	62.073	58.071
25–29	139.655	72.858	66.797
30–34	156.881	82.481	74.400
35–39	153.781	80.264	73.517
40–44	146.735	75.718	71.017
45–49	157.171	79.934	77.237
50–54	152.376	77.379	74.997
55–59	153.920	78.426	75.494
60–64	131.836	65.414	66.422
65–69	95.569	44.664	50.905
70–74	89.001	39.411	49.590
75–79	73.399	28.885	44.514
80+	90.711	26.698	64.013
Total	2.056.262	1.017.414	1.038.848

Population of Slovenia by age and by sex, July 1, 2012.

In the number of inhabitants by statistical regions (following table) the permanent, but not the temporary residence of the Slovenian citizens is used, contrary to the standard "statistical" definition.

Statistical region	Total	Males	Females
Pomurska	118.573	57.916	60.657
Podravska	323.026	159.525	163.501
Koroška	72.267	36.255	36.012
Savinjska	260.545	129.969	130.576
Zasavska	43.775	21.431	22.344
Spodnjeposavska	70.818	35.550	35.268
JV Slovenija	142.146	71.485	70.661
Osrednjeslovenska	537.712	262.946	274.766
Gorenjska	204.170	100.875	103.295
Notranjsko-Kraška	52.423	26.432	25.991
Goriška	119.230	59.459	59.771
Obalno-Kraška	111.577	55.571	56.006
Slovenia	2.056.262	1.017.414	1.038.848

Population by Slovenian statistical regions and by sex, July 1, 2012.

In 2012, 13,277 patients were diagnosed with cancer, 7,240 males and 6,037 females, and 5,821 patients died from cancer, 3,264 males and 2,557 females (*Figure 1*). From those born in 2012, one in two males and one in three females are expected to develop cancer by their age of 74 (*Table 5*).

At the end of December 2012, there were 89,788 people (39,335 males and 50,453 females) alive who were diagnosed with cancer at any time since the foundation of the CRRS (*Figure 1*). It is estimated that in 2015 there was about 14,600 Slovenian inhabitants newly diagnosed with cancer, approximately 8,200 males and 6,400 females. The estimated incidence of different cancer sites together with 5-year average values in the last 10-year period are presented in *Table 1*.

The risk of cancer is slowly increasing and is the highest in older age groups; from all cancer patients, diagnosed in 2012, 60% males and 57% females were aged 65 or more at diagnosis. Cancer among children and young adults (till the age of 20) accounts for less than 1% (*Figure 2*). As Slovenian population is ageing, it is expected that the cancer burden will increase because of longer life expectancy.

As cancer incidence depends on the age structure of a population, *Table 2* presents crude as well as age standardized rates. For better comparison with other countries and as different standard populations are used worldwide, three standard populations, World, European and Slovenian, were applied.

First five most frequent cancers (skin – except melanoma, colorectal, prostate, lung and breast) comprise 59% of all new cancer cases (*Figure 3*). Cancer of these sites is associated with unhealthy lifestyle, such as excessive sunbathing, unhealthy diet, smoking and excessive alcohol consumption; the aim of primary prevention is to lower the risk associated with these factors. In males, the most frequent cancer site in 2012 was prostate (19.7% of all new cases). In females, breast was the most frequent cancer site with one fifth of all new cases (*Figure 3*).

Since 1950, the crude cancer incidence rate in Slovenia increased by 600% in males and by 350% in females. In the last 10 years, the average annual increase in males was 3.1% and 1.6% in females. The increase in crude mortality rate in the last 10 years was substantially lower; on average by 1.5% per year in males and by 1.7% in females (*Figure 4*). More than half of the crude incidence rate increase is a consequence of ageing of the population. In the last 10 years, the average annual increase in cumulative incidence rate in males was 1.4% and 0.4% in females. Cumulative mortality rate is decreasing in both sexes in the last 10 years, in males on average by 1.7% and in females on average by 1.2% annually. The decreasing mortality despite increasing incidence indicates improvement in treatment of cancer patients. It is a proof that more and more are cured of or living with and not dying from cancer.

The time trends of common cancers in males show that lung cancer incidence was increasing till the beginning of the nineties, while it became stable onwards (85/100.000) and is slowly decreasing (by 1.4% per year on average) and was finally overcome by prostate cancer (average increase by 8.1% per year) and colorectal cancer (average increase by 4.0% per year). The huge increase in prostate cancer



incidence rate in the last years is not due to some new risk factor, but more frequent use of prostate specific antigen (PSA) test as an opportunistic screening method, resulting in detection of many cancers that would have never progressed or would even not have been detected during lifetime without screening. In the last 10 years the incidence rate of head and neck cancer is not changing. In females, the incidence rate of breast, lung and uterine corpus cancer is increasing, while the incidence of cervical cancer is slowly decreasing since 2003. In both sexes, the incidence of cancers of colon and rectum, melanoma and other skin cancer is increasing as in other countries, while the incidence of stomach cancer is decreasing. The average annual percentage changes of incidence rates are presented in *Figure 5*.

In *Figure 6*, five-year relative survival of all cancer patients (without patients with non-melanoma skin cancer) and patients with cancer of selected sites diagnosed in 2008–2012 is presented and compared to those diagnosed in 2003–2007. In males, the overall five-year relative survival increased for 7 percentage points, especially because of better detection and reporting of earlier stage prostate cancer with better prognosis, as for these patients with the most common male cancer the survival increased for 7 percentage points. As 95% confidence intervals are not overlapping, it can be concluded that the difference is statistically significant. In females, the overall survival in both time periods was nearly the same, almost 59%; the survival increased for patients with colorectal and thyroid cancer and skin melanoma.

In *Figure 7* average annual percentage changes of crude and age standardised incidence rates of all and most frequent cancers these cancers. In males, both rates were increasing more than in females (even if non-melanoma skin cancer is excluded). In both sexes, the increase of crude rates is bigger than of age standardised, meaning that ageing of population is more important risk factor than all others from the environment. It is important to note that in males, the incidence rate of bladder, head and neck, stomach and lung cancer is decreasing (of cancers associated with smoking), while in females the incidence rates of cancers of uterine corpus, stomach and ovary are decreasing.

The most frequent cancers vary by age. In children and adolescents till the age of 20, cancer is a very rare disease; in the last 5 years (2008–2012) it was diagnosed in 34 boys and 30 girls on average per year. In boys, the most frequent were leukaemias (28.0%), followed by tumours of central and autonomous nervous system (17.3%) and testicular cancer (10.7%), while in girls the most frequent were leukaemias (24.7%), while tumours of central and autonomous nervous system and Hodgkin's lymphoma were sharing the second place (13.3%). In young adult males (aged 20–34) there were on average 126 new cases per year; the most frequent cancer sites were testis (40.1%), followed by equal percentage of melanoma and non-melanoma skin cancer (10.0% each) In younger females (151 new cases on average per year) the most common were breast cancer and skin melanoma (17.1% each), followed by and thyroid cancer (13.1%) (*Figure 8*).

In the majority of new cases, the diagnosis was confirmed microscopically. *Table 3* shows that in 2012, in 94.1% % from 13,277 newly diagnosed cancer cases, the

diagnosis was confirmed by histology or by cytology, in 5.7% with other investigations and only 0.2% of cases were registered from death certificate only. This latter percentage has been similar for several years and represents the patients not treated in the hospital due to age or advanced disease. *Table 3* presents the number of new cases by cancer site by basis of diagnosis, while in *Table 4* their distribution by 5-year age group is presented. In *Table 5*, there are age specific incidence rates for all and specific cancer sites.

In *Table 6a*, the number of new cases of all and selected cancer sites by different statistical regions is presented. While these data are important for planning health care facilities, the age standardised rates in *Table 6b* indicate the differences in the risk of cancer, as these differences are not due to different age structure of population in these regions.

The morphology of tumours in 12,498 microscopically diagnosed cases is presented in *Table 7*. In this table, cases confirmed by histology (95%) and by cytology only (5%) are presented separately.

Table 8 shows the distribution of cancer patients by stage at diagnosis. A simplified definition of stages at diagnosis is used, which takes into account all investigation methods, including surgery or autopsy in case the patient has not been treated before death.

Age distribution of extra nodal and nodal sites of non-Hodgkin's malignant lymphomas is presented in *Table 9*. Owing to a small number of extra nodal sites, only the absolute numbers are given.

Table 10 shows the distribution of malignant neoplasms of lymphoid tissue according to 2008 version of Classification of Tumours of Haematopoietic and Lymphoid Tissues, published by World Health Organization.

Table 11 presents basic data on cancer patients' treatment. As in many cases combined treatment is applied, the sum of patients treated by different modalities is bigger than the number of new cases. *Table 11a* presents the mode of treatment of all cancer patients. *Tables 11b* and *11c* show the hospital where patients had surgery and/or systemic treatment as primary treatment; radiotherapy is performed at Institute of Oncology Ljubljana only (with few exceptions, irradiated abroad).

In *Table 12*, prevalence of all cancer patients and patients with selected cancer diseases on December 31, 2012 is presented. Along with lifetime prevalence, there is also partial prevalence (1-, 3-, 5- and 10-years).

In *Table 13*, there are official data on cancer mortality in 2012. The data for this table have been prepared at the National Institute of Public Health of the RS. Crude and age standardised mortality rates are available on the internet portal Slora (<http://www.slora.si/en/>).

Acknowledgement

Physicians, nurses, and the administrative staff from the Slovenian hospitals and other health institutions have been conscientiously providing data on new cancer cases, on the course of each individual disease as well as of its eventual outcome. If data on new cases had been incomplete, they effectively sought/willingly completed the missing information. If data necessary for the Registry had not been available in hospitals, they were kindly provided by the family and general physicians.

At least half of data presented in the current report have been contributed by Mrs. Maruška Ferjančič and Mrs. Polona Škulj from the Ljubljana Institute of Oncology Hospital Registry. The pathologist Dr. Gorana Gašljević helped us with proper coding of histological diagnoses of malignant neoplasms of lymphoid tissue

The Report could not be published – at least with the currently assured high credibility of data – without the traditional good cooperation of the Republic of Slovenia Population Registry, National Institute of Public Health of RS, and Statistical Office of RS.

The Registry is grateful to the above mentioned as well as to all others who have contributed to the current Report.


Editors

- Ravnihar B, Gruden I. Statističen pregled in kratka analiza prijavljenih rakovnih obolenj iz področja LRS za leto 1950. *Zdrav Vestn* 1951; 20: 264–77.
- Epidemiological and vital statistics report. Geneva: World Health Organization, 1961–1966.
- World health statistics report. Geneva: World Health Organization, 1970–1974.
- Rak v Sloveniji (1965–77). Ljubljana: Onkološki inštitut, Register raka za Slovenijo, 1967–1980.
- Incidenca raka v Sloveniji (1978–2001). Ljubljana: Onkološki inštitut, Register raka za Slovenijo, 1981–2004.
- Doll R, Payne P, Waterhouse J, eds. Cancer incidence in five continents. Vol 1. Berlin: Springer, 1966.
- Doll R, Muir C, Waterhouse J, eds. Cancer incidence in five continents. Vol 2. Lyon: International Agency for Research on Cancer, 1970.
- Waterhouse J, Muir C, Correa C, Powell J, eds. Cancer incidence in five continents. Vol 3. Lyon: International Agency for Research on Cancer, 1976 (IARC Sci Publ 15).
- Waterhouse J, Muir C, Shanmugaratnam K, Powell J, eds. Cancer incidence in five continents. Vol 4. Lyon: International Agency for Research on Cancer, 1982 (IARC Sci Publ 42).
- Muir C, Waterhouse J, Mack T, Powell J, Whelan S, eds. Cancer incidence in five continents. Vol 5. Lyon: International Agency for Research on Cancer, 1987 (IARC Sci Publ 88).
- Parkin DM, Muir C, Whelan S, Gao Y, Ferlay J, Powell J, eds. Cancer incidence in five continents Lyon. Vol 6. International Agency for Research on Cancer, 1992 (IARC Sci Publ 120).
- Parkin DM, Whelan S, Ferlay J, Raymond L, Young J, eds. Cancer incidence in five continents. Vol 7. Lyon: International Agency for Research on Cancer, 1997 (IARC Sci Publ 143).
- Parkin DM, Whelan S, Ferlay J, Teppo L, Thomas DB, eds. Cancer incidence in five continents. Vol 8. Lyon: International Agency for Research on Cancer, 2002 (IARC Sci Publ 155).
- Curado MP, Edwards B, Shin HR, Storm H, Ferlay J, Heanue M, Boyle P, eds. Cancer incidence in five continents. Vol 9. Lyon: International Agency for Research on Cancer, 2007 (IARC Sci Publ 160).
- Forman D, Bray F, Brewster DH, Gombe Mbalawa C, Kohler B, Piñeros M, Steliarova-Foucher E, Swaminathan R and Ferlay J eds. Cancer Incidence in Five Continents, Vol. X (electronic version) Lyon, IARC, 2013. URL: <http://ci5.iarc.fr>.
- Ferlay J, Soerjomataram I, Ervik M, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D, Bray, F. GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11 [Internet]. Lyon, France: International Agency for Research on Cancer; 2013. URL: <http://globocan.iarc.fr>.
- Steliarova-Foucher E, O'Callaghan M, Ferlay J, Masuyer E, Forman D, Comber H, Bray F: European Cancer Observatory: Cancer Incidence, Mortality, Prevalence and Survival in Europe. Version 1.0 (September 2012) European Network of Cancer Registries, International Agency for Research on Cancer. URL: <http://eco.iarc.fr>.
- Berrino F, Capocaccia R, Esteve J et al, eds. Survival of cancer patients in Europe: the EUROCORE-2 study. Lyon: International Agency for Research on Cancer, 1999.
- Berrino F, Capocaccia R, Gatta G et al, eds. Survival of cancer patients in Europe: the EUROCORE-3 study. *Ann Oncol* 2003; 14 (Suppl 5).
- Berrino F, DeAngelis R, Sant M et al. Survival for eight major cancers and all cancers combined for European adults diagnosed in 1995–1999: Results of the EUROCORE-4 study. *Lancet Oncol* 2007; 8: 773–83.
- De Angelis R, Sant M, Coleman MP et al. Cancer survival in Europe 1999–2007 by country and age: results of EUROCORE-5 - a population-based study. *Lancet Oncol* 2013; published online Dec 5.
- Gatta G, Botta L, Rossi S et al. Childhood cancer survival in Europe 1999–2007: results of EUROCORE-5 - a population-based study. *Lancet Oncol* 2013; published online Dec 5.
- Gatta G, van der Zwan JM, Casali PG et al. Rare cancers are not so rare: the rare cancer burden in Europe. *Eur J Cancer* 2011; 47; 2493–511.
- Pompe-Kirn V, Primic Žakelj M, Ferligoj A, Škrk J. Zemljevidi incidence raka v Sloveniji 1978–1987 (Atlas of cancer incidence in Slovenia 1978–1987). Ljubljana: Onkološki inštitut, Register raka za Slovenijo, 1992.
- Pompe-Kirn V, Zakotnik B, Benulič T, Volk N, Škrk J. Preživetje bolnikov z rakom v Sloveniji 1963–1990 (Cancer patients' survival in Slovenia 1963–1990). Ljubljana: Onkološki inštitut, Register raka za Slovenijo, 1995.
- Pompe-Kirn V, Zakotnik B, Zadnik V. Preživetje bolnikov z rakom v Sloveniji 1983–1997 (Cancer patients' survival in Slovenia 1983–1997). Ljubljana: Onkološki inštitut, Register raka za Slovenijo, 2003.

- Primic-Žakelj M, Zadnik V, Žagar T, Zakotnik B. Preživetje bolnikov z rakom, zbolelih v letih 1991–2005 v Sloveniji (Survival of cancer patients, diagnosed in 1991–2005 in Slovenia). Ljubljana: Onkološki inštitut, 2009.
- Uredba o standardni klasifikaciji teritorialnih enot – SKTE. Ur. l. RS št. 28/2000.
- Savezni zavod za zdravstveno zaščito. Mednarodna klasifikacija bolezni, povreda i uzroka smrti. 8. revizija. Novi sad: Savezni zavod za zdravstveno zaščito, 1970.
- Inštitut za varovanje zdravja RS. Mednarodna klasifikacija bolezni in sorodnih zdravstvenih problemov za statistične namene. 10. revizija (International statistical classification of diseases and related health problems). Ljubljana: Inštitut za varovanje zdravja, 1995.
- World Health Organisation. International statistical classification of diseases and related health problems. Tenth revision, edition 2010 (4th edition). Geneva: WHO Press, 2011.
- World Health Organisation. International classification of diseases for Oncology. 3rd Edition. Geneva: World Health Organisation, 2000.
- World Health Organisation. International Classification of Diseases for Oncology, Third Edition, First Revision. Geneva: World Health Organization, 2013.
- Swerdlow SH., Campo E, Harris NL et al, eds. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. WHO/IARC Classification of Tumours, 4th Edition, Volume 2. Geneva: World Health Organization, 2008.
- Jensen OM, Parkin M et al, eds. Cancer registration: principles and methods. Lyon: International Agency for Research on Cancer, 1991. (IARC Sci Publ 95).
- Dos Santos Silva I. Cancer epidemiology: principles and methods. Lyon: International Agency for Research on Cancer, 1999.
- Moller B, Fekjaer H, Hakulinen T et al. Prediction of cancer incidence in the Nordic countries: empirical comparison of different approaches. Stat Med 2003; 15: 2751–66.
- SI-STAT podatkovni portal. Ljubljana, Statistični urad Republike Slovenije, 2014. URL: <http://pxweb.stat.si/>.
- SI-STAT Data Portal. Ljubljana, Statistical Office of Republic of Slovenia, 2014. URL: <http://pxweb.stat.si/>.
- Dyba T, Hakulinen T, Pääväranta L. A simple non-linear model in incidence prediction. Statistics in Medicine 16: 2297–309, 1997.
- Kim HJ, Fay MP, Feuer EJ, Midthune DN. Permutation tests for joinpoint regression with applications to cancer rates. Statistics in medicine 2000; 19(3): 335–51.
- Pohar M, Stare J. Relative survival analysis in R. Computer Methods and Programs in Biomedicine 2006; 81: 272–8.
- Žagar T. Lifetables for Slovenia 1982–2007. Rostock: Max Planck, 2008.
URL: <http://www.lifetable.de/cgi-bin/Country.plx?Country=Slovenia>.


Slika 1: Breme raka, Slovenija 2012.

Figure 1: Cancer burden, Slovenia 2012.




Slika 2: Odstotni delež vseh rakov po starostnih skupinah in spolu, Slovenija 2012.


Figure 2: Percentage distribution of all cancer sites by age group and by sex, Slovenia 2012.



Slika 3: Najpogostejše lokacije raka in njihov odstotni delež po spolu in pri obeh spolih skupaj, Slovenija 2012.
Figure 3: The leading cancer sites with percentage distribution by sex and for both sexes together, Slovenia 2012.



MOŠKI IN ŽENSKE / MALES AND FEMALES



* Pojasnilo / Explanation:

Glava in vrat / Head and neck (C00–C14, C30–C32)



Debelo črevo in danka / Colorectum (C18–C20)

Sapnik, sapnici in pljuča / Trachea, bronchus and lung (C33–C34)

Ledvica z ledvičnim mehom / Kidney with renal pelvis (C64–C65)

Slika 4: Groba in kumulativna letna incidenčna in umrljivostna stopnja vseh rakov po spolu s povprečno letno spremembo za zadnjih 10 let, Slovenija 1950–2012.

Figure 4: Crude and cumulative annual incidence and mortality rates for all cancer sites by sex with average annual change in last 10 years, Slovenia 1950–2012.




* Povprečna letna sprememba je statistično značilna pri stopnji tveganja 0,05

* Average annual change is statistically significant at 0.05 significance level

Slika 5: Groba letna incidenčna stopnja izbranih rakov po spolu s povprečno letno spremembo za zadnjih 10 let, Slovenija 1950–2012.

Figure 5: Crude annual incidence rates of selected primary cancer sites by sex with average annual change in last 10 years, Slovenia 1950–2012.




* Povprečna letna sprememba je statistično značilna pri stopnji tveganja 0,05

* Average annual change is statistically significant at 0.05 significance level


Slika 6: Petletno relativno preživetje (s 95 % intervalom zaupanja) bolnikov, zbolelih za izbranimi raki v letih 2003–2007 in 2008–2012 po spolu.

Figure 6: Five-year relative survival (with 95% confidence interval) of patients diagnosed with selected cancers in periods 2003–2007 and 2008–2012 by sex.




Slika 6: Nadaljevanje.
Figure 6: Continued.

ŽENSKE / FEMALES



Slika 6: Nadaljevanje.


Figure 6: Continued.




Slika 7: Povprečni letni delež spremembe grobe in starostno standardizirane (SSS; po svetovni standardni populaciji) incidenčne stopnje desetih najpogostejših rakov po spolu, Slovenija 2003–2012.

Figure 7: Average annual percentage change in crude and age standardized (ASR; according to World standard population) incidence rates for ten leading cancer sites by sex, Slovenia 2003–2012.

MOŠKI / MALES



ŽENSKE / FEMALES



** Pojasnilo / Explanation:

Glava in vrat / Head and neck (C00–C14, C30–C32)

Debelo črevo in danka / Colorectum (C18–C20)

Ledvica z ledvičnim mehom / Kidney with renal pelvis (C64–C65)


NHL: ne-Hodgkinovi limfomi / NHL: non-Hodgkin's lymphoma (C82–C85)

* Povprečna letna sprememba je statistično značilna pri stopnji tveganja 0,05

* Average annual change is statistically significant at 0.05 significance level

Slika 8: Odstotni deleži napogostejših rakov po starostnih skupinah in spolu, Slovenija 2008–2012.
Figure 8: Percentage distribution of leading cancer sites by age group and by sex, Slovenia 2008–2012.

MOŠKI / MALES



Pojasnilo / Explanation:

Glava in vrat / Head and neck (C00–C14, C30–C32)

Želodec / Stomach (C16)

Debelo črevo in danka / Colorectum (C18–C20)

Pljuča / Lung (C33–C34)

Kosti / Bone (C40–C41)

Koža, melanom / Skin, melanoma (C43)

Koža, razen melanoma / Skin, non-melanoma (C44)

Prostata / Prostate (C61)

Modo / Testis (C62)

Ledvica z ledvičnim mehom / Kidney with renal pelvis (C64–C65)

Sečni mehur / Bladder (C67)

Centralni in avtonomni živčni sistem / Central and autonomic nervous system (C70–C72)


Hodgkinova bolezen / Hodgkin's disease (C81)

Ne-Hodgkinovi limfomi (NHL) / Non-Hodgkin's lymphoma (NHL) (C82–C85)

Levkemije / Leukaemias (C91–C95)

Slika 8: Nadaljevanje.
Figure 8: Continued.

ŽENSKE / FEMALES



Pojasnilo / Explanation:

Želodec / Stomach (C16)

Debelo črevo in danka / Colorectum (C18–C20)

Trebušna slinavka / Pancreas (C25)

Pljuča / Lung (C33–C34)

Koža, melanom / Skin, melanoma (C43)

Koža, razen melanoma / Skin, non-melanoma (C44)

Vezivno in mehko tkivo / Connective and soft tissue (C48–C49)

Dojka / Breast (C50)

Maternični vrat / Cervix uteri (C53)

Maternično telo / Corpus uteri (C54)

Jajčnik / Ovary (C56)

Centralni in avtonomni živčni sistem / Central and autonomic nervous system (C70–C72)

Ščitnica / Thyroid gland (C73)

Hodgkinova bolezen / Hodgkin's disease (C81)

Levkemije / Leukaemias (C91–C95)

Tabela 1: Opazovana in ocenjena incidenca raka, Slovenija 2003–2012 in 2015.

Table 1: Observed and estimated cancer incidence, Slovenia 2003–2012 and 2015.

Šifra MKB ICD code	Primarna lokacija Primary site	Spol Sex	Povprečne letne opazovane vrednosti 2003–2007		Povprečne letne opazovane vrednosti 2008–2012		Ocena za 2015			
			Število	Incidenčna stopnja na 100.000	Število	Incidenčna stopnja na 100.000	Število (95 % napovedni interval)		Incidenčna stopnja na 100.000 (95 % napovedni interval)	
							Average annual observed values 2003–2007		Average annual observed values 2008–2012	
Number	Incidence rate per 100,000	Number	Incidence rate per 100,000	Number (95% prediction interval)		Incidence rate per 100,000 (95% prediction interval)				
C00–C96	Vse lokacije All sites	M+Ž	11180	557,6	12899	630,8	14611	14297–14926	708	693–724
		M	5811	590,9	6997	691,8	8231	7994–8467	805	782–828
		Ž	5369	525,6	5902	571,2	6381	6173–6589	613	593–633
C00–C14	Usta in žrelo Mouth and pharynx	M	255	25,9	273	27,0	278	234–322	27	23–32
		Ž	65	6,4	70	6,8	75	51–99	7	5–10
C15	Požiralnik Oesophagus	M	76	7,7	67	6,7	64	44–85	6	4–8
		Ž	16	1,6	17	1,6	16	6–27	2	1–3
C16	Želodec Stomach	M	292	29,7	293	29,0	288	243–332	28	24–32
		Ž	182	17,8	184	17,8	176	142–211	17	14–20
C18	Debelo črevo Colon	M	392	39,9	527	52,1	657	589–724	64	58–71
		Ž	328	32,1	400	38,7	457	401–513	44	39–49
C19–C20	Rektum in rektosigmoidna zveza Rectum and rectosigmoid junction	M	341	34,7	414	40,9	469	411–527	46	40–52
		Ž	237	23,2	245	23,7	243	201–285	23	19–27
C22	Jetra in intrahepatični vodi Liver and intrahepatic bile ducts	M	105	10,7	122	12,0	157	124–190	15	12–19
		Ž	47	4,6	44	4,3	42	24–60	4	2–6
C23–C24	Žolčnik in žolčevodi Gallbladder and biliary tract	M	56	5,7	69	6,8	82	57–106	8	6–10
		Ž	90	8,8	102	9,8	128	98–158	12	9–15
C25	Trebušna slinavka Pancreas	M	138	14,0	169	16,7	213	174–251	21	17–25
		Ž	143	14,0	180	17,4	210	171–248	20	16–24
C32	Grlo Larynx	M	97	9,9	92	9,1	90	65–114	9	6–11
		Ž	11	1,1	11	1,1	11	2–21	1	0–2
C33–C34	Sapnik, sapnici in pljuča Trachea, bronchus and lung	M	906	92,2	866	85,6	816	743–890	80	73–87
		Ž	308	30,1	367	35,5	429	375–483	41	36–46
C43	Maligni melanom kože Malignant melanoma of skin	M	176	17,9	234	23,1	296	252–340	29	25–33
		Ž	198	19,4	246	23,8	295	250–339	28	24–33
C44	Druge maligne neoplazme kože Skin, other malignomas	M	808	82,2	1051	103,9	1323	1226–1419	129	120–139
		Ž	895	87,6	1090	105,4	1250	1157–1343	120	111–129
C48–C49	Vezivno in mehko tkivo Connective and soft tissue	M	27	2,7	28	2,8	28	14–42	3	1–4
		Ž	37	3,6	38	3,7	41	28–54	4	3–5
C50	Dojka Breast	M	8	0,8	12	1,2	16	4–27	2	0–3
		Ž	1129	110,5	1208	116,9	1287	1192–1382	124	115–133
C53	Maternični vrat Cervix uteri	M	—	—	—	—	—	—	—	—
		Ž	181	17,8	132	12,8	106	82–130	10	8–12
C54	Maternično telo Corpus uteri	M	—	—	—	—	—	—	—	—
		Ž	296	28,9	304	29,4	323	275–371	31	26–36
C56	Jajčnik Ovary	M	—	—	—	—	—	—	—	—
		Ž	180	17,6	165	16,0	148	117–179	14	11–17
C61	Prostata Prostate	M	916	93,1	1402	138,6	1914	1801–2026	187	176–198
		Ž	—	—	—	—	—	—	—	—
C62	Modo Testis	M	98	9,9	104	10,2	100	74–126	10	7–12
		Ž	—	—	—	—	—	—	—	—
C64–C65	Ledvica z ledvičnim mehom Kidney with renal pelvis	M	181	18,4	232	22,9	283	239–328	28	23–32
		Ž	104	10,2	116	11,3	126	96–156	12	9–15
C67	Sečni mehur Bladder	M	199	20,2	216	21,4	239	196–281	23	19–28
		Ž	71	6,9	78	7,6	86	61–111	8	6–11
C70–C72	Centralni in avtonomni živčni sistem Central and autonomic nervous system	M	76	7,8	78	7,7	77	53–101	8	5–10
		Ž	63	6,2	64	6,2	63	42–85	6	4–8
C73	Ščitnica Thyroid gland	M	28	2,9	38	3,8	50	30–70	5	3–7
		Ž	108	10,6	116	11,3	114	92–136	11	9–13
C81	Hodgkinova bolezen Hodgkin's disease	M	29	2,9	23	2,3	18	8–29	2	1–3
		Ž	19	1,9	25	2,4	25	12–38	2	1–4
C82–C85	Ne-Hodgkinovi limfomi Non-Hodgkin's lymphoma	M	116	11,8	158	15,6	199	163–236	19	16–23
		Ž	139	13,6	158	15,3	164	138–191	16	13–18
C90	Difuzni plazmocitom in maligne neoplazme plazmocitov Multiple myeloma and malignant plasma cell neoplasms	M	54	5,5	65	6,5	77	53–101	7	5–10
		Ž	56	5,5	58	5,6	62	41–83	6	4–8
C91–C95	Levkemije Leukaemias	M	132	13,4	146	14,4	167	140–193	16	14–19
		Ž	103	10,1	111	10,7	120	97–143	12	9–14

Tabela 2: Incidenca, groba incidenčna stopnja in po svetovni, evropski ter slovenski standardni populaciji standardizirane incidenčne stopnje raka, Slovenija 2012.

Table 2: Incidence, crude incidence rate and according to World, European and Slovenian standard population standardized cancer incidence rates, Slovenia 2012.

Šifra MKB ICD code	Primarna lokacija Primary site	Spol Sex	Število Number	Groba incidenčna stopnja na 100.000 Crude incidence rate per 100,000	SSS* – svetovni standard ASR** – World standard	SSS* – evropski standard ASR** – European standard	SSS* – slovenski standard ASR** – Slovenian standard
C00–C96	Vse lokacije All sites	M+Ž	13277	645,7	328,9	468,2	555,0
		M	7240	711,6	391,8	573,2	693,3
		Ž	6037	581,1	284,2	395,7	460,8
C00–C14	Usta in žrelo Mouth and pharynx	M	271	26,6	16,1	22,0	24,6
		Ž	66	6,4	3,5	4,8	5,3
C15	Požiralnik Oesophagus	M	73	7,2	4,0	5,8	7,0
		Ž	14	1,3	0,6	0,9	1,1
C16	Želodec Stomach	M	294	28,9	15,4	23,1	28,5
		Ž	167	16,1	6,5	9,7	11,7
C18	Debelo črevo Colon	M	534	52,5	27,5	41,6	51,2
		Ž	387	37,3	16,1	23,3	28,0
C19–C20	Rektum in rektosigmoidna zveza Rectum and rectosigmoid junction	M	389	38,2	20,8	30,7	37,2
		Ž	220	21,2	9,4	13,7	16,3
C22	Jetra in intrahepatični vodi Liver and intrahepatic bile ducts	M	161	15,8	8,6	12,7	15,3
		Ž	40	3,9	1,5	2,3	2,9
C23–C24	Žolčnik in žolčevodi Gallbladder and biliary tract	M	72	7,1	3,3	5,5	7,0
		Ž	106	10,2	3,3	5,3	6,8
C25	Trebušna slinavka Pancreas	M	183	18,0	9,2	14,2	17,6
		Ž	173	16,7	6,4	9,6	11,8
C32	Grlo Larynx	M	77	7,6	4,4	6,2	7,2
		Ž	13	1,3	0,8	1,1	1,1
C33–C34	Sapnik, sapnici in pljuča Trachea, bronchus and lung	M	872	85,7	46,5	68,7	82,0
		Ž	385	37,1	18,3	26,0	29,7
C43	Maligni melanom kože Malignant melanoma of skin	M	257	25,3	15,5	21,0	24,6
		Ž	259	24,9	15,5	19,6	22,2
C44	Druge maligne neoplazme kože Skin, other malignomas	M	1175	115,5	59,8	91,8	114,5
		Ž	1157	111,4	46,0	67,7	82,0
C48–C49	Vezivno in mehko tkivo Connective and soft tissue	M	32	3,1	1,8	2,6	3,0
		Ž	46	4,4	2,7	3,3	3,6
C50	Dojka Breast	M	15	1,5	0,8	1,2	1,4
		Ž	1296	124,8	69,9	94,6	106,9
C53	Maternični vrat Cervix uteri	M	—	—	—	—	—
		Ž	118	11,4	7,7	9,6	10,6
C54	Maternično telo Corpus uteri	M	—	—	—	—	—
		Ž	336	32,3	16,3	23,0	26,4
C56	Jajčnik Ovary	M	—	—	—	—	—
		Ž	155	14,9	8,7	11,6	13,0
C61	Prostata Prostate	M	1425	140,1	75,4	111,5	136,9
		Ž	—	—	—	—	—
C62	Modo Testis	M	105	10,3	9,2	9,7	10,4
		Ž	—	—	—	—	—
C64–C65	Ledvica z ledvičnim mehom Kidney with renal pelvis	M	229	22,5	12,5	18,2	21,6
		Ž	109	10,5	4,7	6,9	8,1
C67	Sečni mehur Bladder	M	224	22,0	11,0	17,3	21,4
		Ž	80	7,7	2,9	4,4	5,5
C70–C72	Centralni in avtonomni živčni sistem Central and autonomic nervous system	M	59	5,8	4,4	5,2	5,7
		Ž	63	6,1	3,8	4,7	5,2
C73	Ščitnica Thyroid gland	M	42	4,1	2,7	3,5	3,9
		Ž	107	10,3	7,5	9,0	9,7
C81	Hodgkinova bolezen Hodgkin's disease	M	17	1,7	1,4	1,5	1,6
		Ž	17	1,6	1,6	1,6	1,7
C82–C85	Ne-Hodgkinovi limfomi Non-Hodgkin's lymphoma	M	177	17,4	9,8	14,3	17,0
		Ž	194	18,7	8,4	12,0	14,3
C90	Difuzni plazmocitom in maligne neoplazme plazmocitov Multiple myeloma and malignant plasma cell neoplasms	M	71	7,0	3,9	5,7	6,9
		Ž	57	5,5	2,3	3,4	4,0
C91–C95	Levkemije Leukaemias	M	152	14,9	9,5	12,6	14,5
		Ž	105	10,1	6,1	7,4	8,2

* SSS – starostno standardizirana incidenčna stopnja na 100.000

**ASR – age-standardised incidence rate per 100,000

Tabela 3: Incidenca raka glede na način postavitve diagnoze po lokaciji in spolu, Slovenija 2012.

Table 3: Cancer incidence according to basis of diagnosis by site and by sex, Slovenia 2012.

Šifra MKB ICD code	Primarna lokacija Primary site	Spol Sex	Število novih primerov Number of new cases	Mikroskopsko potrjeni primeri		Ugotovljeni z drugimi preiskavami		Registrirani samo iz zdravniških poročil o vzroku smrti	
				Število	%*	Število	%*	Število	%*
				Microscopically confirmed cases		Confirmed by other investigations		Registered from death certificates only	
				Number	%*	Number	%*	Number	%*
C00–C96	Vse lokacije All sites	M+Ž	13277	12498	94,1	757	5,7	22	0,2
		M	7240	6843	94,5	391	5,4	6	0,1
		Ž	6037	5655	93,7	366	6,1	16	0,3
C00	Ustnica Lip	M	14	14	—	0	—	0	—
		Ž	6	6	—	0	—	0	—
C01	Baza jezika Base of tongue	M	24	24	100	0	0	0	0
		Ž	4	4	—	0	—	0	—
C02	Jezik, drugi deli Tongue, other & unspecified parts	M	22	21	95,5	1	4,5	0	0
		Ž	5	5	—	0	—	0	—
C03	Dlesen Gum	M	7	7	—	0	—	0	—
		Ž	7	7	—	0	—	0	—
C04	Ustno dno Floor of mouth	M	27	27	100	0	0	0	0
		Ž	8	8	—	0	—	0	—
C05	Nebo Palate	M	18	18	100	0	0	0	0
		Ž	4	4	—	0	—	0	—
C06	Usta, drugi deli Mouth, other & unspecified parts	M	9	9	—	0	—	0	—
		Ž	3	3	—	0	—	0	—
C07	Parotidna žleza Parotid gland	M	3	3	—	0	—	0	—
		Ž	5	5	—	0	—	0	—
C08	Druge in neopredeljene velike žleze slinavke Other & unspecified major salivary glands	M	4	4	—	0	—	0	—
		Ž	1	1	—	0	—	0	—
C09	Tonzila Tonsil	M	43	43	100	0	0	0	0
		Ž	6	6	—	0	—	0	—
C10	Orofarinks Oropharynx	M	44	43	97,7	1	2,3	0	0
		Ž	7	7	—	0	—	0	—
C11	Nazofarinks Nasopharynx	M	5	5	—	0	—	0	—
		Ž	5	5	—	0	—	0	—
C12	Piriformni sinus Pyriform sinus	M	32	32	100	0	0	0	0
		Ž	2	2	—	0	—	0	—
C13	Hipofarinks Hypopharynx	M	18	18	100	0	0	0	0
		Ž	3	3	—	0	—	0	—
C14	Druge in slabo opredeljena mesta na ustnici, v ustni votlini in farinksu Other and ill-defined sites in the lip, oral cavity and pharynx	M	1	1	—	0	—	0	—
		Ž	0	0	—	0	—	0	—
C15	Požiralnik Oesophagus	M	73	71	97,3	2	2,7	0	0
		Ž	14	13	—	1	—	0	—
C16	Želodec Stomach	M	294	284	96,6	10	3,4	0	0
		Ž	167	156	93,4	11	6,6	0	0
C17	Tanko črevo Small intestine	M	17	17	100	0	0	0	0
		Ž	15	14	93,3	1	6,7	0	0
C18	Debelo črevo Colon	M	534	525	98,3	8	1,5	1	0,2
		Ž	387	357	92,2	29	7,5	1	0,3
C19	Rektosigmoidna zveza Rectosigmoid junction	M	79	78	98,7	1	1,3	0	0
		Ž	46	44	95,7	2	4,3	0	0
C20	Rektum Rectum	M	310	307	99,0	3	1,0	0	0
		Ž	174	163	93,7	11	6,3	0	0
C21	Anus in analni kanal Anus and anal canal	M	4	4	—	0	—	0	—
		Ž	6	6	—	0	—	0	—
C22	Jetra in intrahepatični vodi Liver and intrahepatic bile ducts	M	161	80	49,7	81	50,3	0	0
		Ž	40	18	45,0	22	55,0	0	0
C23	Žolčnik Gallbladder	M	16	4	25,0	11	68,8	1	6,3
		Ž	50	30	60,0	19	38,0	1	2,0
C24	Drugi in neopredeljeni deli biliarnega trakta Biliary tract, other and unspecified parts	M	56	34	60,7	22	39,3	0	0
		Ž	56	22	39,3	33	58,9	1	1,8

Nadaljevanje —>

Continued —>

Tabela 3: Nadaljevanje.

Table 3: Continued.

Šifra MKB ICD code	Primarna lokacija Primary site	Spol Sex	Število novih primerov Number of new cases	Mikroskopsko potrjeni primeri		Ugotovljeni z drugimi preiskavami		Registrirani samo iz zdravniških poročil o vzroku smrti	
				Število	%*	Število	%*	Število	%*
				Microscopically confirmed cases		Confirmed by other investigations		Registered from death certificates only	
				Number	%*	Number	%*	Number	%*
C25	Trebušna slinavka Pancreas	M	183	101	55,2	82	44,8	0	0
		Ž	173	84	48,6	88	50,9	1	0,6
C26	Druga in slabo opredeljena mesta v prebavnih organih Other and ill-defined digestive organs	M	2	1	—	1	—	0	—
		Ž	5	3	—	1	—	1	—
C30	Nosna votlina in srednje uho Nasal cavity and middle ear	M	8	8	—	0	—	0	—
		Ž	5	5	—	0	—	0	—
C31	Obnosni sinusi Accessory sinuses	M	4	4	—	0	—	0	—
		Ž	4	4	—	0	—	0	—
C32	Grlo Larynx	M	77	74	96,1	2	2,6	1	1,3
		Ž	13	13	—	0	—	0	—
C33	Sapnik Trachea	M	5	4	—	1	—	0	—
		Ž	1	1	—	0	—	0	—
C34	Sapnica in pljuča Bronchus and lung	M	867	821	94,7	45	5,2	1	0,1
		Ž	384	351	91,4	31	8,1	2	0,5
C37	Timus Thymus	M	3	3	—	0	—	0	—
		Ž	2	2	—	0	—	0	—
C38	Srce, mediastinum, plevra Heart, mediastinum, pleura	M	4	3	—	1	—	0	—
		Ž	2	1	—	1	—	0	—
C39	Druga in slabo opredeljena mesta v dihalih in prsni organih Other and ill-defined sites in the respiratory system and intrathoracic organs	M	0	0	—	0	—	0	—
		Ž	0	0	—	0	—	0	—
C40	Kosti, sklepni hrustanec udov Bone and articular cartilage of limbs	M	1	1	—	0	—	0	—
		Ž	5	5	—	0	—	0	—
C41	Kosti, sklepni hrustanec, drugje Bone and articular cartilage of other and unspecified parts	M	4	4	—	0	—	0	—
		Ž	5	5	—	0	—	0	—
C43	Maligni melanom kože Malignant melanoma of skin	M	257	257	100	0	0	0	0
		Ž	259	259	100	0	0	0	0
C44	Druge maligne neoplazme kože Skin, other malignomas	M	1175	1172	99,7	3	0,3	0	0
		Ž	1157	1152	99,6	5	0,4	0	0
C45	Mezoteliom Mesothelioma	M	32	32	100	0	0	0	0
		Ž	11	11	—	0	—	0	—
C46	Kaposijev sarkom Kaposi's sarcoma	M	5	5	—	0	—	0	—
		Ž	0	0	—	0	—	0	—
C47	Periferni živci in avtonomno živčevje Peripheral nerves and autonomic nervous system	M	1	1	—	0	—	0	—
		Ž	0	0	—	0	—	0	—
C48	Peritonej in retroperitonej Retroperitoneum and peritoneum	M	4	4	—	0	—	0	—
		Ž	17	17	100	0	0	0	0
C49	Drugo vezivno in mehko tkivo Other connective and soft tissue	M	28	28	100	0	0	0	0
		Ž	29	28	96,6	1	3,4	0	0
C50	Dojka Breast	M	15	15	100	0	0	0	0
		Ž	1296	1287	99,3	7	0,5	2	0,2
C51	Žensko zunanje spolovilo Vulva	M	—	—	—	—	—	—	—
		Ž	35	35	100	0	0	0	0
C52	Nožnica Vagina	M	—	—	—	—	—	—	—
		Ž	11	11	—	0	—	0	—
C53	Maternični vrat Cervix uteri	M	—	—	—	—	—	—	—
		Ž	118	117	99,2	1	0,8	0	0
C54	Maternično telo Corpus uteri	M	—	—	—	—	—	—	—
		Ž	336	334	99,4	2	0,6	0	0
C55	Maternica, neopredeljeno Uterus, unspecified	M	—	—	—	—	—	—	—
		Ž	15	14	93,3	0	0	1	6,7
C56	Jajčnik Ovary	M	—	—	—	—	—	—	—
		Ž	155	148	95,5	6	3,9	1	0,6

Tabela 3: Nadaljevanje.

Table 3: Continued.

Šifra MKB ICD code	Primarna lokacija Primary site	Spol Sex	Število novih primerov Number of new cases	Mikroskopsko potrjeni primeri		Ugotovljeni z drugimi preiskavami		Registrirani samo iz zdravniških poročil o vzroku smrti	
				Število	%*	Število	%*	Število	%*
				Microscopically confirmed cases		Confirmed by other investigations		Registered from death certificates only	
				Number	%*	Number	%*	Number	%*
C57	Drugi in neopredeljeni ženski spolni organi Other and unspecified parts of female genital organs	M	—	—	—	—	—	—	—
		Ž	10	10	—	0	—	0	—
C58	Posteljica Placenta	M	—	—	—	—	—	—	—
		Ž	0	0	—	0	—	0	—
C60	Penis Penis	M	10	10	—	0	—	0	—
		Ž	—	—	—	—	—	—	—
C61	Prostata Prostate	M	1425	1376	96,6	48	3,4	1	0,1
		Ž	—	—	—	—	—	—	—
C62	Modo Testis	M	105	105	100	0	0	0	0
		Ž	—	—	—	—	—	—	—
C63	Drugi in neopredeljeni moški spolni organi Other and unspecified male genital organs	M	3	3	—	0	—	0	—
		Ž	—	—	—	—	—	—	—
C64	Ledvica razen meha Kidney, except renal pelvis	M	211	200	94,8	11	5,2	0	0
		Ž	100	85	85,0	15	15,0	0	0
C65	Ledvični meh Renal pelvis	M	18	17	94,4	1	5,6	0	0
		Ž	9	6	—	3	—	0	—
C66	Sečevod Ureter	M	14	13	—	1	—	0	—
		Ž	8	8	—	0	—	0	—
C67	Sečni mehur Bladder	M	224	221	98,7	3	1,3	0	0
		Ž	80	76	95,0	3	3,8	1	1,3
C68	Drugi in neopredeljeni sečni organi Other and unspecified urinary organs	M	0	0	—	0	—	0	—
		Ž	1	1	—	0	—	0	—
C69	Okoli očesni adneksi Eye and adnexa	M	14	14	—	0	—	0	—
		Ž	6	6	—	0	—	0	—
C70	Meninge Meninges	M	1	1	—	0	—	0	—
		Ž	2	2	—	0	—	0	—
C71	Možgani Brain	M	58	52	89,7	6	10,3	0	0
		Ž	61	52	85,2	9	14,8	0	0
C72	Hrbtani mozeg, možganski živci in drugi deli CŽS Spinal cord, cranial nerves and other parts of CNS	M	0	0	—	0	—	0	—
		Ž	0	0	—	0	—	0	—
C73	Ščitnica Thyroid gland	M	42	42	100	0	0	0	0
		Ž	107	107	100	0	0	0	0
C74	Nadledvična žleza Adrenal gland	M	2	2	—	0	—	0	—
		Ž	4	4	—	0	—	0	—
C75	Druge endokrine žleze in sorodne strukture Other endocrine glands and related structures	M	0	0	—	0	—	0	—
		Ž	1	1	—	0	—	0	—
C76	Druga in slabo opredeljena mesta Other and ill-defined sites	M	9	5	—	4	—	0	—
		Ž	35	19	54,3	15	42,9	1	2,9
C77	Metastaza in neopredeljena maligna neoplazma bezgavk Metastasis and unspecified malignant neoplasm of lymph nodes	M	20	20	100	0	0	0	0
		Ž	7	7	—	0	—	0	—
C78	Metastaze dihal in prebavil Metastases of respiratory and digestive organs	M	31	17	54,8	13	41,9	1	3,2
		Ž	52	24	46,2	27	51,9	1	1,9
C79	Metastaze, drugje Metastases of other sites	M	19	13	68,4	6	31,6	0	0
		Ž	14	9	—	5	—	0	—
C80	Maligna neoplazma brez opredeljenega mesta Malignant neoplasm without specification of site	M	64	41	64,1	23	35,9	0	0
		Ž	55	36	65,5	17	30,9	2	3,6
C81	Hodgkinova bolezen Hodgkin's disease	M	17	17	100	0	0	0	0
		Ž	17	17	100	0	0	0	0
C82	Folikularni ne-Hodgkinov limfom Follicular non-Hodgkin's lymphoma	M	44	44	100	0	0	0	0
		Ž	41	41	100	0	0	0	0
C83	Difuzni ne-Hodgkinov limfom Diffuse non-Hodgkin's lymphoma	M	104	104	100	0	0	0	0
		Ž	125	125	100	0	0	0	0

Nadaljevanje —>

Continued —>

Tabela 3: Nadaljevanje.

Table 3: Continued.

Šifra MKB ICD code	Primarna lokacija Primary site	Spol Sex	Število novih primerov Number of new cases	Mikroskopsko potrjeni primeri		Ugotovljeni z drugimi preiskavami		Registrirani samo iz zdravniških poročil o vzroku smrti	
				Število	%*	Število	%*	Število	%*
				Microscopically confirmed cases		Confirmed by other investigations		Registered from death certificates only	
				Number	%*	Number	%*	Number	%*
C84	Limfomi celic T in kožni limfom celic T Peripheral and cutaneous T-cell lymphomas	M	21	21	100	0	0	0	0
		Ž	12	12	—	0	—	0	—
C85	Druge in neopredeljene vrste ne-Hodgkinovega limfoma Other and unspecified types of non-Hodgkin's lymphoma	M	8	8	—	0	—	0	—
		Ž	16	16	100	0	0	0	0
C88	Maligne imunoproliferativne bolezni Malignant immunoproliferative diseases	M	5	5	—	0	—	0	—
		Ž	2	2	—	0	—	0	—
C90	Difuzni plazmocitom in maligne neoplazme plazmocitov Multiple myeloma and malignant plasma cell neoplasms	M	71	71	100	0	0	0	0
		Ž	57	57	100	0	0	0	0
C91.0	Limfatična levkemija, akutna Lymphoblastic leukaemia, acute	M	16	16	100	0	0	0	0
		Ž	11	11	—	0	—	0	—
C91.1–C91.9	Limfatična levkemija, druga Lymphoid leukaemia, other	M	63	63	100	0	0	0	0
		Ž	40	40	100	0	0	0	0
C92	Mieloična levkemija Myeloid leukaemia	M	62	62	100	0	0	0	0
		Ž	41	41	100	0	0	0	0
C93	Monocitna levkemija Monocytic leukaemia	M	3	3	—	0	—	0	—
		Ž	4	4	—	0	—	0	—
C94	Druge opredeljene levkemije Other leukaemias of specified cells	M	7	7	—	0	—	0	—
		Ž	8	8	—	0	—	0	—
C95	Levkemija z neopredeljenim celičnim tipom Leukaemia, unspecified cell type	M	1	1	—	0	—	0	—
		Ž	1	1	—	0	—	0	—
C96	Druge in neopredeljene maligne neoplazme limfatičnega, krvotvornega ali sorodnega tkiva Other and unspecified malignant neoplasms of lymphoid, haematopoietic and related tissue	M	58	58	100	0	0	0	0
		Ž	51	51	100	0	0	0	0

Zgoraj neupoštevani

Not included above

Šifra MKB ICD code	Primarna lokacija Primary site	Spol Sex	Število novih primerov Number of new cases	Mikroskopsko potrjeni primeri		Ugotovljeni z drugimi preiskavami		Registrirani samo iz zdravniških poročil o vzroku smrti	
				Število	%*	Število	%*	Število	%*
				Microscopically confirmed cases		Confirmed by other investigations		Registered from death certificates only	
				Number	%*	Number	%*	Number	%*
D03	Melanom, in situ Melanoma, in situ	M	102	102	100	0	0	0	0
		Ž	113	113	100	0	0	0	0
D05	Dojka, in situ Breast, in situ	M	1	1	—	0	—	0	—
		Ž	92	92	100	0	0	0	0
D06	Maternični vrat, CIN III Cervix uteri, in situ	M	—	—	—	—	—	—	—
		Ž	919	919	100	0	0	0	0
D09.0	Sečni mehur, in situ Bladder, in situ	M	141	141	100	0	0	0	0
		Ž	44	44	100	0	0	0	0
D32.0	Meninge, benigna neoplazma Benign neoplasm of meninges	M	19	19	100	0	0	0	0
		Ž	65	64	98,5	1	1,5	0	0
D33.0–D33.2	Možgani, benigna neoplazma Benign neoplasm of brain	M	0	0	—	0	—	0	—
		Ž	0	0	—	0	—	0	—
D39.1	Jajčnik, neoplazma negotovega značaja Ovary, neoplasm of uncertain behavior	M	—	—	—	—	—	—	—
		Ž	41	41	100	0	0	0	0
D43.0–D43.2	Možgani, neopredeljeno CNS, uncertain or unknown	M	6	2	—	3	—	1	—
		Ž	7	2	—	5	—	0	—

* Odstotki niso računani, če je število novih primerov manjše od 15

* Percentages are not calculated when number of new cases is less than 15

Tabela 4: Incidenca raka po lokaciji, spolu in starosti, Slovenija 2012.

Table 4: Cancer incidence by site, by sex and by age, Slovenia 2012.

Šifra MKB ICD code	Primarna lokacija Primary site	Spol Sex	Vse starosti All ages	Starost Age																
				0–	5–	10–	15–	20–	25–	30–	35–	40–	45–	50–	55–	60–	65–	70–	75–	80+
C00–C96	Vse lokacije All sites	M+Ž	13277	15	6	12	23	41	81	162	195	356	537	923	1371	1773	1674	1970	1904	2234
		M	7240	7	6	3	13	23	37	63	72	128	230	448	803	1049	1054	1221	1080	1003
		Ž	6037	8	0	9	10	18	44	99	123	228	307	475	568	724	620	749	824	1231
C00	Ustnica Lip	M	14	0	0	0	0	0	0	0	1	1	0	0	1	2	3	0	4	2
		Ž	6	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	6
C01	Baza jezika Base of tongue	M	24	0	0	0	0	0	0	0	0	0	1	5	4	6	4	0	4	0
		Ž	4	0	0	0	0	0	0	0	0	0	1	0	1	0	0	1	0	1
C02	Jezik, drugi deli Tongue, other & unspecified parts	M	22	0	0	0	0	0	0	1	0	0	0	1	6	3	3	6	2	0
		Ž	5	0	0	0	0	0	0	0	0	0	0	1	1	0	1	0	0	2
C03	Dlesen Gum	M	7	0	0	0	0	0	0	0	0	1	1	0	1	1	1	0	0	2
		Ž	7	0	0	0	0	0	0	0	0	0	1	1	1	2	1	0	1	0
C04	Ustno dno Floor of mouth	M	27	0	0	0	0	0	0	0	0	2	3	5	3	6	1	7	0	0
		Ž	8	0	0	0	0	0	0	0	0	2	2	0	1	1	2	0	0	0
C05	Nebo Palate	M	18	0	0	0	0	0	0	0	0	0	0	4	7	6	0	0	1	0
		Ž	4	0	0	0	0	0	0	1	0	0	2	1	0	0	0	0	0	0
C06	Usta, drugi deli Mouth, other & unspecified parts	M	9	0	0	0	0	0	0	0	0	1	0	0	2	3	2	0	1	0
		Ž	3	0	0	0	0	0	0	0	0	0	1	1	0	0	1	0	0	0
C07	Parotidna žleza Parotid gland	M	3	0	0	0	0	0	0	0	0	1	0	1	0	1	0	0	0	0
		Ž	5	0	0	0	0	0	1	0	0	0	0	0	0	1	1	1	0	1
C08	Druge in neopredeljene velike žleze slinavke Other & unspecified major salivary glands	M	4	0	0	0	0	0	0	1	0	0	0	1	0	1	0	0	0	1
		Ž	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1
C09	Tonzila Tonsil	M	43	0	0	0	0	0	0	0	1	1	6	8	9	6	6	3	2	1
		Ž	6	0	0	0	0	0	0	0	0	0	1	2	1	1	0	0	1	0
C10	Orofaringks Oropharynx	M	44	0	0	0	0	0	0	0	1	1	4	6	10	11	5	1	2	3
		Ž	7	0	0	0	0	0	0	0	0	1	1	0	1	1	1	2	0	0
C11	Nazofaringks Nasopharynx	M	5	0	0	0	1	0	0	0	1	0	1	0	1	1	0	0	0	0
		Ž	5	0	0	0	0	0	0	0	0	0	0	2	1	0	1	0	0	1
C12	Piriformni sinus Pyriform sinus	M	32	0	0	0	0	0	0	0	0	4	3	5	5	7	4	3	1	0
		Ž	2	0	0	0	0	0	0	0	0	0	0	1	0	1	0	0	0	0
C13	Hipofaringks Hypopharynx	M	18	0	0	0	0	0	0	0	0	0	3	0	1	4	4	2	3	1
		Ž	3	0	0	0	0	0	0	0	0	0	0	0	2	0	0	0	1	0
C14	Druga in slabo opredeljena mesta na ustnici, v ustni votlini in farinksu Other and ill-defined sites in the lip, oral cavity and pharynx	M	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0
		Ž	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
C15	Požiralnik Oesophagus	M	73	0	0	0	0	0	0	0	0	0	4	9	10	7	12	19	8	4
		Ž	14	0	0	0	0	0	0	0	0	0	0	0	2	2	3	2	4	1
C16	Želodec Stomach	M	294	0	0	0	0	0	0	4	5	6	11	18	25	34	46	42	56	47
		Ž	167	0	0	0	0	0	0	1	3	2	9	11	17	11	11	23	30	49
C17	Tanko črevo Small intestine	M	17	0	0	0	0	0	0	0	0	2	1	2	3	1	1	6	1	0
		Ž	15	0	0	0	0	0	0	0	0	0	0	0	4	1	1	2	2	5
C18	Debelo črevo Colon	M	534	0	0	0	0	1	0	3	2	9	9	37	52	84	62	96	100	79
		Ž	387	0	0	0	2	0	2	0	1	10	11	26	25	44	49	52	61	104
C19	Rektosigmoidna zveza Rectosigmoid junction	M	79	0	0	0	0	0	0	0	1	1	2	3	8	11	13	15	15	10
		Ž	46	0	0	0	0	0	0	0	0	2	1	3	4	8	6	6	7	9
C20	Rektum Rectum	M	310	0	0	0	0	0	0	0	4	8	10	26	31	54	46	42	51	38
		Ž	174	0	0	0	0	0	0	1	0	8	4	12	14	18	23	25	31	38
C21	Anus in analni kanal Anus and anal canal	M	4	0	0	0	0	0	0	0	0	0	0	1	1	0	1	0	0	1
		Ž	6	0	0	0	0	0	0	0	0	0	0	1	2	0	0	0	1	1
C22	Jetra in intrahepatični vodi Liver and intrahepatic bile ducts	M	161	0	0	0	0	0	0	0	0	1	3	11	17	33	29	23	29	15
		Ž	40	0	0	0	0	0	0	0	0	0	0	2	1	4	6	8	11	8
C23	Žolčnik Gallbladder	M	16	0	0	0	0	0	0	0	0	0	0	0	2	1	1	2	3	7
		Ž	50	0	0	0	0	0	0	0	0	0	0	0	2	6	3	13	10	16
C24	Drugi in neopredeljeni deli biliarnega trakta Biliary tract, other and unspecified parts	M	56	0	0	0	0	0	0	0	0	0	1	2	2	7	7	7	14	16
		Ž	56	0	0	0	0	0	0	0	0	0	2	2	2	3	1	10	10	26
C25	Trebušna slinavka Pancreas	M	183	0	0	0	0	0	0	0	1	1	5	9	21	24	23	33	34	32
		Ž	173	0	0	0	0	0	0	0	1	4	4	8	8	22	13	24	34	55
C26	Druga in slabo opredeljena mesta v prebavnih organih Other and ill-defined digestive organs	M	2	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	1
		Ž	5	0	0	0	0	0	0	0	0	0	0	0	1	0	0	1	0	3

Nadaljevanje —>

Continued —>

Tabela 4: Nadaljevanje.

Table 4: Continued.

Šifra MKB ICD code	Primarna lokacija Primary site	Spol Sex	Vse starosti All ages	Starost Age																
				0–	5–	10–	15–	20–	25–	30–	35–	40–	45–	50–	55–	60–	65–	70–	75–	80+
C30	Nosna votlina in srednje uho Nasal cavity and middle ear	M	8	0	0	0	0	0	0	0	1	1	1	2	1	1	0	0	0	1
		Ž	5	0	0	0	0	0	0	0	1	0	1	0	0	2	0	0	1	0
C31	Obnosni sinusi Accessory sinuses	M	4	0	0	0	0	0	0	0	0	0	1	0	0	0	1	0	0	2
		Ž	4	0	0	0	0	0	0	0	0	0	0	1	0	1	0	1	0	1
C32	Grlo Larynx	M	77	0	0	0	0	0	0	1	0	3	2	13	11	12	10	14	8	3
		Ž	13	0	0	0	0	0	0	0	0	0	1	4	4	2	2	0	0	0
C33	Sapnik Trachea	M	5	0	0	0	0	0	0	0	0	1	1	0	1	1	0	1	0	0
		Ž	1	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0
C34	Sapnica in pljuča Bronchus and lung	M	867	0	0	0	0	0	0	1	1	6	23	59	144	129	147	143	123	91
		Ž	384	0	0	1	0	1	1	2	3	6	9	36	63	54	50	57	46	55
C37	Timus Thymus	M	3	0	0	0	0	0	1	0	0	1	0	0	0	0	0	1	0	0
		Ž	2	0	0	0	0	0	0	0	0	0	0	1	0	0	1	0	0	0
C38	Srce, mediastinum, plevra Heart, mediastinum, pleura	M	4	0	0	0	0	0	0	0	0	0	0	0	1	1	0	1	0	1
		Ž	2	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	1
C39	Druga in slabo opredeljena mesta v dihalih in prsni organih Other and ill-defined sites in the respiratory system and intrathoracic organs	M	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
		Ž	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
C40	Kosti, sklepni hrustanec udov Bone and articular cartilage of limbs	M	1	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0
		Ž	5	0	0	0	1	0	0	0	1	0	0	0	0	1	0	0	1	1
C41	Kosti, sklepni hrustanec, drugje Bone and articular cartilage of other and unspecified parts	M	4	1	0	0	0	0	0	0	0	0	1	2	0	0	0	0	0	0
		Ž	5	0	0	0	0	0	0	0	1	0	0	1	0	1	1	0	0	1
C43	Maligni melanom kože Malignant melanoma of skin	M	257	0	0	1	1	5	6	4	11	9	17	19	28	34	35	31	26	30
		Ž	259	0	0	0	2	3	13	20	14	21	21	26	15	21	21	21	25	36
C44	Druge maligne neoplazme kože Skin, other malignomas	M	1175	0	0	0	0	2	1	10	15	24	42	47	98	115	156	201	208	256
		Ž	1157	0	0	0	0	1	3	16	16	30	32	67	67	128	102	154	211	330
C45	Mezoteliom Mesothelioma	M	32	0	0	0	0	0	0	0	1	0	0	1	4	8	5	5	3	3
		Ž	11	0	0	0	0	0	0	0	0	1	0	0	1	1	0	3	3	2
C46	Kaposijev sarkom Kaposi's sarcoma	M	5	0	0	0	0	0	0	1	0	1	0	0	0	1	1	0	1	0
		Ž	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
C47	Periferni žvci in avtonomno živčevje Peripheral nerves and autonomic nervous system	M	1	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0
		Ž	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
C48	Peritonej in retroperitonej Retroperitoneum and peritoneum	M	4	0	0	0	0	0	0	1	0	0	0	2	0	0	0	1	0	0
		Ž	17	1	0	0	0	0	0	0	0	0	0	1	3	5	0	2	2	3
C49	Drugo vezivno in mehko tkivo Other connective and soft tissue	M	28	0	0	0	0	0	0	2	0	0	4	2	3	5	1	4	3	4
		Ž	29	1	0	0	0	0	1	0	1	2	1	4	2	3	5	3	2	4
C50	Dojka Breast	M	15	0	0	0	0	0	0	0	0	0	0	1	0	5	2	1	3	3
		Ž	1296	0	0	0	0	3	6	23	41	79	115	154	160	164	149	141	109	152
C51	Žensko zunanje spolovilo Vulva	M	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
		Ž	35	0	0	0	0	0	0	0	0	1	2	1	1	4	5	3	8	10
C52	Nožnica Vagina	M	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
		Ž	11	0	0	0	0	0	0	0	0	1	2	0	0	2	0	1	4	1
C53	Maternični vrat Cervix uteri	M	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
		Ž	118	0	0	0	0	0	7	4	8	14	13	12	10	22	7	10	4	7
C54	Maternično telo Corpus uteri	M	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
		Ž	336	0	0	0	0	0	0	2	1	7	17	24	50	54	54	48	40	39
C55	Maternica, neopredeljeno Uterus, unspecified	M	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
		Ž	15	0	0	0	0	0	0	0	0	2	0	0	2	1	1	2	4	3
C56	Jajčnik Ovary	M	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
		Ž	155	0	0	0	0	2	1	5	7	10	13	23	16	19	12	16	14	17
C57	Drugi in neopredeljeni ženski spolni organi Other and unspecified parts of female genital organs	M	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
		Ž	10	0	0	0	0	0	0	0	0	0	0	0	2	2	2	1	3	0
C58	Posteljica Placenta	M	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
		Ž	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
C60	Penis Penis	M	10	0	0	0	0	0	0	0	0	0	2	0	1	1	1	0	2	3
		Ž	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
C61	Prostata Prostate	M	1425	0	0	0	0	0	0	0	0	1	18	49	153	263	271	315	213	142
		Ž	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—

Tabela 4: Nadaljevanje.

Table 4: Continued.

Šifra MKB ICD code	Primarna lokacija Primary site	Spol Sex	Vse starosti All ages	Starost Age																
				0–	5–	10–	15–	20–	25–	30–	35–	40–	45–	50–	55–	60–	65–	70–	75–	80+
C62	Modo Testis	M	105	0	0	0	6	5	18	18	16	19	9	5	3	3	1	2	0	0
		Ž	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
C63	Drugi in neopredeljeni moški spolni organi Other and unspecified male genital organs	M	3	0	0	0	0	0	0	0	0	0	0	0	2	0	0	1	0	0
		Ž	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
C64	Ledvica razen meha Kidney, except renal pelvis	M	211	0	0	0	0	0	1	2	3	1	14	24	27	33	20	39	20	27
		Ž	100	0	0	0	0	0	0	2	1	2	2	7	14	12	14	12	18	16
C65	Ledvični meh Renal pelvis	M	18	0	0	0	0	0	0	0	0	0	1	2	1	0	2	5	3	4
		Ž	9	0	0	0	0	0	0	0	0	0	0	0	0	0	1	1	2	5
C66	Sečevod Ureter	M	14	0	0	0	0	0	0	0	0	0	1	0	1	2	2	4	0	4
		Ž	8	0	0	0	0	0	0	0	0	0	0	0	1	1	1	0	2	3
C67	Sečni mehur Bladder	M	224	0	0	0	0	0	0	1	3	0	2	11	27	26	25	34	43	52
		Ž	80	0	0	0	0	0	0	0	1	1	4	3	5	4	5	19	12	26
C68	Drugi in neopredeljeni sečni organi Other and unspecified urinary organs	M	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
		Ž	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1
C69	Okoli očesni adneksi Eye and adnexa	M	14	2	0	0	0	0	0	0	0	0	1	2	1	1	4	2	1	0
		Ž	6	0	0	0	0	0	0	0	0	0	1	0	1	2	0	0	0	2
C70	Meninge Meninges	M	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0
		Ž	2	0	0	0	0	0	0	0	0	0	0	0	0	0	0	2	0	0
C71	Možgani Brain	M	58	0	4	0	2	1	2	0	0	3	6	2	6	10	8	6	7	1
		Ž	61	2	0	2	0	1	1	2	1	1	2	3	7	7	10	6	11	5
C72	Hrbtne možgane, možganski živci in drugi deli CZS Spinal cord, cranial nerves and other parts of CNS	M	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
		Ž	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
C73	Ščitnica Thyroid gland	M	42	0	0	0	0	1	4	3	2	3	1	2	5	8	2	6	4	1
		Ž	107	0	0	0	3	4	4	10	9	8	8	8	12	21	5	5	4	6
C74	Nadledvična žleza Adrenal gland	M	2	0	0	0	0	0	0	0	0	0	0	0	1	0	0	1	0	0
		Ž	4	0	0	0	0	1	0	0	0	0	0	0	0	1	0	0	1	1
C75	Druge endokrine žleze in sorodne strukture Other endocrine glands and related structures	M	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
		Ž	1	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0
C76	Druga in slabo opredeljena mesta Other and ill-defined sites	M	9	0	0	0	0	0	0	0	0	0	0	0	1	3	0	1	2	2
		Ž	35	1	0	0	0	0	0	0	0	0	0	0	0	1	2	3	6	22
C77	Metastaza in neopredeljena maligna neoplazma bezgavk Metastasis and unspecified malignant neoplasm of lymph nodes	M	20	0	0	0	0	0	0	0	0	0	1	1	5	0	5	4	2	2
		Ž	7	0	0	0	0	0	0	0	0	0	2	1	0	1	0	1	2	0
C78	Metastaze dihal in prebavih Metastases of respiratory and digestive organs	M	31	0	0	0	0	0	0	1	0	1	0	1	1	2	3	3	7	12
		Ž	52	0	0	0	0	0	2	0	0	0	0	0	3	2	2	7	5	31
C79	Metastaze, drugje Metastases of other sites	M	19	0	0	0	0	0	0	0	0	1	0	2	0	4	2	2	5	3
		Ž	14	0	0	0	0	0	0	0	0	0	0	1	3	3	1	1	2	3
C80	Maligna neoplazma brez opredeljenega mesta Malignant neoplasm without specification of site	M	64	0	0	0	0	0	0	0	0	2	1	1	9	7	14	10	8	12
		Ž	55	0	0	0	0	0	0	1	0	1	3	2	5	7	0	7	10	19
C81	Hodgkinova bolezen Hodgkin's disease	M	17	0	0	0	0	2	2	4	1	1	0	3	1	1	2	0	0	0
		Ž	17	0	0	1	2	1	1	2	1	1	0	2	1	0	2	2	1	0
C82	Folikularni ne-Hodgkinov limfom Follicular non-Hodgkin's lymphoma	M	44	0	0	0	0	0	1	2	0	1	5	7	3	6	4	9	3	3
		Ž	41	0	0	0	0	0	1	2	0	1	1	2	4	13	3	5	3	6
C83	Difuzni ne-Hodgkinov limfom Diffuse non-Hodgkin's lymphoma	M	104	0	0	0	0	2	0	1	0	5	3	14	10	11	11	16	11	20
		Ž	125	0	0	0	0	0	0	2	1	3	6	5	8	9	14	20	23	34
C84	Limfomi celic T in kožni limfom celic T Peripheral and cutaneous T-cell lymphomas	M	21	0	0	0	0	0	0	0	1	0	0	2	2	0	4	4	3	5
		Ž	12	0	0	0	0	0	0	0	1	0	1	2	0	3	2	1	1	1
C85	Druge in neopredeljene vrste ne-Hodgkinovega limfoma Other and unspecified types of non-Hodgkin's lymphoma	M	8	0	0	0	0	0	0	0	0	1	0	1	2	0	1	1	1	1
		Ž	16	0	0	0	0	0	0	0	0	1	0	0	1	2	2	2	3	4

Nadaljevanje —>

Continued —>

Tabela 4: Nadaljevanje.

Table 4: Continued.

Šifra MKB ICD code	Primarna lokacija Primary site	Spol Sex	Vse starosti All ages	Starost Age																	
				0–	5–	10–	15–	20–	25–	30–	35–	40–	45–	50–	55–	60–	65–	70–	75–	80+	
C88	Maligne imunoproliferativne bolezni Malignant immunoproliferative diseases	M Ž	5 2	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 0	1 1	1 1	0 1	1 0	1 0	1 0	
	Difuzni plazmocitom in maligne neoplazme plazmocitov Multiple myeloma and malignant plasma cell neoplasms	M Ž	71 57	0 0	0 0	0 0	0 0	0 0	1 0	0 0	0 1	1 3	0 1	6 3	4 3	11 8	16 5	12 6	6 11	14 16	
C91.0	Limfatična levkemija, akutna Lymphoblastic leukaemia, acute	M Ž	16 11	3 3	2 0	1 3	1 0	2 0	0 0	1 0	0 0	0 0	0 0	1 0	1 2	2 0	1 1	1 0	1 1	0 0	
	Limfatična levkemija, druga Lymphoid leukaemia, other	M Ž	63 40	0 0	0 0	0 0	1 0	0 0	0 0	0 0	0 0	0 0	0 3	4 3	8 2	14 4	8 6	10 4	9 6	9 12	
C92	Mieloična levkemija Myeloid leukaemia	M Ž	62 41	1 0	0 0	0 2	1 0	0 1	0 0	0 2	0 3	1 2	2 2	4 4	6 6	6 10	10 5	5 16	8 0	16 8	
	Monocitna levkemija Monocytic leukaemia	M Ž	3 4	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 1	0 1	1 1	0 0	1 0	1 2	0 0	
C94	Druge opredeljene levkemije Other leukaemias of specified cells	M Ž	7 8	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 0	1 1	0 0	1 0	1 0	1 0	0 0	2 3	1 2	1 2	
	Levkemija z neopredeljenim celičnim tipom Leukaemia, unspecified cell type	M Ž	1 1	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 1	0 0	1 0	
C96	Druge in neopredeljene maligne neoplazme limfatičnega, krovotvornega ali sorodnega tkiva Other and unspecified malignant neoplasms of lymphoid, haematopoietic and related tissue	M Ž	58 51	0 0	0 0	0 0	0 0	1 0	0 0	1 0	0 3	1 0	2 1	2 1	7 6	6 2	5 4	8 5	12 12	13 17	

Zgoraj neupoštevani

Not included above

Not included above				Starost Age																	
Šifra MKB ICD code	Primarna lokacija Primary site	Spol Sex	Vse starosti All ages	0–	5–	10–	15–	20–	25–	30–	35–	40–	45–	50–	55–	60–	65–	70–	75–	80+	
D03	Melanom, in situ	M	102	0	0	0	1	2	3	4	5	4	8	8	9	18	11	12	8	9	
	Melanoma, in situ	Ž	113	0	0	0	0	0	8	11	17	8	16	9	8	9	9	7	6	5	
D05	Dojka, in situ	M	1	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	
	Breast, in situ	Ž	92	0	0	0	0	0	0	2	2	4	6	16	16	19	16	5	4	2	
D06	Maternični vrat, CIN III	M	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	
	Cervix uteri, in situ	Ž	919	0	0	0	1	82	187	190	173	105	81	34	25	18	11	8	3	1	
D09.0	Sečni mehur, in situ	M	141	0	0	0	0	0	0	0	0	4	5	11	11	17	25	28	20	20	
	Bladder, in situ	Ž	44	0	0	0	0	0	0	0	0	0	2	1	11	5	3	7	3	12	
D32.0	Meninge, benigna neoplazma	M	19	0	0	0	0	0	0	0	0	0	1	3	2	3	2	5	1	2	
	Benign neoplasm of meninges	Ž	65	0	0	0	0	0	1	1	4	2	4	5	6	10	7	12	4	9	
D33.0–D33.2	Možgani, benigna neoplazma	M	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
	Benign neoplasm of brain	Ž	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
D39.1	Jajčnik, neoplazma negotovega značaja	M	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	
	Ovary, neoplasm of uncertain behavior	Ž	41	0	0	0	1	1	2	2	3	5	3	7	5	1	3	4	3	1	
D43.0–D43.2	Možgani, neopredeljeno	M	6	0	0	0	0	0	0	0	1	0	0	1	0	1	1	1	1	0	
	CNS, uncertain or unknown	Ž	7	0	0	0	0	0	0	0	0	1	1	0	1	2	0	0	0	2	

Tabela 5: Groba in starostno specifična incidenčna stopnja na 100.000 prebivalcev ter komulativna stopnja (KS) po lokaciji in spolu, Slovenija 2012.

Table 5: Crude and age specific cancer incidence rate per 100,000 and comulative rate (CR) by site and by sex, Slovenia 2012.

Šifra MKB ICD code	Primarna lokacija Primary site	Spol Sex	Vse starosti All ages	Starost Age																		KS CR
				0–	5–	10–	15–	20–	25–	30–	35–	40–	45–	50–	55–	60–	65–	70–	75–	80+	0–74	
C00–C96	Vse lokacije All sites	M+Ž	645,7	13,6	6,4	13,1	23,1	34,1	58,0	103,3	126,8	242,6	341,7	605,7	890,7	1344,9	1751,6	2213,5	2594,0	2462,8	38,9	
		M	711,6	12,3	12,5	6,3	25,4	37,1	50,8	76,4	89,7	169,0	287,7	579,0	1023,9	1603,6	2359,8	3098,1	3739,0	3756,8	47,2	
		Ž	581,1	14,9	0	20,3	20,7	31,0	65,9	133,1	167,3	321,0	397,5	633,4	752,4	1090,0	1218,0	1510,4	1851,1	1923,0	31,9	
C00	Ustnica Lip	M	1,4	0	0	0	0	0	0	0	1,2	1,3	0	0	1,3	3,1	6,7	0	13,8	7,5	0,1	
		Ž	0,6	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	9,4	0,0	
C01	Baza jezika Base of tongue	M	2,4	0	0	0	0	0	0	0	0	0	1,3	6,5	5,1	9,2	9,0	0	13,8	0	0,2	
		Ž	0,4	0	0	0	0	0	0	0	0	0	1,3	0	1,3	0	0	2,0	0	1,6	0,0	
C02	Jezik, drugi deli Tongue, other & unspecified parts	M	2,2	0	0	0	0	0	0	1,2	0	0	0	1,3	7,7	4,6	6,7	15,2	6,9	0	0,2	
		Ž	0,5	0	0	0	0	0	0	0	0	0	0	1,3	1,3	0	2,0	0	0	3,1	0,0	
C03	Dlesen Gum	M	0,7	0	0	0	0	0	0	0	0	1,3	1,3	0	1,3	1,5	2,2	0	0	7,5	0,0	
		Ž	0,7	0	0	0	0	0	0	0	0	0	1,3	1,3	1,3	3,0	2,0	0	2,2	0	0,0	
C04	Ustno dno Floor of mouth	M	2,7	0	0	0	0	0	0	0	0	2,6	3,8	6,5	3,8	9,2	2,2	17,8	0	0	0,2	
		Ž	0,8	0	0	0	0	0	0	0	0	2,8	2,6	0	1,3	1,5	3,9	0	0	0	0,1	
C05	Nebo Palate	M	1,8	0	0	0	0	0	0	0	0	0	0	5,2	8,9	9,2	0	0	3,5	0	0,1	
		Ž	0,4	0	0	0	0	0	0	1,3	0	0	2,6	1,3	0	0	0	0	0	0	0,0	
C06	Usta, drugi deli Mouth, other & unspecified parts	M	0,9	0	0	0	0	0	0	0	0	1,3	0	0	2,6	4,6	4,5	0	3,5	0	0,1	
		Ž	0,3	0	0	0	0	0	0	0	0	0	1,3	1,3	0	0	2,0	0	0	0	0,0	
C07	Parotidna žleza Parotid gland	M	0,3	0	0	0	0	0	0	0	0	1,3	0	1,3	0	1,5	0	0	0	0	0,0	
		Ž	0,5	0	0	0	0	0	1,5	0	0	0	0	0	0	1,5	2,0	2,0	0	1,6	0,0	
C08	Druge in neopredeljene velike žleze slinavke Other & unspecified major salivary glands	M	0,4	0	0	0	0	0	0	1,2	0	0	0	1,3	0	1,5	0	0	0	3,7	0,0	
		Ž	0,1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1,6	0,0	
C09	Tonzila Tonsil	M	4,2	0	0	0	0	0	0	0	1,2	1,3	7,5	10,3	11,5	9,2	13,4	7,6	6,9	3,7	0,3	
		Ž	0,6	0	0	0	0	0	0	0	0	0	1,3	2,7	1,3	1,5	0	0	2,2	0	0,0	
C10	Orofarinks Oropharynx	M	4,3	0	0	0	0	0	0	0	1,2	1,3	5,0	7,8	12,8	16,8	11,2	2,5	6,9	11,2	0,3	
		Ž	0,7	0	0	0	0	0	0	0	0	1,4	1,3	0	1,3	1,5	2,0	4,0	0	0	0,1	
C11	Nazofarinks Nasopharynx	M	0,5	0	0	0	2,0	0	0	0	1,2	0	1,3	0	1,3	1,5	0	0	0	0	0,0	
		Ž	0,5	0	0	0	0	0	0	0	0	0	0	2,7	1,3	0	2,0	0	0	1,6	0,0	
C12	Piriformni sinus Pyriform sinus	M	3,1	0	0	0	0	0	0	0	0	5,3	3,8	6,5	6,4	10,7	9,0	7,6	3,5	0	0,2	
		Ž	0,2	0	0	0	0	0	0	0	0	0	0	1,3	0	1,5	0	0	0	0	0,0	
C13	Hipofarinks Hypopharynx	M	1,8	0	0	0	0	0	0	0	0	0	3,8	0	1,3	6,1	9,0	5,1	10,4	3,7	0,1	
		Ž	0,3	0	0	0	0	0	0	0	0	0	0	0	2,6	0	0	0	2,2	0	0,0	
C14	Druga in slabo opredeljena mesta na ustnici, v ustni votlini in farinksu Other and ill-defined sites in the lip, oral cavity and pharynx	M	0,1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	2,5	0	0	0,0	
		Ž	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0,0	
C15	Požiralnik Oesophagus	M	7,2	0	0	0	0	0	0	0	0	0	5,0	11,6	12,8	10,7	26,9	48,2	27,7	15,0	0,6	
		Ž	1,3	0	0	0	0	0	0	0	0	0	0	0	2,6	3,0	5,9	4,0	9,0	1,6	0,1	
C16	Želodec Stomach	M	28,9	0	0	0	0	0	0	4,8	6,2	7,9	13,8	23,3	31,9	52,0	103,0	106,6	193,9	176,0	1,7	
		Ž	16,1	0	0	0	0	0	0	1,3	4,1	2,8	11,7	14,7	22,5	16,6	21,6	46,4	67,4	76,5	0,7	
C17	Tanko črevo Small intestine	M	1,7	0	0	0	0	0	0	0	0	2,6	1,3	2,6	3,8	1,5	2,2	15,2	3,5	0	0,1	
		Ž	1,4	0	0	0	0	0	0	0	0	0	0	0	5,3	1,5	2,0	4,0	4,5	7,8	0,1	
C18	Debelo črevo Colon	M	52,5	0	0	0	0	1,6	0	3,6	2,5	11,9	11,3	47,8	66,3	128,4	138,8	243,6	346,2	295,9	3,3	
		Ž	37,3	0	0	0	4,1	0	3,0	0	1,4	14,1	14,2	34,7	33,1	66,2	96,3	104,9	137,0	162,5	1,9	

Nadaljevanje —>
Continued —>

Tabela 5: Nadaljevanje.

Table 5: Continued.

Šifra MKB ICD code	Primarna lokacija Primary site	Spol Sex	Vse starosti All ages	Starost Age																		KS CR
				0–	5–	10–	15–	20–	25–	30–	35–	40–	45–	50–	55–	60–	65–	70–	75–	80+	0–74	
C19	Rektosigmoidna zveza Rectosigmoid junction	M	7,8	0	0	0	0	0	0	0	1,2	1,3	2,5	3,9	10,2	16,8	29,1	38,1	51,9	37,5	0,5	
		Ž	4,4	0	0	0	0	0	0	0	0	2,8	1,3	4,0	5,3	12,0	11,8	12,1	15,7	14,1	0,2	
C20	Rektum Rectum	M	30,5	0	0	0	0	0	0	0	5,0	10,6	12,5	33,6	39,5	82,6	103,0	106,6	176,6	142,3	2,0	
		Ž	16,7	0	0	0	0	0	0	1,3	0	11,3	5,2	16,0	18,5	27,1	45,2	50,4	69,6	59,4	0,9	
C21	Anus in analni kanal Anus and anal canal	M	0,4	0	0	0	0	0	0	0	0	0	0	1,3	1,3	0	2,2	0	0	3,7	0,0	
		Ž	0,6	0	0	0	0	0	0	0	0	0	1,3	2,7	0	0	2,0	0	2,2	1,6	0,0	
C22	Jetra in intrahepatični vodi Liver and intrahepatic bile ducts	M	15,8	0	0	0	0	0	0	0	0	1,3	3,8	14,2	21,7	50,4	64,9	58,4	100,4	56,2	1,1	
		Ž	3,9	0	0	0	0	0	0	0	0	0	0	2,7	1,3	6,0	11,8	16,1	24,7	12,5	0,2	
C23	Žolčnik Gallbladder	M	1,6	0	0	0	0	0	0	0	0	0	0	0	2,6	1,5	2,2	5,1	10,4	26,2	0,1	
		Ž	4,8	0	0	0	0	0	0	0	0	0	0	0	2,6	9,0	5,9	26,2	22,5	25,0	0,2	
C24	Drugi in neopredeljeni deli biliarnega trakta Biliary tract, other and unspecified parts	M	5,5	0	0	0	0	0	0	0	0	0	1,3	2,6	2,6	10,7	15,7	17,8	48,5	59,9	0,3	
		Ž	5,4	0	0	0	0	0	0	0	0	0	2,6	2,7	2,6	4,5	2,0	20,2	22,5	40,6	0,2	
C25	Trebušna slinavka Pancreas	M	18,0	0	0	0	0	0	0	0	1,2	1,3	6,3	11,6	26,8	36,7	51,5	83,7	117,7	119,9	1,1	
		Ž	16,7	0	0	0	0	0	0	0	1,4	5,6	5,2	10,7	10,6	33,1	25,5	48,4	76,4	85,9	0,7	
C26	Druga in slabo opredeljena mesta v prebavnih organih Other and ill-defined digestive organs	M	0,2	0	0	0	0	0	0	0	0	0	0	0	0	0	2,2	0	0	3,7	0,0	
		Ž	0,5	0	0	0	0	0	0	0	0	0	0	0	1,3	0	0	2,0	0	4,7	0,0	
C30	Nosna votlina in srednje uho Nasal cavity and middle ear	M	0,8	0	0	0	0	0	0	0	1,2	1,3	1,3	2,6	1,3	1,5	0	0	0	3,7	0,0	
		Ž	0,5	0	0	0	0	0	0	0	1,4	0	1,3	0	0	3,0	0	0	2,2	0	0,0	
C31	Obnosni sinusi Accessory sinuses	M	0,4	0	0	0	0	0	0	0	0	0	1,3	0	0	0	2,2	0	0	7,5	0,0	
		Ž	0,4	0	0	0	0	0	0	0	0	0	0	1,3	0	1,5	0	2,0	0	1,6	0,0	
C32	Grlo Larynx	M	7,6	0	0	0	0	0	0	1,2	0	4,0	2,5	16,8	14,0	18,3	22,4	35,5	27,7	11,2	0,6	
		Ž	1,3	0	0	0	0	0	0	0	0	0	1,3	5,3	5,3	3,0	3,9	0	0	0	0,1	
C33	Sapnik Trachea	M	0,5	0	0	0	0	0	0	0	0	1,3	1,3	0	1,3	1,5	0	2,5	0	0	0,0	
		Ž	0,1	0	0	0	0	0	0	0	1,4	0	0	0	0	0	0	0	0	0	0,0	
C34	Sapnica in pljuča Bronchus and lung	M	85,2	0	0	0	0	0	0	1,2	1,2	7,9	28,8	76,2	183,6	197,2	329,1	362,8	425,8	340,8	5,9	
		Ž	37,0	0	0	2,3	0	1,7	1,5	2,7	4,1	8,4	11,7	48,0	83,5	81,3	98,2	114,9	103,3	85,9	2,3	
C37	Timus Thymus	M	0,3	0	0	0	0	0	1,4	0	0	1,3	0	0	0	0	0	2,5	0	0	0,0	
		Ž	0,2	0	0	0	0	0	0	0	0	0	0	1,3	0	0	2,0	0	0	0	0,0	
C38	Srce, mediastinum, plevra Heart, mediastinum, pleura	M	0,4	0	0	0	0	0	0	0	0	0	0	0	1,3	1,5	0	2,5	0	3,7	0,0	
		Ž	0,2	0	0	0	0	0	0	0	0	0	1,3	0	0	0	0	0	0	1,6	0,0	
C39	Druga in slabo opredeljena mesta v dihalih in prsni organih Other and ill-defined sites in the respiratory system and intrathoracic organs	M	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0,0	
		Ž	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0,0	
C40	Kosti, sklepni hrustanec udov Bone and articular cartilage of limbs	M	0,1	0	0	2,1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0,0	
		Ž	0,5	0	0	0	2,1	0	0	0	0	1,4	0	0	0	1,5	0	0	2,2	1,6	0,0	

Tabela 5: Nadaljevanje.

Table 5: Continued.

Šifra MKB ICD code	Primarna lokacija Primary site	Spol Sex	Vse starosti All ages	Starost Age																		KS CR
				0–	5–	10–	15–	20–	25–	30–	35–	40–	45–	50–	55–	60–	65–	70–	75–	80+	0–74	
C41	Kosti, sklepni hrustanec, drugje Bone and articular cartilage of other and unspecified parts	M	0,4	1,8	0	0	0	0	0	0	0	0	1,3	2,6	0	0	0	0	0	0	0,0	
		Ž	0,5	0	0	0	0	0	0	0	1,4	0	0	1,3	0	1,5	2,0	0	0	1,6	0,0	
C43	Malignni melanom kože Malignant melanoma of skin	M	25,3	0	0	2,1	2,0	8,1	8,2	4,8	13,7	11,9	21,3	24,6	35,7	52,0	78,4	78,7	90,0	112,4	1,7	
		Ž	24,9	0	0	0	4,1	5,2	19,5	26,9	19,0	29,6	27,2	34,7	19,9	31,6	41,3	42,3	56,2	56,2	1,5	
C44	Druge maligne neoplazme kože Skin, other malignomas	M	115,5	0	0	0	0	3,2	1,4	12,1	18,7	31,7	52,5	60,7	125,0	175,8	349,3	510,0	720,1	958,9	6,7	
		Ž	111,4	0	0	0	0	1,7	4,5	21,5	21,8	42,2	41,4	89,3	88,7	192,7	200,4	310,5	474,0	515,5	5,1	
C45	Mezoteliom Mesothelioma	M	3,1	0	0	0	0	0	0	0	1,2	0	0	1,3	5,1	12,2	11,2	12,7	17,3	11,2	0,2	
		Ž	1,1	0	0	0	0	0	0	0	0	1,4	0	0	1,3	1,5	0	6,0	6,7	3,1	0,1	
C46	Kaposijev sarkom Kaposi's sarcoma	M	0,5	0	0	0	0	0	0	1,2	0	1,3	0	0	0	1,5	2,2	0	3,5	0	0,0	
		Ž	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0,0	
C47	Periferni živci in avtonomno živčevje Peripheral nerves and autonomic nervous system	M	0,1	0	0	0	0	1,6	0	0	0	0	0	0	0	0	0	0	0	0	0,0	
		Ž	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0,0	
C48	Peritonej in retroperitonej Retroperitoneum and peritoneum	M	0,4	0	0	0	0	0	0	1,2	0	0	0	2,6	0	0	0	2,5	0	0	0,0	
		Ž	1,6	1,9	0	0	0	0	0	0	0	0	0	1,3	4,0	7,5	0	4,0	4,5	4,7	0,1	
C49	Drugo vezivno in mehko tkivo Other connective and soft tissue	M	2,8	0	0	0	0	0	0	2,4	0	0	5,0	2,6	3,8	7,6	2,2	10,1	10,4	15,0	0,2	
		Ž	2,8	1,9	0	0	0	0	1,5	0	1,4	2,8	1,3	5,3	2,6	4,5	9,8	6,0	4,5	6,2	0,2	
C50	Dojka Breast	M	1,5	0	0	0	0	0	0	0	0	0	0	1,3	0	7,6	4,5	2,5	10,4	11,2	0,1	
		Ž	124,8	0	0	0	0	5,2	9,0	30,9	55,8	111,2	148,9	205,3	211,9	246,9	292,7	284,3	244,9	237,5	8,0	
C51	Žensko zunanje spolovilo Vulva	M	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	
		Ž	3,4	0	0	0	0	0	0	0	0	1,4	2,6	1,3	1,3	6,0	9,8	6,0	18,0	15,6	0,1	
C52	Nožnica Vagina	M	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	
		Ž	1,1	0	0	0	0	0	0	0	0	1,4	2,6	0	0	3,0	0	2,0	9,0	1,6	0,0	
C53	Maternični vrat Cervix uteri	M	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	
		Ž	11,4	0	0	0	0	0	10,5	5,4	10,9	19,7	16,8	16,0	13,2	33,1	13,8	20,2	9,0	10,9	0,8	
C54	Maternično telo Corpus uteri	M	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	
		Ž	32,3	0	0	0	0	0	0	2,7	1,4	9,9	22,0	32,0	66,2	81,3	106,1	96,8	89,9	60,9	2,1	
C55	Maternica, neopredeljeno Uterus, unspecified	M	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	
		Ž	1,4	0	0	0	0	0	0	0	0	2,8	0	0	2,6	1,5	2,0	4,0	9,0	4,7	0,1	
C56	Jajčnik Ovary	M	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	
		Ž	14,9	0	0	0	0	3,4	1,5	6,7	9,5	14,1	16,8	30,7	21,2	28,6	23,6	32,3	31,5	26,6	0,9	
C57	Drugi in neopredeljeni ženski spolni organi Other and unspecified parts of female genital organs	M	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	
		Ž	1,0	0	0	0	0	0	0	0	0	0	0	0	2,6	3,0	3,9	2,0	6,7	0	0,1	
C58	Posteljica Placenta	M	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	
		Ž	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0,0	
C60	Penis Penis	M	1,0	0	0	0	0	0	0	0	0	0	2,5	0	1,3	1,5	2,2	0	6,9	11,2	0,0	
		Ž	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	

Nadaljevanje —>

Continued —>

Tabela 5: Nadaljevanje.

Table 5: Continued.

Šifra MKB ICD code	Primarna lokacija Primary site	Spol Sex	Vse starosti All ages	Starost Age																		KS CR
				0–	5–	10–	15–	20–	25–	30–	35–	40–	45–	50–	55–	60–	65–	70–	75–	80+	0–74	
C61	Prostata Prostate	M	140,1	0	0	0	0	0	0	0	0	1,3	22,5	63,3	195,1	402,1	606,8	799,3	737,4	531,9	10,5	
		Ž	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	
C62	Modo Testis	M	10,3	0	0	0	11,7	8,1	24,7	21,8	19,9	25,1	11,3	6,5	3,8	4,6	2,2	5,1	0	0	0,7	
		Ž	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	
C63	Drugi in neopredeljeni moški spolni organi Other and unspecified male genital organs	M	0,3	0	0	0	0	0	0	0	0	0	0	0	2,6	0	0	2,5	0	0	0,0	
		Ž	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	
C64	Ledvica razen meha Kidney, except renal pelvis	M	20,7	0	0	0	0	0	1,4	2,4	3,7	1,3	17,5	31,0	34,4	50,4	44,8	99,0	69,2	101,1	1,4	
		Ž	9,6	0	0	0	0	0	0	2,7	1,4	2,8	2,6	9,3	18,5	18,1	27,5	24,2	40,4	25,0	0,5	
C65	Ledvični meh Renal pelvis	M	1,8	0	0	0	0	0	0	0	0	0	1,3	2,6	1,3	0	4,5	12,7	10,4	15,0	0,1	
		Ž	0,9	0	0	0	0	0	0	0	0	0	0	0	0	0	2,0	2,0	4,5	7,8	0,0	
C66	Sečevod Ureter	M	1,4	0	0	0	0	0	0	0	0	0	1,3	0	1,3	3,1	4,5	10,1	0	15,0	0,1	
		Ž	0,8	0	0	0	0	0	0	0	0	0	0	0	1,3	1,5	2,0	0	4,5	4,7	0,0	
C67	Sečni mehur Bladder	M	22,0	0	0	0	0	0	0	1,2	3,7	0	2,5	14,2	34,4	39,7	56,0	86,3	148,9	194,8	1,2	
		Ž	7,7	0	0	0	0	0	0	0	1,4	1,4	5,2	4,0	6,6	6,0	9,8	38,3	27,0	40,6	0,4	
C68	Drugi in neopredeljeni sečni organi Other and unspecified urinary organs	M	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0,0	
		Ž	0,1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1,6	0,0	
C69	Oko in očesni adneksi Eye and adnexa	M	1,4	3,5	0	0	0	0	0	0	0	0	1,3	2,6	1,3	1,5	9,0	5,1	3,5	0	0,1	
		Ž	0,6	0	0	0	0	0	0	0	0	0	1,3	0	1,3	3,0	0	0	0	3,1	0,0	
C70	Meninge Meninges	M	0,1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	3,5	0	0,0	
		Ž	0,2	0	0	0	0	0	0	0	0	0	0	0	0	0	0	4,0	0	0	0,0	
C71	Možgani Brain	M	5,7	0	8,3	0	3,9	1,6	2,7	0	0	4,0	7,5	2,6	7,7	15,3	17,9	15,2	24,2	3,7	0,4	
		Ž	5,9	3,7	0	4,5	0	1,7	1,5	2,7	1,4	1,4	2,6	4,0	9,3	10,5	19,6	12,1	24,7	7,8	0,4	
C72	Hrbtni mozeg, možganski živci in drugi deli ČZS Spinal cord, cranial nerves and other parts of CNS	M	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0,0	
		Ž	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0,0	
C73	Ščitnica Thyroid gland	M	4,1	0	0	0	0	1,6	5,5	3,6	2,5	4,0	1,3	2,6	6,4	12,2	4,5	15,2	13,8	3,7	0,3	
		Ž	10,3	0	0	0	6,2	6,9	6,0	13,4	12,2	11,3	10,4	10,7	15,9	31,6	9,8	10,1	9,0	9,4	0,7	
C74	Nadledvična žleza Adrenal gland	M	0,2	0	0	0	0	0	0	0	0	0	0	0	1,3	0	0	2,5	0	0	0,0	
		Ž	0,4	0	0	0	0	1,7	0	0	0	0	0	0	0	1,5	0	0	2,2	1,6	0,0	
C75	Druge endokrine žleze in sorodne strukture Other endocrine glands and related structures	M	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0,0	
		Ž	0,1	0	0	0	0	0	0	1,3	0	0	0	0	0	0	0	0	0	0	0,0	
C76	Druga in slabo opredeljena mesta Other and ill-defined sites	M	0,9	0	0	0	0	0	0	0	0	0	0	0	1,3	4,6	0	2,5	6,9	7,5	0,0	
		Ž	3,4	1,9	0	0	0	0	0	0	0	0	0	0	0	1,5	3,9	6,0	13,5	34,4	0,1	
C77	Metastaza in neopredeljena maligna neoplazma bezgavk Metastasis and unspecified malignant neoplasm of lymph nodes	M	2,0	0	0	0	0	0	0	0	0	0	1,3	1,3	6,4	0	11,2	10,1	6,9	7,5	0,2	
		Ž	0,7	0	0	0	0	0	0	0	0	0	2,6	1,3	0	1,5	0	2,0	4,5	0	0,0	

Tabela 5: Nadaljevanje.

Table 5: Continued.

Šifra MKB ICD code	Primarna lokacija Primary site	Spol Sex	Vse starosti All ages	Starost Age																		KS CR
				0–	5–	10–	15–	20–	25–	30–	35–	40–	45–	50–	55–	60–	65–	70–	75–	80+	0–74	
C78	Metastaze dihal in prebavil	M	3,0	0	0	0	0	0	0	1,2	0	1,3	0	1,3	1,3	3,1	6,7	7,6	24,2	44,9	0,1	
	Metastases of respiratory and digestive organs	Ž	5,0	0	0	0	0	0	3,0	0	0	0	0	0	4,0	3,0	3,9	14,1	11,2	48,4	0,1	
C79	Metastaze, druge	M	1,9	0	0	0	0	0	0	0	0	1,3	0	2,6	0	6,1	4,5	5,1	17,3	11,2	0,1	
	Metastases of other sites	Ž	1,3	0	0	0	0	0	0	0	0	0	0	1,3	4,0	4,5	2,0	2,0	4,5	4,7	0,1	
C80	Maligna neoplazma brez opredeljenega mesta	M	6,3	0	0	0	0	0	0	0	0	2,6	1,3	1,3	11,5	10,7	31,3	25,4	27,7	44,9	0,4	
	Malignant neoplasm without specification of site	Ž	5,3	0	0	0	0	0	0	1,3	0	1,4	3,9	2,7	6,6	10,5	0	14,1	22,5	29,7	0,2	
C81	Hodgkinova bolezen	M	1,7	0	0	0	0	3,2	2,7	4,8	1,2	1,3	0	3,9	1,3	1,5	4,5	0	0	0	0,1	
	Hodgkin's disease	Ž	1,6	0	0	2,3	4,1	1,7	1,5	2,7	1,4	1,4	0	2,7	1,3	0	3,9	4,0	2,2	0	0,1	
C82	Folikularni ne-Hodgkinov limfom	M	4,3	0	0	0	0	0	1,4	2,4	0	1,3	6,3	9,0	3,8	9,2	9,0	22,8	10,4	11,2	0,3	
	Follicular non-Hodgkin's lymphoma	Ž	3,9	0	0	0	0	0	1,5	2,7	0	1,4	1,3	2,7	5,3	19,6	5,9	10,1	6,7	9,4	0,3	
C83	Difuzni ne-Hodgkinov limfom	M	10,2	0	0	0	0	3,2	0	1,2	0	6,6	3,8	18,1	12,8	16,8	24,6	40,6	38,1	74,9	0,6	
	Diffuse non-Hodgkin's lymphoma	Ž	12,0	0	0	0	0	0	0	2,7	1,4	4,2	7,8	6,7	10,6	13,5	27,5	40,3	51,7	53,1	0,6	
C84	Limfomi celic T in kožni limfom celic T	M	2,1	0	0	0	0	0	0	0	1,2	0	0	2,6	2,6	0	9,0	10,1	10,4	18,7	0,1	
	Peripheral and cutaneous T-cell lymphomas	Ž	1,2	0	0	0	0	0	0	0	1,4	0	1,3	2,7	0	4,5	3,9	2,0	2,2	1,6	0,1	
C85	Druge in neopredeljene vrste ne-Hodgkinovega limfoma	M	0,8	0	0	0	0	0	0	0	0	1,3	0	1,3	2,6	0	2,2	2,5	3,5	3,7	0,0	
	Other and unspecified types of non-Hodgkin's lymphoma	Ž	1,5	0	0	0	0	0	0	0	1,4	1,4	0	0	1,3	3,0	3,9	4,0	6,7	6,2	0,1	
C88	Maligne imunoproliferativne bolezni	M	1	0	0	0	0	0	0	0	0	0	0	0	1,3	1,5	0	2,5	3,5	3,7	0,0	
	Malignant immunoproliferative diseases	Ž	0,2	0	0	0	0	0	0	0	0	0	0	0	0	1,5	2,0	0	0	0	0,0	
C90	Difuzni plazmocitom in maligne neoplazme plazmocitov	M	7,0	0	0	0	0	0	1,4	0	0	1,3	0	7,8	5,1	16,8	35,8	30,4	20,8	52,4	0,5	
	Multiple myeloma and malignant plasma cell neoplasms	Ž	5,5	0	0	0	0	0	0	0	1,4	4,2	1,3	4,0	4,0	12,0	9,8	12,1	24,7	25,0	0,2	
C91.0	Limfatična levkemija, akutna	M	1,6	5,3	4,2	2,1	2,0	3,2	0	1,2	0	0	0	1,3	1,3	3,1	0	2,5	3,5	0	0,1	
	Lymphoblastic leukaemia, acute	Ž	1,1	5,6	0	6,8	0	0	0	0	0	0	0	0	2,6	0	2,0	2,0	0	1,6	0,1	
C91.1–C91.9	Limfatična levkemija, druga	M	6,2	0	0	0	2,0	0	0	0	0	0	0	5,2	10,2	21,4	17,9	25,4	31,2	33,7	0,4	
	Lymphoid leukaemia, other	Ž	3,9	0	0	0	0	0	0	0	0	0	3,9	4,0	2,6	6,0	11,8	8,1	13,5	18,7	0,2	
C92	Mieloična levkemija	M	6,1	1,8	0	0	2,0	0	0	0	0	1,3	2,5	5,2	7,7	9,2	22,4	25,4	17,3	59,9	0,4	
	Myeloid leukaemia	Ž	3,9	0	0	4,5	0	1,7	0	2,7	4,1	4,2	2,6	2,7	5,3	9,0	3,9	4,0	9,0	12,5	0,2	

Nadaljevanje —>

Continued —>

Tabela 5: Nadaljevanje.

Table 5: Continued.

Šifra MKB ICD code	Primarna lokacija Primary site	Spol Sex	Vse starosti All ages	Starost Age																		KS CR
				0–	5–	10–	15–	20–	25–	30–	35–	40–	45–	50–	55–	60–	65–	70–	75–	80+	0–74	
C93	Monocitna levkemija	M	0,3	0	0	0	0	0	0	0	0	0	0	0	0	1,5	0	2,5	3,5	0	0,0	
	Monocytic leukaemia	Ž	0,4	0	0	0	0	0	0	0	0	0	0	0	1,3	1,5	0	0	4,5	0	0,0	
C94	Druge opredeljene levkemije	M	0,7	0	0	0	0	0	0	0	0	0	1,3	0	1,3	1,5	0	5,1	3,5	3,7	0,0	
	Other leukaemias of specified cells	Ž	0,8	0	0	0	0	0	0	0	0	0	1,3	0	0	0	0	6,0	4,5	3,1	0,0	
C95	Levkemija z neopredeljenim celičnim tipom	M	0,1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	3,7	0,0	
	Leukaemia, unspecified cell type	Ž	0,1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	2,0	0	0	0,0	
C96	Druge in neopredeljene maligne neoplazme limfatičnega, krvotvornega ali sorodnega tkiva	M	5,7	0	0	0	0	1,6	0	1,2	0	1,3	2,5	2,6	8,9	9,2	11,2	20,3	41,5	48,7	0,3	
	Other and unspecified malignant neoplasms of lymphoid, haematopoietic and related tissue	Ž	4,9	0	0	0	0	0	0	0	4,1	0	1,3	1,3	7,9	3,0	7,9	10,1	27,0	26,6	0,2	

Zgoraj neupoštevani

Not included above

Šifra MKB ICD code		Primarna lokacija Primary site	Spol Sex	Vse starosti All ages	Starost Age																		KS CR
					0—	5—	10—	15—	20—	25—	30—	35—	40—	45—	50—	55—	60—	65—	70—	75—	80+	0–74	
D03	Melanom, in situ	M	10,0	0	0	0	2,0	3,2	4,1	4,8	6,2	5,3	10,0	10,3	11,5	27,5	24,6	30,4	27,7	33,7	0,7		
	Melanoma, in situ	Ž	10,9	0	0	0	0	0	12,0	14,8	23,1	11,3	20,7	12,0	10,6	13,5	17,7	14,1	13,5	7,8	0,7		
D05	Dojka, in situ	M	0,1	0	0	0	0	0	0	0	0	0	0	0	1,3	0	0	0	0	0	0,0		
	Breast, in situ	Ž	8,9	0	0	0	0	0	0	0	2,7	2,7	5,6	7,8	21,3	21,2	28,6	31,4	10,1	9,0	3,1	0,7	
D06	Maternični vrat, CIN III	M	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—		
	Cervix uteri, in situ	Ž	88,5	0	0	0	2,1	141,2	280,0	255,4	235,3	147,9	104,9	45,3	33,1	27,1	21,6	16,1	6,7	1,6	6,5		
D09.0	Sečni mehur, in situ	M	13,9	0	0	0	0	0	0	0	0	5,3	6,3	14,2	14,0	26,0	56,0	71,0	69,2	74,9	1,0		
	Bladder, in situ	Ž	4,2	0	0	0	0	0	0	0	0	0	2,6	1,3	14,6	7,5	5,9	14,1	6,7	18,7	0,2		
D32.0	Meninge, benigna neoplazma	M	1,9	0	0	0	0	0	0	0	0	0	1,3	3,9	2,6	4,6	4,5	12,7	3,5	7,5	0,1		
	Benign neoplasm of meninges	Ž	6,3	0	0	0	0	0	1,5	1,3	5,4	2,8	5,2	6,7	7,9	15,1	13,8	24,2	9,0	14,1	0,4		
D33.0 D33.2	Možgani, benigna neoplazma	M	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0,0		
	Benign neoplasm of brain	Ž	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0,0		
D39.1	Jajčnik, neopl. negotovega značaja	M	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—		
	Ovary, neopl. of uncertain behavior	Ž	3,9	0	0	0	2,1	1,7	3,0	2,7	4,1	7,0	3,9	9,3	6,6	1,5	5,9	8,1	6,7	1,6	0,3		
D43.0 D43.2	Možgani, neopredeljeno	M	0,6	0	0	0	0	0	0	0	1,2	0	0	1,3	0	1,5	2,2	2,5	3,5	0	0,0		
	CNS, uncertain or unknown	Ž	0,7	0	0	0	0	0	0	0	0	1,4	1,3	0	1,3	3,0	0	0	0	3,1	0,0		

Tabela 6a: Incidenca najpogostejših lokacij raka po statističnih regijah in spolu, Slovenija 2012.

Table 6a: Incidence of most frequent cancer sites by statistical regions and by sex, Slovenia 2012.

Statistična regija Statistical region	Spol Sex	Skupaj All sites	Primarna lokacija (šifra MKB) Primary site (ICD code)											
		C00–C96	C16	C18	C19	C20	C34	C44	C50	C53	C54	C61	Drugo Other	D06*
Slovenija, skupaj Slovenia, total	M	7240	294	534	79	310	867	1175	15	—	—	1425	2541	—
	Ž	6037	167	387	46	174	384	1157	1296	118	336	—	1972	919
Pomurska	M	474	19	32	8	28	58	86	0	—	—	118	125	—
	Ž	362	9	20	5	15	20	93	58	7	20	—	115	42
Podravska	M	1058	56	76	8	59	134	126	4	—	—	198	397	—
	Ž	868	35	60	9	37	62	116	203	24	65	—	257	182
Koroška	M	264	16	14	3	12	39	37	0	—	—	55	88	—
	Ž	209	12	12	1	8	13	54	34	2	10	—	63	40
Savinjska	M	757	37	65	8	36	98	116	1	—	—	105	291	—
	Ž	696	25	45	6	19	31	130	157	12	39	—	232	134
Zasavska	M	165	12	12	4	11	26	15	0	—	—	22	63	—
	Ž	122	3	12	1	5	13	8	20	2	7	—	51	11
Spodnjeposavska	M	244	9	20	4	8	21	30	2	—	—	52	98	—
	Ž	197	6	10	2	4	12	39	37	5	14	—	68	41
Jugovzhodna Slovenija	M	538	17	40	5	23	61	93	0	—	—	121	178	—
	Ž	416	9	29	6	14	25	81	96	10	22	—	124	43
Osrednjeslovenska	M	1968	63	132	26	74	228	357	3	—	—	430	655	—
	Ž	1732	32	97	8	42	114	331	424	42	83	—	559	222
Gorenjska	M	781	21	51	4	28	83	147	3	—	—	184	260	—
	Ž	635	13	42	1	17	43	147	105	9	37	—	221	84
Notranjsko-kraška	M	165	5	13	2	6	14	23	0	—	—	34	68	—
	Ž	145	2	9	2	0	9	23	35	0	8	—	57	25
Goriška	M	441	20	48	2	11	47	70	1	—	—	62	180	—
	Ž	321	11	26	4	7	21	48	65	2	18	—	119	31
Obalno-kraška	M	385	19	31	5	14	58	75	1	—	—	44	138	—
	Ž	334	10	25	1	6	21	87	62	3	13	—	106	64

Opis šifer MKB/Description of the ICD code

C16 Želodec
StomachC18 Debelo črevo
ColonC19 Rektosigmoidna zveza
Rectosigmoid junctionC20 Rektum
RectumC34 Sapnica in pljuča
Bronchus and lungC44 Koža, razen melanoma
Skin, non-melanomaC50 Dojka
BreastC53 Maternični vrat
Cervix uteriC54 Maternično telo
Corpus uteriC61 Prostata
ProstateD06 Maternični vrat, in situ (CIN III)
Cervix uteri, in situ (CIN III)

* Neupoštevano v skupnem številu: D06 – maternični vrat, in situ (CIN III)

* Not included in All sites: D06 – Cervix uteri, in situ (CIN III)

Tabela 6b: Starostno standardizirana* incidenčna stopnja najpogostejših lokacij raka po statističnih regijah in spolu, Slovenija 2012.

Table 6b: Age standardised* incidence rate of most frequent cancer sites by statistical regions and by sex, Slovenia 2012.

Statistična regija Statistical region	Spol Sex	Skupaj All sites	Primarna lokacija (šifra MKB) Primary site (ICD code)											
		C00–C96	C16	C18	C19	C20	C34	C44	C50	C53	C54	C61	Drugo Other	D06**
Slovenija, skupaj Slovenia, total	M	693,3	28,5	51,2	7,6	29,5	81,5	114,5	1,4	—	—	136,9	268,9	—
	Ž	460,8	11,7	28,0	3,4	12,9	29,6	82,0	106,9	10,6	26,4	—	181,4	96,9
Pomurska	M	761,9	31,6	55,3	11,8	44,0	85,8	143,3	0,0	—	—	189,3	224,8	—
	Ž	444,7	8,5	27,3	6,1	20,1	27,3	104,1	78,4	10,5	25,3	—	167,1	79,7
Podravska	M	626,6	33,5	44,3	4,8	34,8	77,2	77,2	2,2	—	—	117,1	251,3	—
	Ž	404,6	15,0	26,8	4,0	16,5	28,8	50,7	102,5	12,8	30,5	—	133,8	123,7
Koroška	M	694,5	43,8	36,5	8,8	31,9	100,5	104,0	0,0	—	—	141,7	263,3	—
	Ž	445,5	26,3	25,4	2,4	14,1	30,0	107,7	84,1	3,2	23,6	—	140,2	127,8
Savinjska	M	583,1	28,1	51,7	5,9	27,3	73,4	91,6	0,9	—	—	78,9	239,8	—
	Ž	440,9	15,7	27,1	3,6	11,2	19,6	74,5	106,4	9,4	25,2	—	171,2	111,1
Zasavska	M	708,3	53,9	49,0	17,7	49,8	109,3	67,3	0,0	—	—	93,3	281,6	—
	Ž	432,0	11,3	38,3	1,6	18,1	48,5	27,4	74,2	7,7	21,7	—	205,8	59,5
Spodnjeposavska	M	649,4	24,9	55,0	12,5	20,9	51,6	77,2	6,2	—	—	141,2	286,1	—
	Ž	427,0	12,9	18,5	3,8	10,4	27,5	78,3	87,9	15,0	33,5	—	163,4	130,8
Jugovzhodna Slovenija	M	766,3	23,6	57,8	6,8	32,6	86,4	135,3	0,0	—	—	174,6	274,6	—
	Ž	479,0	8,3	31,7	7,0	15,1	27,5	82,1	119,2	13,7	26,0	—	170,1	67,8
Osrednjeslovenska	M	760,8	24,1	50,3	10,3	28,5	88,4	139,4	1,1	—	—	168,4	291,0	—
	Ž	521,1	8,6	27,3	2,3	12,4	34,7	93,7	137,2	14,5	24,8	—	221,1	85,4
Gorenjska	M	757,4	20,7	49,6	4,0	27,5	78,9	142,9	2,8	—	—	179,5	281,5	—
	Ž	491,3	8,5	30,6	0,7	12,0	34,5	110,1	84,8	8,7	30,3	—	203,4	90,3
Notranjsko-kraška	M	601,1	18,6	46,7	7,3	24,7	47,1	85,0	0,0	—	—	127,5	281,3	—
	Ž	443,2	5,6	28,5	7,1	0,0	26,0	65,8	113,2	0,0	25,7	—	204,2	109,2
Goriška	M	660,8	32,2	69,5	3,0	15,3	71,6	105,4	1,6	—	—	90,2	290,1	—
	Ž	397,5	12,9	25,2	6,3	10,2	24,9	56,6	89,1	3,1	26,3	—	170,2	58,5
Obalno-kraška	M	640,0	31,7	52,7	9,0	22,6	94,6	126,0	1,6	—	—	71,0	262,6	—
	Ž	454,6	13,4	32,5	1,3	7,4	27,9	107,4	91,9	4,6	18,9	—	175,9	125,6

Opis šifer MKB/Description of the ICD code

C16 Želodec
Stomach
C18 Debelo črevo
Colon
C19 Rektosigmoidna zveza
Rectosigmoid junction
C20 Rektum
Rectum
C34 Sapnica in pljuča
Bronchus and lung

C44 Koža, razen melanoma
Skin, non-melanoma
C50 Dojka
Breast
C53 Maternični vrat
Cervix uteri
C54 Maternično telo
Corpus uteri
C61 Prostata
Prostate
D06 Maternični vrat, in situ (CIN III)
Cervix uteri, in situ (CIN III)

* Standard – prebivalstvo Slovenije po popisu 2002

* Standard – population of Slovenia according to census 2002

** Neupoštevano v skupnem številu: D06 – maternični vrat, in situ (CIN III)

** Not included in All sites: D06 – Cervix uteri, in situ (CIN III)

Tabela 7: Incidenca histološko (H) in citološko (C) potrjenih primerov raka po histološki vrsti in lokaciji, Slovenija 2012.

Table 7: Incidence of histologically (H) and cytologically (C) confirmed cancer cases by histological type and by site, Slovenia 2012.

Histološka vrsta Histologic type	Skupaj All sites		Primarna lokacija (šifra MKB) Primary site (ICD code)																				
	C00–C96		C00		C01		C02		C03		C04		C05		C06		C07		C08		C09		
	H	C	H	C	H	C	H	C	H	C	H	C	H	C	H	C	H	C	H	C	H	C	
Vse vrste/All types	11835	663	20	–	28	–	26	–	14	–	35	–	22	–	12	–	7	1	5	–	49	–	
Small cell carcinoma	160	43	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	
Non-small cell carcinoma	45	32	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	
Squamous cell carcinoma	1340	65	20	–	25	–	25	–	12	–	35	–	18	–	10	–	–	–	–	–	–	49	–
Basal cell carcinoma	1849	21	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	
Transitional cell carcinoma	332	9	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	
Adenocarcinoma	6123	209	–	–	3	–	1	–	1	–	–	–	–	–	2	–	4	–	5	–	–	–	
Other specified carcinomas	119	8	–	–	–	–	–	–	1	–	–	–	3	–	–	–	1	–	–	–	–	–	
Carcinoma, unspecified	83	143	–	–	–	–	–	–	–	–	–	–	1	–	–	–	–	1	–	–	–	–	
Malignant thymoma	4	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	
Malignant paraganglioma/pheochromocytoma	2	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	
Malignant melanoma	542	4	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	
Fibrosarcoma	15	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	
Fibrohistiocytic sarcoma	6	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	
Liposarcoma	18	1	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	
Leiomyosarcoma	22	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	
Rhabdomyosarcoma	2	1	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	
Synovial sarcoma	2	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	
Angiosarcoma	–	1	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	
Kaposi sarcoma	4	1	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	
Osteosarcoma	4	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	
Chondrosarcoma	6	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	
Ewing sarcoma/PNET	1	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	
Other specified sarcomas	1	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	
Sarcoma, unspecified	20	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	
Malignant complex mixed and stromal tumors	62	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	2	–	–	–	–	–	
Malignant fibroepithelial tumors	1	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	
Malignant mesothelioma	40	3	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	
Malignant gonadal stromal tumors	1	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	
Dysgerminoma and seminoma	63	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	
Other malignant germ cell tumors	44	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	
Malignant trophoblastic tumors	9	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	
Malignant gliomas	102	1	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	
Malignant neuroepithelial tumors	5	1	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	
Malignant meningioma	3	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	
Malignant nerve sheath tumors	3	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	
Non Hodgkin lymphoma	339	39	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	
Hodgkin lymphoma	34	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	
Plasma cell tumors	118	10	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	
Chronic lymphoid leukemia	75	18	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	
Leukemia except chronic lymphoid	129	20	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	
Other lymphoreticular neoplasms	2	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	
Chronic myeloproliferative diseases	51	2	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	
Myelodysplastic syndromes	44	25	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	
Other specified malignant tumors	3	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	
Malignant tumor, unspecified	7	6	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	

Nadaljevanje —>
Continued —>

Table 7: Continued.

[illegible]

Tabela 7: Nadaljevanje.

Table 7: Continued.

Histološka vrsta Histologic type	Skupaj All sites		Primarna lokacija (šifra MKB) Primary site (ICD code)																			
	C00–C96		C20		C21		C22		C23		C24		C25		C26		C30		C31		C32	
	H	C	H	C	H	C	H	C	H	C	H	C	H	C	H	C	H	C	H	C	H	C
Vse vrste/All types	11835	663	467	3	10	—	77	21	32	2	49	7	143	42	4	—	12	1	8	—	87	—
Small cell carcinoma	160	43	—	—	—	—	—	—	—	—	—	—	2	—	—	—	2	—	—	—	—	—
Non-small cell carcinoma	45	32	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Squamous cell carcinoma	1340	65	1	—	5	—	—	—	1	—	—	—	—	—	—	—	3	—	4	—	82	—
Basal cell carcinoma	1849	21	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Transitional cell carcinoma	332	9	—	—	1	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Adenocarcinoma	6123	209	460	—	4	—	77	20	28	1	47	4	130	28	4	—	2	—	4	—	—	—
Other specified carcinomas	119	8	1	—	—	—	—	—	2	—	—	—	2	—	—	—	2	—	—	—	1	—
Carcinoma, unspecified	83	143	5	3	—	—	—	1	1	1	1	3	8	13	—	—	—	—	—	—	4	—
Malignant thymoma	4	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Malignant paraganglioma/pheochromocytoma	2	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Malignant melanoma	542	4	—	—	—	—	—	—	—	—	—	—	—	—	—	—	1	—	—	—	—	—
Fibrosarcoma	15	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Fibrohistiocytic sarcoma	6	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Liposarcoma	18	1	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Leiomyosarcoma	22	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Rhabdomyosarcoma	2	1	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Synovial sarcoma	2	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Angiosarcoma	—	1	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Kaposi sarcoma	4	1	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Osteosarcoma	4	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Chondrosarcoma	6	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Ewing sarcoma/PNET	1	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Other specified sarcomas	1	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Sarcoma, unspecified	20	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Malignant complex mixed and stromal tumors	62	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Malignant fibroepithelial tumors	1	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Malignant mesothelioma	40	3	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Malignant gonadal stromal tumors	1	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Dysgerminoma and seminoma	63	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Other malignant germ cell tumors	44	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Malignant trophoblastic tumors	9	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Malignant gliomas	102	1	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Malignant neuroepithelial tumors	5	1	—	—	—	—	—	—	—	—	—	—	—	—	—	—	2	1	—	—	—	—
Malignant meningioma	3	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Malignant nerve sheath tumors	3	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Non Hodgkin lymphoma	339	39	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Hodgkin lymphoma	34	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Plasma cell tumors	118	10	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Chronic lymphoid leukemia	75	18	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Leukemia except chronic lymphoid	129	20	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Other lymphoreticular neoplasms	2	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Chronic myeloproliferative diseases	51	2	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Myelodysplastic syndromes	44	25	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Other specified malignant tumors	3	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Malignant tumor, unspecified	7	6	—	—	—	—	—	—	—	—	1	—	1	1	—	—	—	—	—	—	—	—

Nadaljevanje —>
Continued —>

Tabela 7: Nadaljevanje.

Table 7: Continued.

Histološka vrsta Histologic type	Skupaj All sites		Primarna lokacija (šifra MKB) Primary site (ICD code)																			
	C00–C96		C33		C34		C37		C38		C39		C40		C41		C43		C44		C45	
	H	C	H	C	H	C	H	C	H	C	H	C	H	C	H	C	H	C	H	C	H	C
Vse vrste/All types	11835	663	5	—	957	215	5	—	4	—	—	—	6	—	9	—	513	3	2291	33	40	3
Small cell carcinoma	160	43	—	—	147	42	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Non-small cell carcinoma	45	32	—	—	45	32	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Squamous cell carcinoma	1340	65	3	—	294	50	1	—	—	—	—	—	—	—	—	—	—	—	421	9	—	—
Basal cell carcinoma	1849	21	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	1848	21	—	—
Transitional cell carcinoma	332	9	—	—	1	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Adenocarcinoma	6123	209	1	—	407	75	—	—	—	—	—	—	—	—	—	—	—	—	10	1	—	—
Other specified carcinomas	119	8	—	—	55	4	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Carcinoma, unspecified	83	143	—	—	6	11	—	—	—	—	—	—	—	—	—	—	—	—	4	2	—	—
Malignant thymoma	4	—	—	—	—	—	4	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Malignant paraganglioma/pheochromocytoma	2	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Malignant melanoma	542	4	—	—	—	—	—	—	—	—	—	—	—	—	—	—	513	3	—	—	—	—
Fibrosarcoma	15	—	—	—	—	—	—	—	2	—	—	—	—	—	—	—	—	—	—	—	—	—
Fibrohistiocytic sarcoma	6	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	6	—	—	—
Liposarcoma	18	1	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Leiomyosarcoma	22	—	—	—	—	—	—	—	—	—	—	—	1	—	—	—	—	—	1	—	—	—
Rhabdomyosarcoma	2	1	—	—	—	—	—	—	—	—	—	—	—	—	1	—	—	—	—	—	—	—
Synovial sarcoma	2	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Angiosarcoma	—	1	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Kaposi sarcoma	4	1	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Osteosarcoma	4	—	—	—	—	—	—	—	—	—	—	—	2	—	1	—	—	—	—	—	—	—
Chondrosarcoma	6	—	—	—	—	—	—	—	—	—	—	—	2	—	4	—	—	—	—	—	—	—
Ewing sarcoma/PNET	1	—	—	—	—	—	—	—	—	—	—	—	1	—	—	—	—	—	—	—	—	—
Other specified sarcomas	1	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Sarcoma, unspecified	20	—	—	—	1	—	—	—	1	—	—	—	—	—	—	—	—	—	1	—	—	—
Malignant complex mixed and stromal tumors	62	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Malignant fibroepithelial tumors	1	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Malignant mesothelioma	40	3	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	40	3
Malignant gonadal stromal tumors	1	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Dysgerminoma and seminoma	63	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Other malignant germ cell tumors	44	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Malignant trophoblastic tumors	9	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Malignant gliomas	102	1	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Malignant neuroepithelial tumors	5	1	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Malignant meningioma	3	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Malignant nerve sheath tumors	3	—	—	—	—	—	—	—	1	—	—	—	—	—	—	—	—	—	—	—	—	—
Non Hodgkin lymphoma	339	39	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Hodgkin lymphoma	34	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Plasma cell tumors	118	10	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Chronic lymphoid leukemia	75	18	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Leukemia except chronic lymphoid	129	20	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Other lymphoreticular neoplasms	2	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Chronic myeloproliferative diseases	51	2	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Myelodysplastic syndromes	44	25	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Other specified malignant tumors	3	—	—	—	—	—	—	—	—	—	—	—	—	—	3	—	—	—	—	—	—	—
Malignant tumor, unspecified	7	6	1	—	1	1	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—

Tabela 7: Nadaljevanje.

Table 7: Continued.

Histološka vrsta Histologic type	Skupaj All sites		Primarna lokacija (šifra MKB) Primary site (ICD code)																			
	C00–C96		C46		C47		C48		C49		C50		C51		C52		C53		C54		C55	
	H	C	H	C	H	C	H	C	H	C	H	C	H	C	H	C	H	C	H	C	H	C
Vse vrste/All types	11835	663	4	1	1	—	20	1	53	3	1205	97	35	—	11	—	117	—	334	—	14	—
Small cell carcinoma	160	43	—	—	—	—	—	—	—	—	—	—	—	—	—	—	1	—	—	—	—	—
Non-small cell carcinoma	45	32	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Squamous cell carcinoma	1340	65	—	—	—	—	—	—	—	—	1	—	32	—	8	—	89	—	—	—	—	—
Basal cell carcinoma	1849	21	—	—	—	—	—	—	—	—	—	—	1	—	—	—	—	—	—	—	—	—
Transitional cell carcinoma	332	9	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Adenocarcinoma	6123	209	—	—	—	—	10	—	—	—	1185	22	1	—	—	—	26	—	300	—	—	—
Other specified carcinomas	119	8	—	—	—	—	—	—	—	—	10	—	—	—	1	—	—	—	18	—	—	—
Carcinoma, unspecified	83	143	—	—	—	—	—	—	—	—	7	75	—	—	—	—	—	—	1	—	1	—
Malignant thymoma	4	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Malignant paraganglioma/pheochromocytoma	2	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Malignant melanoma	542	4	—	—	—	—	—	—	—	—	—	—	1	—	—	—	—	—	—	—	—	—
Fibrosarcoma	15	—	—	—	—	—	1	—	11	—	—	—	—	—	—	—	—	—	—	—	—	—
Fibrohistiocytic sarcoma	6	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Liposarcoma	18	1	—	—	—	—	4	—	11	1	—	—	—	—	—	—	—	—	—	—	—	—
Leiomyosarcoma	22	—	—	—	—	—	—	—	11	—	—	—	—	—	1	—	—	—	—	—	8	—
Rhabdomyosarcoma	2	1	—	—	—	—	—	—	1	1	—	—	—	—	—	—	—	—	—	—	—	—
Synovial sarcoma	2	—	—	—	—	—	—	—	2	—	—	—	—	—	—	—	—	—	—	—	—	—
Angiosarcoma	—	1	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Kaposi sarcoma	4	1	4	1	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Osteosarcoma	4	—	—	—	—	—	1	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Chondrosarcoma	6	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Ewing sarcoma/PNET	1	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Other specified sarcomas	1	—	—	—	—	—	—	—	1	—	—	—	—	—	—	—	—	—	—	—	—	—
Sarcoma, unspecified	20	—	—	—	—	—	—	—	15	—	1	—	—	—	—	—	—	—	—	—	—	—
Malignant complex mixed and stromal tumors	62	—	—	—	—	—	1	—	1	—	—	—	—	—	1	—	1	—	14	—	5	—
Malignant fibroepithelial tumors	1	—	—	—	—	—	—	—	—	—	1	—	—	—	—	—	—	—	—	—	—	—
Malignant mesothelioma	40	3	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Malignant gonadal stromal tumors	1	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Dysgerminoma and seminoma	63	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Other malignant germ cell tumors	44	—	—	—	—	—	1	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Malignant trophoblastic tumors	9	—	—	—	—	—	1	—	—	—	—	—	—	—	—	—	—	—	1	—	—	—
Malignant gliomas	102	1	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Malignant neuroepithelial tumors	5	1	—	—	—	—	1	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Malignant meningioma	3	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Malignant nerve sheath tumors	3	—	—	—	1	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Non Hodgkin lymphoma	339	39	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Hodgkin lymphoma	34	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Plasma cell tumors	118	10	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Chronic lymphoid leukemia	75	18	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Leukemia except chronic lymphoid	129	20	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Other lymphoreticular neoplasms	2	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Chronic myeloproliferative diseases	51	2	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Myelodysplastic syndromes	44	25	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Other specified malignant tumors	3	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Malignant tumor, unspecified	7	6	—	—	—	—	—	1	—	1	—	—	—	—	—	—	—	—	—	—	—	—

Nadaljevanje —>
Continued —>

Tabela 7: Nadaljevanje.

Table 7: Continued.

Histološka vrsta Histologic type	Skupaj All sites		Primarna lokacija (šifra MKB) Primary site (ICD code)																			
	C00–C96		C56		C57		C58		C60		C61		C62		C63		C64		C65		C66	
	H	C	H	C	H	C	H	C	H	C	H	C	H	C	H	C	H	C	H	C	H	C
Vse vrste/All types	11835	663	142	6	10	—	—	—	10	—	1375	1	105	—	3	—	274	11	21	2	21	—
Small cell carcinoma	160	43	—	—	—	—	—	—	—	—	3	—	—	—	—	—	—	—	—	—	—	—
Non-small cell carcinoma	45	32	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Squamous cell carcinoma	1340	65	—	—	—	—	—	—	10	—	—	—	—	—	1	—	—	—	1	—	—	—
Basal cell carcinoma	1849	21	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Transitional cell carcinoma	332	9	2	—	—	—	—	—	—	—	8	—	—	—	—	—	—	—	20	2	21	—
Adenocarcinoma	6123	209	122	4	10	—	—	—	—	—	1362	1	—	—	—	—	273	8	—	—	—	—
Other specified carcinomas	119	8	4	—	—	—	—	—	—	—	1	—	—	—	—	—	—	—	—	—	—	—
Carcinoma, unspecified	83	143	3	2	—	—	—	—	—	—	1	—	—	—	—	—	1	3	—	—	—	—
Malignant thymoma	4	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Malignant paraganglioma/pheochromocytoma	2	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Malignant melanoma	542	4	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Fibrosarcoma	15	—	1	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Fibrohistiocytic sarcoma	6	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Liposarcoma	18	1	—	—	—	—	—	—	—	—	—	—	—	—	2	—	—	—	—	—	—	—
Leiomyosarcoma	22	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Rhabdomyosarcoma	2	1	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Synovial sarcoma	2	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Angiosarcoma	—	1	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Kaposi sarcoma	4	1	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Osteosarcoma	4	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Chondrosarcoma	6	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Ewing sarcoma/PNET	1	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Other specified sarcomas	1	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Sarcoma, unspecified	20	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Malignant complex mixed and stromal tumors	62	—	2	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Malignant fibroepithelial tumors	1	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Malignant mesothelioma	40	3	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Malignant gonadal stromal tumors	1	—	—	—	—	—	—	—	—	—	—	—	1	—	—	—	—	—	—	—	—	—
Dysgerminoma and seminoma	63	—	1	—	—	—	—	—	—	—	—	—	61	—	—	—	—	—	—	—	—	—
Other malignant germ cell tumors	44	—	5	—	—	—	—	—	—	—	—	—	37	—	—	—	—	—	—	—	—	—
Malignant trophoblastic tumors	9	—	1	—	—	—	—	—	—	—	—	—	6	—	—	—	—	—	—	—	—	—
Malignant gliomas	102	1	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Malignant neuroepithelial tumors	5	1	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Malignant meningioma	3	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Malignant nerve sheath tumors	3	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Non Hodgkin lymphoma	339	39	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Hodgkin lymphoma	34	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Plasma cell tumors	118	10	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Chronic lymphoid leukemia	75	18	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Leukemia except chronic lymphoid	129	20	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Other lymphoreticular neoplasms	2	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Chronic myeloproliferative diseases	51	2	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Myelodysplastic syndromes	44	25	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Other specified malignant tumors	3	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Malignant tumor, unspecified	7	6	1	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—

Tabela 7: Nadaljevanje.

Table 7: Continued.

Histološka vrsta Histologic type	Skupaj All sites		Primarna lokacija (šifra MKB) Primary site (ICD code)																			
	C00–C96		C67		C68		C69		C70		C71		C72		C73		C74		C75		C76	
	H	C	H	C	H	C	H	C	H	C	H	C	H	C	H	C	H	C	H	C	H	C
Vse vrste/All types	11835	663	288	9	–	1	20	–	3	–	103	1	–	–	140	9	5	1	1	–	12	12
Small cell carcinoma	160	43	1	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Non-small cell carcinoma	45	32	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Squamous cell carcinoma	1340	65	1	–	–	–	2	–	–	–	–	–	–	–	–	–	–	–	–	–	–	1
Basal cell carcinoma	1849	21	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Transitional cell carcinoma	332	9	279	6	–	1	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Adenocarcinoma	6123	209	2	–	–	–	1	–	–	–	–	–	–	–	139	5	2	1	–	–	6	8
Other specified carcinomas	119	8	1	–	–	–	–	–	–	–	–	–	–	–	1	3	–	–	–	–	–	–
Carcinoma, unspecified	83	143	4	2	–	–	–	–	–	–	–	–	–	–	–	1	–	–	–	–	1	2
Malignant thymoma	4	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Malignant paraganglioma/pheochromocytoma	2	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	2	–	–	–	–	–
Malignant melanoma	542	4	–	–	–	–	15	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Fibrosarcoma	15	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Fibrohistiocytic sarcoma	6	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Liposarcoma	18	1	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	1	–
Leiomyosarcoma	22	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Rhabdomyosarcoma	2	1	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Synovial sarcoma	2	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Angiosarcoma	–	1	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	1
Kaposi sarcoma	4	1	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Osteosarcoma	4	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Chondrosarcoma	6	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Ewing sarcoma/PNET	1	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Other specified sarcomas	1	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Sarcoma, unspecified	20	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	1	–	–	–
Malignant complex mixed and stromal tumors	62	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	3	–
Malignant fibroepithelial tumors	1	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Malignant mesothelioma	40	3	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Malignant gonadal stromal tumors	1	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Dysgerminoma and seminoma	63	–	–	–	–	–	–	–	–	–	1	–	–	–	–	–	–	–	–	–	–	–
Other malignant germ cell tumors	44	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	1	–	–
Malignant trophoblastic tumors	9	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Malignant gliomas	102	1	–	–	–	–	–	–	–	–	102	1	–	–	–	–	–	–	–	–	–	–
Malignant neuroepithelial tumors	5	1	–	–	–	–	2	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Malignant meningioma	3	–	–	–	–	–	–	–	3	–	–	–	–	–	–	–	–	–	–	–	–	–
Malignant nerve sheath tumors	3	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Non Hodgkin lymphoma	339	39	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Hodgkin lymphoma	34	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Plasma cell tumors	118	10	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Chronic lymphoid leukemia	75	18	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Leukemia except chronic lymphoid	129	20	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Other lymphoreticular neoplasms	2	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Chronic myeloproliferative diseases	51	2	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Myelodysplastic syndromes	44	25	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Other specified malignant tumors	3	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Malignant tumor, unspecified	7	6	–	1	–	–	–	–	–	–	–	–	–	–	–	–	1	–	–	–	–	–

Nadaljevanje →
Continued →

Tabela 7: Nadaljevanje.

Table 7: Continued.

Histološka vrsta Histologic type	Skupaj All sites		Primarna lokacija (šifra MKB) Primary site (ICD code)																			
	C00–C96		C77		C78		C79		C80		C81		C82		C83		C84		C85		C88	
	H	C	H	C	H	C	H	C	H	C	H	C	H	C	H	C	H	C	H	C	H	C
Vse vrste/All types	11835	663	23	4	20	21	22	–	52	25	34	–	74	11	211	18	29	4	18	6	7	–
Small cell carcinoma	160	43	–	–	–	–	1	–	3	1	–	–	–	–	–	–	–	–	–	–	–	–
Non-small cell carcinoma	45	32	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Squamous cell carcinoma	1340	65	12	2	1	–	1	–	5	2	–	–	–	–	–	–	–	–	–	–	–	–
Basal cell carcinoma	1849	21	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Transitional cell carcinoma	332	9	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Adenocarcinoma	6123	209	9	2	17	12	13	–	25	12	–	–	–	–	–	–	–	–	–	–	–	–
Other specified carcinomas	119	8	1	–	–	–	2	–	2	1	–	–	–	–	–	–	–	–	–	–	–	–
Carcinoma, unspecified	83	143	–	–	2	9	1	–	8	7	–	–	–	–	–	–	–	–	–	–	–	–
Malignant thymoma	4	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Malignant paraganglioma/pheochromocytoma	2	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Malignant melanoma	542	4	1	–	–	–	4	–	7	1	–	–	–	–	–	–	–	–	–	–	–	–
Fibrosarcoma	15	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Fibrohistiocytic sarcoma	6	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Liposarcoma	18	1	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Leiomyosarcoma	22	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Rhabdomyosarcoma	2	1	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Synovial sarcoma	2	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Angiosarcoma	–	1	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Kaposi sarcoma	4	1	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Osteosarcoma	4	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Chondrosarcoma	6	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Ewing sarcoma/PNET	1	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Other specified sarcomas	1	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Sarcoma, unspecified	20	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Malignant complex mixed and stromal tumors	62	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Malignant fibroepithelial tumors	1	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Malignant mesothelioma	40	3	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Malignant gonadal stromal tumors	1	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Dysgerminoma and seminoma	63	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Other malignant germ cell tumors	44	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Malignant trophoblastic tumors	9	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Malignant gliomas	102	1	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Malignant neuroepithelial tumors	5	1	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Malignant meningioma	3	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Malignant nerve sheath tumors	3	–	–	–	–	–	–	–	1	–	–	–	–	–	–	–	–	–	–	–	–	–
Non Hodgkin lymphoma	339	39	–	–	–	–	–	–	–	–	–	–	74	11	211	18	29	4	18	6	7	–
Hodgkin lymphoma	34	–	–	–	–	–	–	–	–	–	34	–	–	–	–	–	–	–	–	–	–	–
Plasma cell tumors	118	10	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Chronic lymphoid leukemia	75	18	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Leukemia except chronic lymphoid	129	20	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Other lymphoreticular neoplasms	2	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Chronic myeloproliferative diseases	51	2	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Myelodysplastic syndromes	44	25	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Other specified malignant tumors	3	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Malignant tumor, unspecified	7	6	–	–	–	–	–	–	1	1	–	–	–	–	–	–	–	–	–	–	–	–

Tabela 7: Nadaljevanje.

Table 7: Continued.

Histološka vrsta Histologic type	Skupaj All sites		Primarna lokacija (šifra MKB) Primary site (ICD code)															
			C00–C96		C90		C91		C92		C93		C94		C95		C96	
	H	C	H	C	H	C	H	C	H	C	H	C	H	C	H	C	H	C
Vse vrste/All types	11835	663	118	10	107	23	90	13	6	1	14	1	1	1	83	26		
Small cell carcinoma	160	43	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Non-small cell carcinoma	45	32	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Squamous cell carcinoma	1340	65	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Basal cell carcinoma	1849	21	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Transitional cell carcinoma	332	9	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Adenocarcinoma	6123	209	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Other specified carcinomas	119	8	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Carcinoma, unspecified	83	143	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Malignant thymoma	4	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Malignant paraganglioma/pheochromocytoma	2	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Malignant melanoma	542	4	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Fibrosarcoma	15	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Fibrohistiocytic sarcoma	6	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Liposarcoma	18	1	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Leiomyosarcoma	22	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Rhabdomyosarcoma	2	1	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Synovial sarcoma	2	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Angiosarcoma	–	1	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Kaposi sarcoma	4	1	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Osteosarcoma	4	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Chondrosarcoma	6	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Ewing sarcoma/PNET	1	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Other specified sarcomas	1	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Sarcoma, unspecified	20	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Malignant complex mixed and stromal tumors	62	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Malignant fibroepithelial tumors	1	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Malignant mesothelioma	40	3	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Malignant gonadal stromal tumors	1	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Dysgerminoma and seminoma	63	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Other malignant germ cell tumors	44	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Malignant trophoblastic tumors	9	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Malignant gliomas	102	1	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Malignant neuroepithelial tumors	5	1	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Malignant meningioma	3	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Malignant nerve sheath tumors	3	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Non Hodgkin lymphoma	339	39	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Hodgkin lymphoma	34	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Plasma cell tumors	118	10	118	10	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Chronic lymphoid leukemia	75	18	–	–	75	18	–	–	–	–	–	–	–	–	–	–	–	–
Leukemia except chronic lymphoid	129	20	–	–	32	5	90	13	6	1	–	–	1	1	–	–	–	–
Other lymphoreticular neoplasms	2	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	2	–
Chronic myeloproliferative diseases	51	2	–	–	–	–	–	–	–	–	14	1	–	–	–	–	37	1
Myelodysplastic syndromes	44	25	–	–	–	–	–	–	–	–	–	–	–	–	–	–	44	25
Other specified malignant tumors	3	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Malignant tumor, unspecified	7	6	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–

Tabela 8: Incidenca raka (brez primerov registriranih samo iz zdravniških poročil o vzroku smrti) po stadiju, lokaciji in spolu, Slovenija 2012.

Table 8: Cancer incidence (without cases registered from death certificates only) by stage, by site and by sex, Slovenia 2012.

Šifra MKB ICD code	Primarna lokacija Primary site	Spol Sex	Število novih primerov Number of new cases	Stadij							
				Omejen		Razširjen		Razsejan		Neznan	
				Število	%*	Število	%*	Število	%*	Število	%*
				Stage							
				Localized		Regional		Distant		Unknown	
Number	%*	Number	%*	Number	%*	Number	%*				
C00 – C80	Vse lokacije All sites	M+Ž	12349	6532	52,9	3427	27,8	2275	18,4	115	0,9
		M	6754	3539	52,4	1895	28,1	1249	18,5	71	1,1
		Ž	5595	2993	53,5	1532	27,4	1026	18,3	44	0,8
C00	Ustnica Lip	M	14	13	—	1	—	0	—	0	—
		Ž	6	6	—	0	—	0	—	0	—
C01	Baza jezika Base of tongue	M	24	6	25,0	18	75,0	0	0	0	0
		Ž	4	1	—	3	—	0	—	0	—
C02	Jezik, drugi deli Tongue, other & unspecified parts	M	22	8	36,4	14	63,6	0	0	0	0
		Ž	5	3	—	2	—	0	—	0	—
C03	Dlesen Gum	M	7	2	—	5	—	0	—	0	—
		Ž	7	2	—	5	—	0	—	0	—
C04	Ustno dno Floor of mouth	M	27	10	37,0	16	59,3	1	3,7	0	0
		Ž	8	2	—	6	—	0	—	0	—
C05	Nebo Palate	M	18	8	44,4	10	55,6	0	0	0	0
		Ž	4	2	—	2	—	0	—	0	—
C06	Usta, drugi deli Mouth, other & unspecified parts	M	9	4	—	4	—	1	—	0	—
		Ž	3	2	—	1	—	0	—	0	—
C07	Parotidna žleza Parotid gland	M	3	0	—	1	—	2	—	0	—
		Ž	5	4	—	1	—	0	—	0	—
C08	Druge in neopredeljene velike žleze slinavke Other & unspecified major salivary glands	M	4	3	—	1	—	0	—	0	—
		Ž	1	1	—	0	—	0	—	0	—
C09	Tonzila Tonsil	M	43	3	7,0	39	90,7	1	2,3	0	0
		Ž	6	0	—	6	—	0	—	0	—
C10	Orofarinks Oropharynx	M	44	3	6,8	40	90,9	0	0	1	2,3
		Ž	7	1	—	6	—	0	—	0	—
C11	Nazofarinks Nasopharynx	M	5	0	—	4	—	1	—	0	—
		Ž	5	0	—	4	—	0	—	1	—
C12	Piriformni sinus Pyriform sinus	M	32	3	9,4	26	81,3	3	9,4	0	0
		Ž	2	0	—	2	—	0	—	0	—
C13	Hipofarinks Hypopharynx	M	18	2	11,1	14	77,8	2	11,1	0	0
		Ž	3	2	—	1	—	0	—	0	—
C14	Druga in slabo opredeljena mesta na ustnici, v ustni votlini in farinksu Other and ill-defined sites in the lip, oral cavity and pharynx	M	1	1	—	0	—	0	—	0	—
		Ž	0	0	—	0	—	0	—	0	—
C15	Požiralnik Oesophagus	M	73	15	20,5	36	49,3	20	27,4	2	2,7
		Ž	14	4	—	6	—	4	—	0	—
C16	Želodec Stomach	M	294	52	17,7	145	49,3	92	31,3	5	1,7
		Ž	167	36	21,6	75	44,9	53	31,7	3	1,8
C17	Tanko črevo Small intestine	M	17	8	47,1	6	35,3	3	17,6	0	0
		Ž	15	4	26,7	4	26,7	6	40,0	1	6,7
C18	Debelo črevo Colon	M	533	126	23,6	291	54,6	114	21,4	2	0,4
		Ž	386	85	22,0	202	52,3	94	24,4	5	1,3
C19	Rektosigmoidna zveza Rectosigmoid junction	M	79	17	21,5	45	57,0	17	21,5	0	0
		Ž	46	6	13,0	30	65,2	10	21,7	0	0
C20	Rektum Rectum	M	310	73	23,5	188	60,6	46	14,8	3	1,0
		Ž	174	37	21,3	96	55,2	41	23,6	0	0
C21	Anus in analni kanal Anus and anal canal	M	4	1	—	2	—	1	—	0	—
		Ž	6	1	—	5	—	0	—	0	—
C22	Jetra in intrahepatični vodi Liver and intrahepatic bile ducts	M	161	65	40,4	45	28,0	48	29,8	3	1,9
		Ž	40	14	35,0	11	27,5	14	35,0	1	2,5
C23	Žolčnik Gallbladder	M	15	1	6,7	6	40,0	8	53,3	0	0
		Ž	49	8	16,3	16	32,7	25	51,0	0	0
C24	Drugi in neopredeljeni deli biliarnega trakta Biliary tract, other and unspecified parts	M	56	14	25,0	29	51,8	12	21,4	1	1,8
		Ž	55	17	30,9	24	43,6	12	21,8	2	3,6
C25	Trebušna slinavka Pancreas	M	183	23	12,6	49	26,8	110	60,1	1	0,5
		Ž	172	22	12,8	51	29,7	95	55,2	4	2,3
C26	Druga in slabo opredeljena mesta v prebavnih organih Other and ill-defined digestive organs	M	2	0	—	0	—	2	—	0	—
		Ž	4	0	—	0	—	4	—	0	—

Tabela 8: Nadaljevanje.

Table 8: Continued.

Šifra MKB ICD code	Primarna lokacija Primary site	Spol Sex	Število novih primerov Number of new cases	Stadij							
				Omejen		Razširjen		Razsejan		Neznani	
				Število	%*	Število	%*	Število	%*	Število	%*
				Stage							
				Localized		Regional		Distant		Unknown	
				Number	%*	Number	%*	Number	%*	Number	%*
C30	Nosna votlina in srednje uho Nasal cavity and middle ear	M	8	2	—	6	—	0	—	0	—
		Ž	5	2	—	3	—	0	—	0	—
C31	Obnosni sinusi Accessory sinuses	M	4	1	—	3	—	0	—	0	—
		Ž	4	0	—	3	—	1	—	0	—
C32	Grlo Larynx	M	76	39	51,3	35	46,1	1	1,3	1	1,3
		Ž	13	5	—	8	—	0	—	0	—
C33	Sapnik Trachea	M	5	1	—	3	—	0	—	1	—
		Ž	1	0	—	0	—	0	—	1	—
C34	Sapnica in pljuča Bronchus and lung	M	866	127	14,7	271	31,3	464	53,6	4	0,5
		Ž	382	63	16,5	111	29,1	207	54,2	1	0,3
C37	Timus Thymus	M	3	0	—	2	—	1	—	0	—
		Ž	2	1	—	0	—	1	—	0	—
C38	Srce, mediastinum, plevra Heart, mediastinum, pleura	M	4	2	—	1	—	1	—	0	—
		Ž	2	0	—	1	—	1	—	0	—
C39	Druga in slabo opredeljena mesta v dihalih in prsni organih Other and ill-defined sites in the respiratory system and intrathoracic organs	M	0	0	—	0	—	0	—	0	—
		Ž	0	0	—	0	—	0	—	0	—
C40	Kosti, sklepi hrustanec udov Bone and articular cartilage of limbs	M	1	1	—	0	—	0	—	0	—
		Ž	5	2	—	3	—	0	—	0	—
C41	Kosti, sklepi hrustanec, drugje Bone and articular cartilage of other and unspecified parts	M	4	1	—	3	—	0	—	0	—
		Ž	5	1	—	3	—	1	—	0	—
C43	Maligni melanom kože Malignant melanoma of skin	M	257	195	75,9	55	21,4	4	1,6	3	1,2
		Ž	259	204	78,8	47	18,1	6	2,3	2	0,8
C44	Druge maligne neoplazme kože Skin, other malignomas	M	1175	1163	99,0	11	0,9	1	0,1	0	0
		Ž	1157	1138	98,4	18	1,6	1	0,1	0	0
C45	Mezoteliom Mesothelioma	M	32	10	31,3	16	50,0	4	12,5	2	6,3
		Ž	11	5	—	4	—	2	—	0	—
C46	Kaposijev sarkom Kaposi's sarcoma	M	5	4	—	0	—	1	—	0	—
		Ž	0	0	—	0	—	0	—	0	—
C47	Periferni živci in avtonomno živčevje Peripheral nerves and autonomic nervous system	M	1	0	—	1	—	0	—	0	—
		Ž	0	0	—	0	—	0	—	0	—
C48	Peritonej in retroperitonej Retroperitoneum and peritoneum	M	4	1	—	2	—	1	—	0	—
		Ž	17	2	11,8	3	17,6	11	64,7	1	5,9
C49	Drugo vezivno in mehko tkivo Other connective and soft tissue	M	28	11	39,3	12	42,9	5	17,9	0	0
		Ž	29	15	51,7	9	31,0	4	13,8	1	0
C50	Dojka Breast	M	15	6	40,0	8	53,3	1	6,7	0	0
		Ž	1294	666	51,5	535	41,3	92	7,1	1	0,1
C51	Žensko zunanje spolovilo Vulva	M	—	—	—	—	—	—	—	—	—
		Ž	35	12	34,3	22	62,9	1	2,9	0	0
C52	Nožnica Vagina	M	—	—	—	—	—	—	—	—	—
		Ž	11	1	—	7	—	2	—	1	—
C53	Maternični vrat Cervix uteri	M	—	—	—	—	—	—	—	—	—
		Ž	118	56	47,5	50	42,4	10	8,5	2	1,7
C54	Maternično telo Corpus uteri	M	—	—	—	—	—	—	—	—	—
		Ž	336	257	76,5	59	17,6	17	5,1	3	0,9
C55	Maternica, neopredeljeno Uterus, unspecified	M	—	—	—	—	—	—	—	—	—
		Ž	14	7	—	3	—	3	—	1	—
C56	Jajčnik Ovary	M	—	—	—	—	—	—	—	—	—
		Ž	154	12	7,8	8	5,2	133	86,4	1	0,6
C57	Drugi in neopredeljeni ženski spolni organi Other and unspecified parts of female genital organs	M	—	—	—	—	—	—	—	—	—
		Ž	10	0	—	0	—	10	—	0	—
C58	Posteljica Placenta	M	—	—	—	—	—	—	—	—	—
		Ž	0	0	—	0	—	0	—	0	—
C60	Penis Penis	M	10	8	—	1	—	0	—	1	—
		Ž	—	—	—	—	—	—	—	—	—
C61	Prostata Prostate	M	1424	988	69,4	326	22,9	90	6,3	20	1,4
		Ž	—	—	—	—	—	—	—	—	—

Nadaljevanje —>

Continued —>

Tabela 8: Nadaljevanje.

Table 8: Continued.

Šifra MKB ICD code	Primarna lokacija Primary site	Spol Sex	Število novih primerov Number of new cases	Stadij							
				Omejen		Razširjen		Razsejan		Neznan	
				Število	%*	Število	%*	Število	%*	Število	%*
				Stage							
				Localized		Regional		Distant		Unknown	
Number	%*	Number	%*	Number	%*	Number	%*				
C62	Modo	M	105	80	76,2	12	11,4	13	12,4	0	0
	Testis	Ž	—	—	—	—	—	—	—	—	—
C63	Drugi in neopredeljeni moški spolni organi	M	3	3	—	0	—	0	—	0	—
	Other and unspecified male genital organs	Ž	—	—	—	—	—	—	—	—	—
C64	Ledvica razen meha	M	211	136	64,5	38	18,0	37	17,5	0	0
	Kidney, except renal pelvis	Ž	100	67	67,0	20	20,0	13	13,0	0	0
C65	Ledvični meh	M	18	6	33,3	7	38,9	5	27,8	0	0
	Renal pelvis	Ž	9	4	—	3	—	2	—	0	—
C66	Sečevod	M	14	12	—	1	—	1	—	0	—
	Ureter	Ž	8	4	—	3	—	1	—	0	—
C67	Sečni mehur	M	224	185	82,6	26	11,6	13	5,8	0	0
	Bladder	Ž	79	59	74,7	12	15,2	6	7,6	2	2,5
C68	Drugi in neopredeljeni sečni organi	M	0	0	—	0	—	0	—	0	—
	Other and unspecified urinary organs	Ž	1	0	—	0	—	1	—	0	—
C69	Oko in očesni adneksi	M	14	9	—	4	—	1	—	0	—
	Eye and adnexa	Ž	6	3	—	3	—	0	—	0	—
C70	Meninge	M	1	1	—	0	—	0	—	0	—
	Meninges	Ž	2	1	—	1	—	0	—	0	—
C71	Možgani	M	58	58	100	0	0	0	0	0	0
	Brain	Ž	61	61	100	0	0	0	0	0	0
C72	Hrbtni mozeg, možganski živci in drugi deli ČŽS	M	0	0	—	0	—	0	—	0	—
	Spinal cord, cranial nerves and other parts of CNS	Ž	0	0	—	0	—	0	—	0	—
C73	Ščitnica	M	42	26	61,9	13	31,0	2	4,8	1	2,4
	Thyroid gland	Ž	107	82	76,6	19	17,8	5	4,7	1	0,9
C74	Nadledvična žleza	M	2	2	—	0	—	0	—	0	—
	Adrenal gland	Ž	4	2	—	0	—	2	—	0	—
C75	Druge endokrine žleze in sorodne strukture	M	0	0	—	0	—	0	—	0	—
	Other endocrine glands and related structures	Ž	1	1	—	0	—	0	—	0	—
C76	Druga in slabo opredeljena mesta	M	9	0	—	3	—	6	—	0	—
	Other and ill-defined sites	Ž	34	0	0	15	44,1	17	50,0	2	5,9
C77	Metastaza in neopredeljena maligna neoplazma bezgavk	M	20	0	0	0	0	0	0	20	100
	Metastasis and unspecified malignant neoplasm of lymph nodes	Ž	7	0	—	0	—	0	—	7	—
C78	Metastaze dihal in prebavil	M	30	0	0	0	0	30	100	0	0
	Metastases of respiratory and digestive organs	Ž	51	0	0	0	0	51	100	0	0
C79	Metastaze, drugje	M	19	0	0	0	0	19	100	0	0
	Metastases of other sites	Ž	14	0	—	0	—	14	—	0	—
C80	Maligna neoplazma brez opredeljenega mesta	M	64	0	0	0	0	64	100	0	0
	Malignant neoplasm without specification of site	Ž	53	0	0	0	0	53	100	0	0

Šifra MKB	Primarna lokacija	Spol	Število primerov Number of new cases	Stadij (Ann–Arbor)							
				I		II		III+IV		Neznan	
				Število	%*	Število	%*	Število	%*	Število	%*
ICD code	Primary site			Stage (Ann–Arbor)							
				I		II		III+IV		Unknown	
				Number	%*	Number	%*	Number	%*	Number	%*
C81	Hodgkinova bolezen	M	17	3	17,6	3	17,6	10	58,8	1	5,9
	Hodgkin's disease	Ž	17	2	11,8	5	29,4	9	52,9	1	5,9
C82–C85	Ne-Hodgkinov limfom	M	177	37	20,9	25	14,1	69	39,0	46	26,0
	Non-Hodgkin's lymphoma	Ž	194	39	20,1	24	12,4	95	49,0	36	18,6

* Odstotki niso računani, če je število novih primerov manjše od 15

* Percentages are not calculated when number of new cases is less than 15

Tabela 9: Incidenca ne-Hodgkinovih limfomov* po lokaciji, spolu in starosti, Slovenija 2012.

Table 9: Incidence of non-Hodgkin's malignant lymphomas* by site, by sex and by age, Slovenia 2012.

Šifra MKB–8 ICD–8 code	Primarna lokacija Primary site	Spol Sex	Vse starosti All ages	Starost Age																	
				0–	5–	10–	15–	20–	25–	30–	35–	40–	45–	50–	55–	60–	65–	70–	75–	80+	
	Vsi NHL	M+Ž	371	0	0	0	0	2	2	7	4	12	16	33	30	44	41	58	48	74	
	All NHL	M	177	0	0	0	0	2	1	3	1	7	8	24	17	17	20	30	18	29	
		Ž	194	0	0	0	0	0	1	4	3	5	8	9	13	27	21	28	30	45	
141	Jezik	M	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	
	Tongue	Ž	2	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	2	
142	Slinavke	M	1	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	
	Salivary glands	Ž	4	0	0	0	0	0	0	2	0	0	0	0	0	1	1	0	0	0	
145	Usta, drugo	M	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	
	Mouth, other parts	Ž	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
146	Orofarinks	M	4	0	0	0	0	0	0	0	0	0	0	1	0	0	2	0	1	0	
	Oropharynx	Ž	8	0	0	0	0	0	0	0	0	0	0	0	0	3	1	1	1	2	
147	Epifarinks	M	1	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	
	Epipharynx	Ž	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
151	Želodec	M	17	0	0	0	0	0	1	0	0	1	2	2	1	2	1	2	3	2	
	Stomach	Ž	14	0	0	0	0	0	0	0	0	0	3	0	1	0	1	2	4	3	
152	Tanko črevo	M	3	0	0	0	0	0	0	0	0	0	0	0	1	0	1	0	1	0	
	Small intestine	Ž	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
153	Debelo črevo	M	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
	Colon	Ž	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	
154	Rektum	M	1	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	
	Rectum	Ž	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
157	Trebušna slinavka	M	1	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	
	Pancreas	Ž	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
160	Nos, obnosne votline, drugo	M	1	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	
	Nose, sinuses, etc.	Ž	1	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	
162	Sapnik, sapnica, pljuča	M	3	0	0	0	0	0	0	0	0	0	0	0	2	0	0	0	1	0	
	Trachea, bronchus, lung	Ž	4	0	0	0	0	0	0	0	0	0	1	0	1	0	2	0	0	0	
163	Plevra, mediastinum, drugo	M	1	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	
	Pleura, mediastinum, etc.	Ž	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	
171	Mehka tkiva	M	2	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	1	
	Soft tissues	Ž	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	
173	Koža, drugi malignomi	M	7	0	0	0	0	0	0	1	0	0	1	1	1	0	0	1	1	1	
	Skin, other malignancies	Ž	8	0	0	0	0	0	0	0	0	0	0	1	0	2	0	1	2	2	
174	Dojka	M	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
	Breast	Ž	3	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	2	0	
188	Mehur	M	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
	Bladder	Ž	1	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	
189	Ledvica, sečevod, drugo	M	2	0	0	0	0	0	0	0	0	0	0	1	0	0	1	0	0	0	
	Kidney, ureter, etc.	Ž	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
190	Oko	M	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	
	Eye	Ž	1	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	
191	Možgani	M	3	0	0	0	0	0	0	0	0	0	0	2	0	0	0	1	0	0	
	Brain	Ž	7	0	0	0	0	0	0	0	0	0	0	0	0	2	0	1	3	1	
202	Bezgavke	M	127	0	0	0	0	2	0	2	0	4	5	17	11	13	14	25	10	24	
	Lymph nodes	Ž	138	0	0	0	0	0	0	2	3	5	4	6	11	19	15	21	18	34	

* Vključeni so samo citološko in histološko potrjeni primeri

* All cases included have been verified citologically and histologically

Tabela 10: Incidenca malignih neoplazem limfatičnega tkiva v skladu s klasifikacijo Svetovne zdravstvene organizacije iz leta 2008, po spolu in starosti, Slovenija 2012.

Table 10: Incidence of malignant neoplasms of lymphoid tissue according to 2008 version of Classification of Tumours of Haematopoietic and Lymphoid Tissues (published by World Health Organization), by sex and by age, Slovenia 2012.

Šifra ICD-O-3 ICD-O-3 code	Histološka vrsta Histology type	Spol Sex	Število Number	Incidenčna stopnja na 100.000 Incidence rate per 100,000
	Vse vrste All types	M+Ž	670	32,6
		M	349	34,3
		Ž	321	30,9
	Neoplazme nezrelih celic B Precursor lymphoid neoplasms B	M	10	1,0
		Ž	8	0,8
9727, 9728, 9835, 9836	Limfoblastna limfom B / levkemija B, BDO B lymphoblastic lymphoma / leukaemia, NOS	M	10	1,0
		Ž	8	0,8
	Neoplazme nezrelih celic T Precursor lymphoid neoplasms T	M	3	0,3
		Ž	1	0,1
9729, 9837	Limfoblastni limfom T / levkemija T T lymphoblastic lymphoma / leukaemia	M	3	0,3
		Ž	1	0,1
	Periferni B-celični limfom / neoplazme zrelih celic B Mature B-cell neoplasms	M	293	28,8
		Ž	278	26,8
9670, 9823	Kronična limfatična levkemija B / drobnocelični limfocitni limfom Chronic lymphocytic leukaemia / small lymphocytic lymphoma	M	59	5,8
		Ž	41	3,9
9689	Vranični limfom robne cone Splenic marginal zone lymphoma	M	4	0,4
		Ž	5	0,5
9591	Ne-Hodgkinovi limfomi, BDO; primarni vranični limfom / levkemija, nerazvrščeni; difuzni drobnocelični limfom B rdeče pulpe; posebna oblika dlakastocelične levkemije Non-Hodgkin lymphoma, NOS; splenic B-cell lymphoma / leukaemia, unclassifiable; splenic diffuse red pulp small B-cell lymphoma; hairy cell leukaemia-variant	M	7	0,7
		Ž	11	1,1
9940	Dlakastocelična levkemija Hairy cell leukaemia	M	5	0,5
		Ž	1	0,1
9671	Limfoplazmatični limfom Lymphoplasmacytic lymphoma	M	5	0,5
		Ž	7	0,7
9761	Waldenströмова makroglobulinemija Waldenström macroglobulinemia	M	5	0,5
		Ž	2	0,2
9732, 9733	Multipli mielom Plasma cell myeloma	M	67	6,6
		Ž	57	5,5
9731, 9734	Solitarni kostni in zunajkostni plazmacitom Solitary plasmacytoma of bone and extraosseous	M	4	0,4
		Ž	0	0,0
9699, nodalni	B-celični limfom robne cone, nodalni Marginal zone B-cell lymphoma, nodal	M	10	1,0
		Ž	7	0,7
9699, ekstranodalni	B-celični limfom robne cone, ekstranodalni Marginal zone B-cell lymphoma, extranodal	M	7	0,7
		Ž	9	0,9
9690	Folikularni limfom, BDO Follicular lymphoma, NOS	M	3	0,3
		Ž	8	0,8
9691, 9695	Folikularni limfom, gradus 1 in 2 Follicular lymphoma, grade 1 and 2	M	14	1,4
		Ž	12	1,2
9698	Folikularni limfom, gradus 3 Follicular lymphoma, grade 3	M	10	1,0
		Ž	4	0,4
9597	Primarni kožni limfom folikularnih centrov Primary cutaneous follicle centre lymphoma	M	0	0,0
		Ž	1	0,1
9673	Limfom plaščnih celic Mantle cell lymphoma	M	19	1,9
		Ž	9	0,9
9680, 9684	Difuzni velikocelični limfom B (DLBCL), BDO; primarni DLBCL CZS; primarni kožni DLBCL, nožni tip; EBV-pozitivni DLBCL starejših; DLBCL, povezan s kroničnim vnetjem; nerazvrščeni B-celični limfom, mejni primer med difuznim velikoceličnim limfomom B in Burkittovim limfomom Malignant lymphoma, large B-cell, diffuse (DLBCL), NOS; primary DLBCL of the CNS; primary cutaneous DLBCL, leg type; EBV positive DLBCL of the elderly; DLBCL associated with chronic inflammation; B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and Burkitt lymphoma	M	67	6,6
		Ž	99	9,5
9687, 9826	Burkittov limfom / levkemija Burkitt lymphoma / leukaemia	M	6	0,6
		Ž	2	0,2
9679	Primarni mediastinalni (timični) velikocelični limfom B Primary mediastinal (thymic) large B-cell lymphoma	M	1	0,1
		Ž	3	0,3

Tabela 10: Nadaljevanje.

Table 10: Continued.

Šifra ICD-O-3 ICD-O-3 code	Histološka vrsta Histology type	Spol Sex	Število Number	Incidenčna stopnja na 100.000 Incidence rate per 100,000
	Neoplazme zrelih celic T/NK Mature T- and NK-cell neoplasms	M	25	2,5
		Ž	12	1,2
	Levemične neoplazme zrelih celic T/NK Leukaemic mature T- and NK-cell neoplasms	M	4	0,4
		Ž	0	0,0
9834	Prolimfocitna levkemija T T-cell prolymphocytic leukaemia	M	2	0,2
		Ž	0	0,0
9827	Limfom T odraslih / levkemija T odraslih Adult T-cell lymphoma / leukaemia	M	2	0,2
		Ž	0	0,0
	Neoplazme zrelih (ekstranodalnih) celic T/NK Mature (extranodal) T- and NK-cell neoplasms	M	12	1,2
		Ž	5	0,5
9719	Ekstranodalni limfom NK/T, nazalni Extranodal NK/T-cell lymphoma, nasal type	M	0	0,0
		Ž	1	0,1
9717	Limfom T z enteropatijo Enteropathy-associated T-cell lymphoma	M	2	0,2
		Ž	0	0,0
9716	Hepatosplečni gama delta limfom T Hepatosplenic gamma delta T-cell lymphoma	M	0	0,0
		Ž	1	0,1
9700	Fungoidna mikoza Mycosis fungoides	M	7	0,7
		Ž	2	0,2
9718	Primarne kožne CD30+ T-celične limfoproliferativne bolezni Primary cutaneous CD30+ T-cell lymphoproliferative disorder	M	1	0,1
		Ž	0	0,0
9709	Primarni kožni periferni limfomi T, redki tipi Primary cutaneous T-cell lymphoma, rare types	M	2	0,2
		Ž	1	0,1
	Zrele (nodalne) neoplazme celic T/NK Mature (nodal) T- and NK-cell neoplasms	M	9	0,9
		Ž	7	0,7
9702	Periferni limfom T (BDO- in ALK-negativni ALCL) Peripheral T-cell lymphoma (NOS and ALK negative ALCL)	M	6	0,6
		Ž	3	0,3
9705	Angioimunoblastni limfom T Angioimmunoblastic T-cell lymphoma	M	1	0,1
		Ž	3	0,3
9714	Anaplastični velikocelični limfom, ALK-pozitivni Anaplastic large cell lymphoma, ALK positive	M	2	0,2
		Ž	1	0,1
	Hodgkinov limfom (HL) Hodgkin lymphoma (HL)	M	17	1,7
		Ž	17	1,6
9659	HL z nodularno limfocitno predominanco Nodular lymphocyte predominant HL	M	2	0,2
		Ž	0	0,0
9650	Klasični HL Classical HL	M	2	0,2
		Ž	2	0,2
9663, 9665, 9667	Klasični HL, tip nodularne skleroze Nodular sclerosis classical HL	M	5	0,5
		Ž	10	1,0
9651	Z limfociti bogat klasični HL Lymphocyte-rich classical HL	M	0	0,0
		Ž	1	0,1
9652	Mešanocelični tip klasičnega HL Mixed cellularity classical HL	M	7	0,7
		Ž	3	0,3
9653	Klasični HL, tip limfocitne deplecije Lymphocyte-depleted classical HL	M	1	0,1
		Ž	1	0,1
	Neopredeljeni limfomi / levkemije Unspecified lymphoma / leukaemia	M	1	0,1
		Ž	5	0,5
9590	Maligni limfom, BDO Malignant lymphoma, NOS	M	1	0,1
		Ž	5	0,5

Tabela 11a: Število in deleži bolnikov (brez primerov registriranih samo iz zdravniških poročil o vzroku smrti), v Sloveniji zbolelih leta 2012, ki so bili v okviru prvega zdravljenja operirani, zdravljeni s sistemsko terapijo ali obsevani.

Table 11a: Number of patients (without cases registered from death certificates only) diagnosed in Slovenia in 2012, that were treated by surgery, systemic therapy or radiotherapy during their first treatment.

Šifra MKB ICD code	Primarna lokacija Primary site	Število novih primerov Number of new cases	Število kakorkoli zdravljenih* Number of all treated*		Število operiranih Number of treated by surgery		Število zdravljenih s sistemskim zdravljenjem Number of treated systemic therapy		Število obsevanih Number of treated by radiotherapy	
			Število Number	%**	Število Number	%**	Število Number	%**	Število Number	%**
C00–C96	Vse lokacije All sites	13255	10689	80,6	8349	63,0	3784	28,5	2925	22,1
C00–C14	Usta in žrelo Mouth and pharynx	337	316	93,8	181	53,7	50	14,8	242	71,8
C15	Požiralnik Oesophagus	87	56	64,4	18	20,7	24	27,6	41	47,1
C16	Želodec Stomach	461	296	64,2	245	53,1	156	33,8	112	24,3
C18	Debelo črevo Colon	919	792	86,2	777	84,5	189	20,6	11	–
C19–C20	Rektum in rektosigmoidna zveza Rectum and rectosigmoid junction	609	528	86,7	479	78,7	202	33,2	229	37,6
C22	Jetra in intrahepatični vodi Liver and intrahepatic bile ducts	201	67	33,3	26	12,9	40	19,9	3	–
C23–C24	Žolčnik in žolčevodi Gallbladder and biliary tract	175	55	31,4	55	31,4	6	–	0	–
C25	Trebušna slinavka Pancreas	355	103	29,0	47	13,2	72	20,3	10	–
C32	Grlo Larynx	89	86	96,6	46	51,7	3	–	73	82,0
C33–C34	Sapnik, sapnici in pljuča Trachea, bronchus and lung	1254	908	72,4	253	20,2	478	38,1	547	43,6
C43	Maligni melanom kože Malignant melanoma of skin	516	509	98,6	505	97,9	2	–	23	4,5
C44	Druge maligne neoplazme kože Skin, other malignomas	2332	2282	97,9	2167	92,9	13	–	81	3,5
C48–C49	Vezivno in mehko tkivo Connective and soft tissue	78	68	87,2	64	82,1	15	19,2	24	30,8
C50	Dojka Breast	1309	1277	97,6	1133	86,6	1183	90,4	729	55,7
C53	Maternični vrat Cervix uteri	118	109	92,4	85	72,0	8	–	57	48,3
C54	Maternično telo Corpus uteri	336	318	94,6	302	89,9	31	9,2	79	23,5
C56	Jajčnik Ovary	154	133	86,4	122	79,2	109	70,8	3	–
C61	Prostata Prostate	1424	1111	78,0	721	50,6	432	30,3	173	12,1
C62	Modo Testis	105	105	100,0	104	99,0	65	61,9	1	–
C64–C65	Ledvica z ledvičnim mehom Kidney with renal pelvis	338	277	82,0	264	78,1	17	5,0	8	–
C67	Sečni mehur Bladder	303	276	91,1	274	90,4	45	14,9	27	8,9
C70–C72	Centralni in avtonomni živčni sistem Central and autonomic nervous system	122	101	82,8	94	77,0	47	38,5	72	59,0
C73	Ščitnica Thyroid gland	149	145	97,3	140	94,0	112	75,2	101	67,8
C81	Hodgkinova bolezen Hodgkin's disease	34	33	97,1	1	–	30	88,2	18	52,9
C82–C85	Ne-Hodgkinovi limfomi Non-Hodgkin's lymphoma	371	267	72,0	42	11,3	211	56,9	100	27,0
C90	Difuzni plazmocitom in maligne neoplazme plazmocitov Multiple myeloma and malignant plasma cell neoplasms	128	53	41,4	3	–	50	39,1	22	17,2
C91–C95	Levkemije Leukaemias	257	83	32,3	1	–	81	31,5	8	–

* Število kakorkoli zdravljenih v okviru prvega zdravljenja, ne glede na način zdravljenja (vključno z drugimi zdravljenji, ki ne spadajo pod operacijo, sistemsko zdravljenje ali obsevanje)

* Number of all treated patients regardless of the means of treatment (including other treatments not included into surgery, systemic therapy or radiotherapy)

** Odstotki niso računani, če je število zdravljenih manjše od 15

** Percentages are not calculated for less than 15 cases

Tabela 11b: Število bolnikov (brez primerov registriranih samo iz zdravniških poročil o vzroku smrti), v Sloveniji zbolelih leta 2012, ki so bili v okviru prvega zdravljenja operirani*, po lokaciji raka in bolnici posega.

Table 11b: Number of patients (without cases registered from death certificates only) diagnosed in Slovenia in 2012, that were treated by surgery during their first treatment* by primary site and treatment institution.

Šifra MKB ICD code	Primarna lokacija Primary site	Število novih primerov Number of new cases	Število operiranih Number of treated by surgery	Splošna bolnišnica Celje	Splošna bolnišnica Golnik	Splošna bolnišnica Jesenice	Splošna bolnišnica Izola	Univerzitetni klinični center Ljubljana	Onkološki inštitut Ljubljana	Univerzitetni klinični center Maribor	Splošna bolnišnica Murska Sobota	Splošna bolnišnica Nova Gorica	Splošna bolnišnica Novo mesto	Splošna bolnišnica Ptuj	Splošna bolnišnica Slovenj Gradec	Zasebne ordinacije Private clinics	Ostale ustanove** Other institutions**
C00–C96	Vse lokacije All sites	13255	8349	557	59	302	270	2791	1073	1215	331	306	397	43	481	438	86
C00–C14	Usta in žrelo Mouth and pharynx	337	181	2	0	1	0	106	1	62	6	0	1	0	0	0	2
C15	Požiralnik Oesophagus	87	18	0	0	0	0	13	0	5	0	0	0	0	0	0	0
C16	Želodec Stomach	461	245	15	2	11	14	108	0	71	3	3	4	0	13	0	1
C18	Debelo črevo Colon	919	777	61	0	64	55	227	31	114	38	51	46	15	25	33	17
C19–C20	Rektum in rektosigmoidna zveza Rectum and rectosigmoid junction	609	479	23	0	40	14	155	71	63	22	8	24	11	21	16	11
C22	Jetra in intrahepatični vodi Liver and intrahepatic bile ducts	201	26	0	0	0	0	17	0	8	0	0	1	0	0	0	0
C23–C24	Žolčnik in žolčevodi Gallbladder and biliary tract	175	55	0	0	1	2	33	0	13	1	0	3	1	0	0	1
C25	Trebušna slinavka Pancreas	355	47	0	0	0	1	34	0	12	0	0	0	0	0	0	0
C32	Grlo Larynx	89	46	0	0	0	0	29	0	17	0	0	0	0	0	0	0
C33–C34	Sapnik, sapnici in pljuča Trachea, bronchus and lung	1254	253	1	55	0	1	131	0	59	0	1	0	1	1	2	1
C43	Maligni melanom kože Malignant melanoma of skin	516	505	48	0	37	21	166	28	47	9	5	25	7	15	87	10
C44	Druge maligne neoplazme kože Skin, other malignomas	2332	2167	185	0	132	72	752	28	170	165	74	188	0	99	294	8
C48–C49	Vezivno in mehko tkivo Connective and soft tissue	78	64	2	0	3	4	14	36	3	0	1	0	0	1	0	0
C50	Dojka Breast	1309	1133	23	0	0	37	5	737	233	2	67	1	0	26	1	1
C53	Maternični vrat Cervix uteri	118	85	2	0	0	1	59	2	4	1	0	3	3	1	0	9
C54	Maternično telo Corpus uteri	336	302	23	0	11	5	124	17	60	11	9	9	5	13	0	15
C56	Jajčnik Ovary	154	122	11	0	1	3	59	13	20	3	7	1	0	3	0	1
C61	Prostata Prostate	1424	721	104	0	0	12	200	0	91	38	30	23	0	221	0	2
C62	Modo Testis	105	104	11	0	0	4	49	0	12	6	4	10	0	8	0	0
C64–C65	Ledvica z ledvičnim mehom Kidney with renal pelvis	338	264	16	0	0	4	133	1	37	10	21	25	0	17	0	0
C67	Sečni mehur Bladder	303	274	21	0	0	13	134	0	43	7	18	28	0	10	0	0
C70–C72	Centralni in avtonomni živčni sistem Central and autonomic nervous system	122	94	0	0	0	0	74	0	20	0	0	0	0	0	0	0
C73	Ščitnica Thyroid gland	149	140	0	2	0	6	28	92	8	0	0	0	0	0	2	2
C81	Hodgkinova bolezen Hodgkin's disease	34	1	0	0	0	0	0	0	1	0	0	0	0	0	0	0
C82–C85	Ne-Hodgkinovi limfomi Non-Hodgkin's lymphoma	371	42	1	0	0	1	24	3	6	0	2	1	0	2	1	1
C90	Difuzni plazmocitom in maligne neoplazme plazmocitov Multiple myeloma and malignant plasma cell neoplasms	128	3	0	0	0	0	2	0	1	0	0	0	0	0	0	0
C91–C95	Levkemije Leukaemias	257	1	0	0	0	0	1	0	0	0	0	0	0	0	0	0

* Bolniki, ki so bili v okviru prvega zdravljenja operirani več kot enkrat, so vključeni le s prvo operacijo

* Patients that underwent multiple surgery procedures in the course of first treatment were included with the first procedure only

** V posamezni ustanovi so operirali manj kot 30 bolnikov

** Less than 30 patients were treated by surgery in individual institution

Tabela 11c: Število bolnikov (brez primerov registriranih samo iz zdravniških poročil o vzroku smrti), v Sloveniji zbolelih leta 2012, ki so v okviru prvega zdravljenja prejeli sistemsko terapijo*, po lokacijah raka in bolnici posega.

Table 11c: Number of patients (without cases registered from death certificates only) diagnosed in Slovenia in 2012, that were treated by systemic therapy during their first treatment* by primary site and treatment institution.

Šifra MKB ICD code	Primarna lokacija Primary site	Število novih primerov Number of new cases	Število zdravljenih s sistemsko terapijo Number of treated systemic therapy	Splošna bolnišnica Celje	Bolnišnica Golnik	Splošna bolnišnica Izola	Univerzitetni klinični center Ljubljana	Onkološki inštitut Ljubljana	Univerzitetni klinični center Maribor	Splošna bolnišnica Murska Sobota	Splošna bolnišnica Nova Gorica	Splošna bolnišnica Novo mesto	Splošna bolnišnica Slovenj Gradec	Zasebne ordinacije Private clinics	Ostale ustanove** Other institutions**
C00–C96	Vse lokacije All sites	13255	3784	60	160	22	272	2572	411	48	68	48	51	61	11
C00–C14	Usta in žrelo Mouth and pharynx	337	50	0	0	0	1	49	0	0	0	0	0	0	0
C15	Požiralnik Oesophagus	87	24	0	0	0	1	23	0	0	0	0	0	0	0
C16	Želodec Stomach	461	156	0	0	0	12	138	5	0	0	0	0	0	1
C18	Debelo črevo Colon	919	189	1	0	0	5	167	12	0	0	0	4	0	0
C19–C20	Rektum in rektosigmoidna zveza Rectum and rectosigmoid junction	609	202	1	0	0	0	197	2	0	1	0	0	0	1
C22	Jetra in intrahepatični vodi Liver and intrahepatic bile ducts	201	40	2	0	0	33	4	1	0	0	0	0	0	0
C23–C24	Žolčnik in žolčevodi Gallbladder and biliary tract	175	6	0	0	0	1	5	0	0	0	0	0	0	0
C25	Trebušna slinavka Pancreas	355	72	0	0	0	25	43	4	0	0	0	0	0	0
C32	Grlo Larynx	89	3	0	0	0	1	2	0	0	0	0	0	0	0
C33–C34	Sapnik, sapnici in pljuča Trachea, bronchus and lung	1254	478	0	147	0	2	284	44	0	0	0	1	0	0
C43	Maligni melanom kože Malignant melanoma of skin	516	2	0	0	0	0	2	0	0	0	0	0	0	0
C44	Druge maligne neoplazme kože Skin, other malignomas	2332	13	1	0	0	0	1	2	0	0	0	0	9	0
C48–C49	Vezivno in mehko tkivo Connective and soft tissue	78	15	0	0	0	2	13	0	0	0	0	0	0	0
C50	Dojka Breast	1309	1183	10	0	12	0	861	233	0	44	0	23	0	0
C53	Maternični vrat Cervix uteri	118	8	0	0	0	0	7	1	0	0	0	0	0	0
C54	Maternično telo Corpus uteri	336	31	1	0	0	0	25	5	0	0	0	0	0	0
C56	Jajčnik Ovary	154	109	0	1	0	0	91	17	0	0	0	0	0	0
C61	Prostata Prostate	1424	432	25	2	6	74	101	59	40	14	40	18	50	3
C62	Modo Testis	105	65	0	0	0	1	64	0	0	0	0	0	0	0
C64–C65	Ledvica z ledvičnim mehom Kidney with renal pelvis	338	17	0	1	0	0	16	0	0	0	0	0	0	0
C67	Sečni mehur Bladder	303	45	0	0	0	7	34	0	3	0	0	1	0	0
C70–C72	Centralni in avtonomni živčni sistem Central and autonomic nervous system	122	47	0	0	0	6	41	0	0	0	0	0	0	0
C73	Ščitnica Thyroid gland	149	112	0	2	2	6	97	1	0	0	0	0	2	2
C81	Hodgkinova bolezen Hodgkin's disease	34	30	0	0	0	3	27	0	0	0	0	0	0	0
C82–C85	Ne-Hodgkinovi limfomi Non-Hodgkin's lymphoma	371	211	3	0	1	8	186	7	0	2	2	0	0	2
C90	Difuzni plazmocitom in maligne neoplazme plazmocitov Multiple myeloma and malignant plasma cell neoplasms	128	50	7	0	1	23	0	6	2	4	4	1	0	2
C91–C95	Levkemije Leukaemias	257	81	7	0	0	48	7	9	2	3	2	3	0	0

* Bolniki, ki so v okviru prvega zdravljenja prejeli več kot eno vrsto sistemskega zdravljenja, so vključeni le enkrat

* Patients that underwent multiple systemic treatments in the course of first treatment were included with the first treatment only

** V posamezni ustanovi so zdravili manj kot 10 bolnikov

** Less than 10 patients were treated in individual institution

Tabela 12: Prevalenca po spolu in izbrani primarni lokaciji raka, Slovenija, 31. 12. 2012.

Table 12: Prevalence of cancer patients by sex and by selected primary cancer site, Slovenia, December 31, 2012.

Šifra MKB ICD code	Primarna lokacija* Primary site*	Spol Sex	Leta po diagnozi Years after diagnosis				Celotna prevalenca Lifetime prevalence
			<1	1–4	5–9	10+	Vsi / All
C00	Vse lokacije	M+Ž	10767	30094	23407	30537	89788
C96	All sites	M	5735	15377	10276	10588	39335
		Ž	5032	14717	13131	19949	50453
C00–C14	Usta in žrelo Mouth and pharynx	M	237	533	331	418	1519
		Ž	59	176	163	212	610
C15	Požiralnik Oesophagus	M	43	32	21	16	112
		Ž	10	13	10	7	40
C16	Želodec Stomach	M	202	312	239	336	1089
		Ž	97	211	185	310	803
C18	Debelo črevo Colon	M	447	1286	692	720	3145
		Ž	309	972	659	828	2768
C19–C20	Rektum in rektosigmoidna zveza Rectum and rectosigmoid junction	M	345	1050	610	620	2625
		Ž	180	619	477	614	1890
C22	Jetra in intrahepatični vodi Liver and intrahepatic bile ducts	M	70	59	20	13	162
		Ž	16	18	7	8	49
C23–C24	Žolčnik in žolčevodi Gallbladder and biliary tract	M	37	46	20	25	128
		Ž	41	54	30	28	153
C25	Trebušna slinavka Pancreas	M	73	50	16	10	149
		Ž	82	46	23	14	165
C32	Grlo Larynx	M	69	258	212	313	852
		Ž	13	35	29	50	127
C33–C34	Sapnik, sapnici in pljuča Trachea, bronchus and lung	M	509	585	326	311	1731
		Ž	252	340	166	135	893
C43	Maligni melanom kože Malignant melanoma of skin	M	251	756	559	553	2119
		Ž	255	841	723	1017	2836
C44	Druge maligne neoplazme kože Skin, other malignomas	M	1154	3560	2804	2804	10322
		Ž	1139	3789	3200	3551	11679
C48–C49	Vezivno in mehko tkivo Connective and soft tissue	M	26	57	64	164	311
		Ž	39	72	80	180	371
C50	Dojka Breast	M	12	33	13	31	89
		Ž	1261	3982	3849	5632	14724
C53	Maternični vrat Cervix uteri	M	—	—	—	—	—
		Ž	107	393	628	2411	3539
C54	Maternično telo Corpus uteri	M	—	—	—	—	—
		Ž	316	952	977	2025	4270
C56	Jajčnik Ovary	M	—	—	—	—	—
		Ž	132	366	290	781	1569
C61	Prostata Prostate	M	1335	4496	2416	1105	9352
		Ž	—	—	—	—	—
C62	Modo Testis	M	104	401	451	1081	2037
		Ž	—	—	—	—	—
C64–C65	Ledvica z ledvičnim mehom Kidney with renal pelvis	M	183	593	424	440	1640
		Ž	90	270	249	342	951
C67	Sečni mehur Bladder	M	188	467	325	314	1294
		Ž	60	128	105	129	422
C70–C72	Centralni in avtonomni živčni sistem Central and autonomic nervous system	M	35	95	63	167	360
		Ž	41	73	57	129	300
C73	Ščitnica Thyroid gland	M	38	129	105	162	434
		Ž	102	447	466	639	1654
C81	Hodgkinova bolezen Hodgkin's disease	M	17	87	112	294	510
		Ž	16	95	80	279	470
C82–C85	Ne-Hodgkinovi limfomi Non-Hodgkin's lymphoma	M	148	399	255	415	1217
		Ž	149	395	321	396	1261
C90	Difuzni plazmocitom in maligne neoplazme plazmocitov Multiple myeloma and malignant plasma cell neoplasms	M	55	128	56	25	264
		Ž	42	116	50	28	236
C91–C95	Levkemije Leukaemias	M	109	268	214	295	886
		Ž	73	188	156	292	709

* Pri posameznih lokacijah je pri prikazu prevalence oseba z več raki vključena pri vsaki lokaciji, pri vseh lokacijah skupaj pa se v prevalenci tudi oseba z več raki šteje le enkrat

* For persons with more than one cancer the person is included as a prevalent cancer in each cancer site, but in the all sites group each person is counted once only

Tabela 13: Umrljivost* za rakom po lokaciji, spolu in starosti, Slovenija 2012.

Table 13: Cancer mortality* by site, by sex and by age, Slovenia 2012.

Šifra MKB ICD code	Primarna lokacija Primary site	Spol Sex	Vse starosti All ages	Starost Age																	
				0–	5–	10–	15–	20–	25–	30–	35–	40–	45–	50–	55–	60–	65–	70–	75–	80+	
C00 – C97	Vse lokacije All sites	M+Ž	5821	0	2	4	2	3	5	19	31	53	142	267	523	650	613	804	991	1712	
		M	3264	0	2	2	2	2	3	7	12	21	79	163	319	403	380	508	568	793	
		Ž	2557	0	0	2	0	1	2	12	19	32	63	104	204	247	233	296	423	919	
C00	Ustnica Lip	M	1	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	
		Ž	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
C01	Baza jezika Base of tongue	M	1	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	
		Ž	3	0	0	0	0	0	0	0	0	0	1	0	1	0	0	0	0	1	
C02	Jezik, drugi deli Tongue, other & unspecified parts	M	9	0	0	0	0	0	0	0	0	0	1	0	2	3	1	2	0	0	
		Ž	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	
C03	Dlesen Gum	M	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
		Ž	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	
C04	Ustno dno Floor of mouth	M	5	0	0	0	0	0	0	0	0	1	0	3	1	0	0	0	0	0	
		Ž	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
C05	Nebo Palate	M	1	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	
		Ž	1	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	
C06	Usta, drugi deli Mouth, other & unspecified parts	M	11	0	0	0	0	0	0	0	0	0	1	0	3	0	3	1	2	1	
		Ž	6	0	0	0	0	0	0	0	0	1	0	0	1	1	0	0	1	2	
C07	Parotidna žleza Parotid gland	M	2	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	1	0	
		Ž	2	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	2	0	
C08	Druge in neopredeljene velike žleze slinavke Other & unspecified major salivary glands	M	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
		Ž	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	
C09	Tonzila Tonsil	M	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
		Ž	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
C10	Orofarinks Oropharynx	M	63	0	0	0	0	0	0	0	0	1	5	9	11	14	4	9	7	3	
		Ž	12	0	0	0	0	0	0	0	0	0	0	2	3	2	1	1	1	2	
C11	Nazofarinks Nasopharynx	M	4	0	0	0	0	0	1	0	0	0	0	0	1	0	1	0	0	1	
		Ž	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
C12	Piriformni sinus Pyriform sinus	M	1	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	
		Ž	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
C13	Hipofarinks Hypopharynx	M	23	0	0	0	0	0	0	0	0	1	3	6	3	1	2	4	1	2	
		Ž	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	
C14	Druga in slabo opredeljena mesta na ustnici, v ustni votlini in farinksu Other and ill-defined sites in the lip, oral cavity and pharynx	M	2	0	0	0	0	0	0	0	0	0	0	1	1	0	0	0	0	0	
		Ž	2	0	0	0	0	0	0	0	0	0	0	0	1	1	0	0	0	0	
C15	Požiralnik Oesophagus	M	76	0	0	0	0	0	0	0	0	1	10	7	10	10	15	7	5	11	
		Ž	15	0	0	0	0	0	0	0	0	1	0	1	1	2	1	3	4	2	
C16	Želodec Stomach	M	195	0	0	0	0	1	0	1	1	3	8	6	20	21	14	33	45	42	
		Ž	155	0	0	0	0	0	0	2	1	1	10	8	7	12	10	20	21	63	
C17	Tanko črevo Small intestine	M	3	0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	0	0	
		Ž	6	0	0	0	0	0	0	0	0	0	0	0	0	1	1	0	0	4	
C18	Debelo črevo Colon	M	253	0	0	0	0	0	1	0	1	3	3	6	19	20	26	50	50	74	
		Ž	217	0	0	0	0	0	1	0	2	1	3	4	9	13	20	27	42	95	
C19	Rektosigmoidna zveza Rectosigmoid junction	M	29	0	0	0	0	0	0	0	0	0	0	2	3	0	8	6	5	5	
		Ž	25	0	0	0	0	0	0	0	0	0	0	1	1	1	1	5	8	8	
C20	Rektum Rectum	M	137	0	0	0	0	0	0	0	0	2	1	5	9	13	23	15	33	36	
		Ž	96	0	0	0	0	0	0	1	0	2	3	1	6	11	4	10	17	41	
C21	Anus in analni kanal Anus and anal canal	M	3	0	0	0	0	0	0	0	0	0	0	0	1	2	0	0	0	0	
		Ž	8	0	0	0	0	0	0	0	0	0	0	0	0	2	0	0	2	3	
C22	Jetra in intrahepatični vodi Liver and intrahepatic bile ducts	M	147	0	0	0	0	0	0	0	0	1	1	8	10	27	22	29	23	26	
		Ž	68	0	0	0	0	0	0	1	1	0	1	3	4	3	8	13	12	22	
C23	Žolčnik Gallbladder	M	19	0	0	0	0	0	0	0	0	0	0	0	3	3	0	2	4	7	
		Ž	50	0	0	0	0	0	0	0	0	0	0	1	2	6	4	10	9	18	
C24	Drugi in neopredeljeni deli biliarnega trakta Biliary tract, other and unspecified parts	M	23	0	0	0	0	0	0	0	1	0	0	2	2	0	4	5	5	4	
		Ž	31	0	0	0	0	0	0	0	0	0	0	0	2	2	1	8	7	11	
C25	Trebušna slinavka Pancreas	M	179	0	0	0	0	0	0	1	1	0	3	8	20	24	19	41	28	34	
		Ž	176	0	0	0	0	0	0	0	1	0	2	5	12	15	15	18	35	73	
C26	Druga in slabo opredeljena mesta v prebavnih organih Other and ill-defined digestive organs	M	6	0	0	0	0	0	0	0	0	0	0	0	1	2	2	0	1	0	
		Ž	13	0	0	0	0	0	0	0	0	0	0	1	0	1	0	2	1	8	
C30	Nosna votlina in srednje uho Nasal cavity and middle ear	M	3	0	0	0	0	0	0	0	1	0	0	0	1	1	0	0	0	0	
		Ž	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
C31	Obnosni sinusi Accessory sinuses	M	7	0	0	0	0	0	0	0	0	0	0	1	0	3	0	1	0	2	
		Ž	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
C32	Grlo Larynx	M	60	0	0	0	0	0	0	0	0	0	0	3	7	8	7	19	10	6	
		Ž	6	0	0	0	0	0	0	0	0	0	0	0	2	1	0	1	0	2	
C33	Sapnik Trachea	M	1	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	
		Ž	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	

Tabela 13: Nadaljevanje.

Table 13: Continued.

Šifra MKB ICD code	Primarna lokacija Primary site	Spol Sex	Vse starosti All ages	Starost Age																
				0–	5–	10–	15–	20–	25–	30–	35–	40–	45–	50–	55–	60–	65–	70–	75–	80+
C34	Sapnica in pljuča Bronchus and lung	M Ž	777 349	0 0	0 0	0 0	0 0	0 0	0 0	0 1	1 0	2 3	17 9	46 14	106 57	124 47	122 43	129 39	122 53	108 83
C37	Timus Thymus	M Ž	2 1	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 0	1 0	0 0	0 0	1 0	0 0	0 1	0 0
C38	Srce, mediastinum, plevra Heart, mediastinum, pleura	M Ž	4 4	0 0	0 0	0 0	0 0	0 0	0 1	0 0	0 0	0 0	0 0	0 0	1 0	0 0	1 0	1 1	0 0	1 2
C39	Druga in slabo opredeljena mesta v dihalih in prsni organih Other and ill-defined sites in the respiratory system and intrathoracic organs	M Ž	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 0
C40	Kosti, sklepní hrustanec udov Bone and articular cartilage of limbs	M Ž	3 1	0 0	0 0	1 0	0 0	0 0	0 0	1 0	0 0	0 0	0 0	1 1	0 0	0 0	0 0	0 0	0 0	0 0
C41	Kosti, sklepní hrustanec, drugje Bone and articular cartilage of other and unspecified parts	M Ž	4 5	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 0	1 0	2 0	1 0	0 1	0 2	0 2
C43	Maligni melanom kože Malignant melanoma of skin	M Ž	68 57	0 0	0 0	0 0	0 0	0 0	0 0	1 1	0 4	4 2	6 5	7 3	5 7	10 9	11 7	7 8	17 13	
C44	Druge maligne neoplazme kože Skin, other malignomas	M Ž	19 16	0 0	0 0	0 0	0 0	0 0	0 1	0 0	1 0	0 1	0 0	0 0	1 0	3 0	0 1	2 4	11 9	
C45	Mezoteliom Mesothelioma	M Ž	23 8	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 1	0 0	5 1	7 0	2 1	4 0	2 2	3 3	
C46	Kaposijev sarkom Kaposi's sarcoma	M Ž	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 0	
C47	Periferni živci in avtonomno živčevje Peripheral and autonomic nervous system	M Ž	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 0	
C48	Peritonej in retroperitonej Retroperitoneum and peritoneum	M Ž	9 13	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 0	1 0	1 1	2 0	1 0	0 2	1 4	3 5	
C49	Drugo vezivno in mehko tkivo Other connective and soft tissue	M Ž	12 14	0 0	0 0	0 0	0 0	0 0	0 0	2 0	0 0	1 0	1 0	0 2	0 0	0 3	2 3	4 2	2 4	
C50	Dojka Breast	M Ž	6 394	0 0	0 0	0 0	0 0	0 0	0 1	0 2	0 7	0 16	0 17	0 33	1 40	0 33	1 35	1 63	2 147	
C51	Žensko zunanje spolovilo Vulva	M Ž	— 19	— 0	— 0	— 0	— 0	— 0	— 0	— 0	— 0	— 2	— 0	— 0	— 0	— 0	— 1	— 2	— 3	— 11
C52	Nožnica Vagina	M Ž	— 7	— 0	— 0	— 0	— 0	— 0	— 0	— 0	— 0	— 1	— 1	— 0	— 0	— 0	— 0	— 2	— 3	
C53	Maternični vrat Cervix uteri	M Ž	— 43	— 0	— 0	— 0	— 0	— 0	— 0	— 0	— 3	— 3	— 7	— 7	— 7	— 2	— 2	— 3	— 9	
C54	Maternično telo Corpus uteri	M Ž	— 35	— 0	— 0	— 0	— 0	— 0	— 0	— 0	— 0	— 1	— 0	— 0	— 3	— 8	— 4	— 5	— 14	
C55	Maternica, neopredeljeno Uterus, unspecified	M Ž	— 56	— 0	— 0	— 0	— 0	— 0	— 1	— 0	— 2	— 0	— 2	— 0	— 5	— 8	— 6	— 10	— 22	
C56	Jajčnik Ovary	M Ž	— 126	— 0	— 0	— 0	— 0	— 0	— 0	— 2	— 2	— 4	— 9	— 13	— 17	— 18	— 16	— 18	— 27	
C57	Drugi in neopredeljeni ženski spolni organi Other and unspecified parts of female genital organs	M Ž	— 0	— 0	— 0	— 0	— 0	— 0	— 0	— 0	— 0	— 0	— 0	— 0	— 0	— 0	— 0	— 0	— 0	
C58	Posteljica Placenta	M Ž	— 0	— 0	— 0	— 0	— 0	— 0	— 0	— 0	— 0	— 0	— 0	— 0	— 0	— 0	— 0	— 0	— 0	
C60	Penis Penis	M Ž	4 —	0 —	0 —	0 —	0 —	0 —	0 —	0 —	0 —	0 —	0 —	0 —	2 —	1 —	0 —	0 —	0 —	
C61	Prostata Prostate	M Ž	388 —	0 —	0 —	0 —	0 —	0 —	0 —	0 —	0 —	2 —	4 —	7 —	22 —	26 —	50 —	100 —	177 —	
C62	Modo Testis	M Ž	5 —	0 —	0 —	0 —	0 —	1 —	0 —	1 —	1 —	0 —	1 —	1 —	0 —	0 —	0 —	0 —	0 —	
C63	Drugi in neopredeljeni moški spolni organi Other and unspecified male genital organs	M Ž	0 —	0 —	0 —	0 —	0 —	0 —	0 —	0 —	0 —	0 —	0 —	0 —	0 —	0 —	0 —	0 —	0 —	
C64	Ledvica razen meha Kidney, except renal pelvis	M Ž	100 43	0 0	0 0	0 0	0 0	0 0	1 0	0 0	0 0	3 0	6 2	14 2	8 1	8 4	15 6	18 11	26 17	
C65	Ledvični meh Renal pelvis	M Ž	3 2	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 2	0 0	2 0	
C66	Sečevod Ureter	M Ž	4 2	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 1	3 1	
C67	Sečni mehur Bladder	M Ž	123 66	0 0	0 0	0 0	0 0	0 0	0 0	0 1	0 2	2 0	4 4	4 3	11 5	7 1	13 9	29 7	53 34	
C68	Drugi in neopredeljeni sečni organi Other and unspecified urinary organs	M Ž	2 0	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 0	
C69	Oko in očesni adneksi Eye and adnexa	M Ž	1 2	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 1	0 0	0 1	0 0	0 1	

Nadaljevanje —>

Continued —>

Tabela 13: Nadaljevanje.

Table 13: Continued.

Šifra MKB ICD code	Primarna lokacija Primary site	Spol Sex	Vse starosti All ages	Starost Age																	
				0–	5–	10–	15–	20–	25–	30–	35–	40–	45–	50–	55–	60–	65–	70–	75–	80+	
C70	Meninge Meninges	M Ž	2 3	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 0	1 1	1 1	0 1	
C71	Možgani Brain	M Ž	85 65	0 0	1 0	1 1	0 0	0 0	0 0	2 2	0 3	1 2	4 2	11 3	12 8	21 6	14 8	9 8	7 10	2 12	
C72	Hrbtni mozeg, možganski živci in drugi deli CZS Spinal cord, cranial nerves and other parts of CNS	M Ž	0 3	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 1	0 0	0 0	0 0	0 0	0 0	0 2	
C73	Ščitnica Thyroid gland	M Ž	4 14	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 2	0 2	3 1	0 3	1 1	0 5	0 5	
C74	Nadledvična žleza Adrenal gland	M Ž	4 3	0 0	0 0	0 0	0 0	0 1	0 0	0 0	0 0	0 0	0 0	0 0	1 1	1 0	0 0	2 0	0 0	0 0	
C75	Druge endokrine žleze in sorodne strukture Other endocrine glands and related structures	M Ž	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 0	
C76	Druga in slabo opredeljena mesta Other and ill-defined sites	M Ž	2 10	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 1	0 0	0 1	0 0	1 0	0 0	0 2	0 6	1 0	
C77	Metastaza in neopredeljena maligna neoplazma bezgavk Metastasis and unspecified malignant neoplasm of lymph nodes	M Ž	2 5	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 0	1 0	0 0	0 0	0 3	1 0	0 0	0 1	0 1	0 1	
C78	Metastaze dihal in prebavil Metastases of respiratory and digestive organs	M Ž	22 27	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 0	1 1	1 3	2 0	3 4	1 8	14 11	
C79	Metastaze, drugje Metastases of other sites	M Ž	7 8	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 2	1 1	2 0	1 3	0 1	2 1	1 1	
C80	Maligna neoplazma brez opredeljenega mesta Malignant neoplasm without specification of site	M Ž	36 27	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 2	6 3	3 4	6 1	3 3	8 3	8 11		
C81	Hodgkinova bolezen Hodgkin's disease	M Ž	5 11	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 1	0 0	0 0	1 1	0 0	1 0	0 2	2 5	0 5		
C82	Folikularni ne-Hodgkinov limfom Follicular non-Hodgkin's lymphoma	M Ž	3 3	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 0	1 0	0 0	0 0	0 0	0 0	1 1	0 1	1 1	
C83	Difuzni ne-Hodgkinov limfom Diffuse non-Hodgkin's lymphoma	M Ž	13 16	0 0	0 0	0 0	0 0	0 0	0 1	0 0	0 0	0 1	0 0	2 0	2 4	1 2	0 4	3 1	1 3	3 3	
C84	Limfomi celic T in kožni limfom celic T Peripheral and cutaneous T-cell lymphomas	M Ž	6 4	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 0	1 0	0 0	1 0	1 2	0 0	3 2	
C85	Druge in neopredeljene vrste ne-Hodgkinovega limfoma Other and unspecified types of non-Hodgkin's lymphoma	M Ž	45 52	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 0	2 3	4 4	5 3	6 6	6 5	6 8	16 23	
C88	Maligne imunoproliferativne bolezni Malignant immunoproliferative diseases	M Ž	1 0	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 0	1 0	
C90	Difuzni plazmocitom in maligne neoplazme plazmocitov Multiple myeloma and malignant plasma cell neoplasms	M Ž	47 40	0 0	0 0	0 0	0 0	0 0	0 0	0 0	1 1	3 0	4 0	2 1	5 6	6 5	5 2	8 9	13 16		
C91	Limfatična levkemija Lymphoid leukaemia	M Ž	38 32	0 0	1 0	0 1	2 0	0 0	0 0	0 0	0 0	0 0	1 0	1 0	3 2	3 1	1 1	2 1	7 2	17 24	
C92	Mieločna levkemija Myeloid leukaemia	M Ž	38 31	0 0	0 0	0 0	0 0	0 0	0 0	0 0	1 2	1 0	1 3	3 3	6 4	1 4	9 3	3 4	13 8		
C93	Monocitna levkemija Monocytic leukaemia	M Ž	1 0	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 0	1 0	0 0	0 0	0 0	0 0		
C94	Druge opredeljene levkemije Other leukaemias of specified cells	M Ž	1 0	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 0	1 0	
C95	Levkemija z neopredeljenim celičnim tipom Leukaemia, unspecified cell type	M Ž	6 5	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 0	1 0	1 1	1 1	1 2	2 1		
C96	Druge in neopredeljene maligne neoplazme limfatičnega, krvotvornega in sorodnega tkiva Other & unspecified malignant neoplasms of lymphoid, haemopoietic & related tissues	M Ž	19 18	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 1	0 0	0 0	0 0	1 1	2 0	2 1	3 1	11 11		
C97	Maligne neoplazme na več neodvisnih (primarnih) mestih Malignant neoplasms of independant (primary) multiple sites	M Ž	56 21	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 0	2 0	0 1	4 1	8 1	5 3	6 2	9 1	22 12		
Zgoraj neupoštevani Not included above																					
D32	Meninge, benigna neoplazma Benign neoplasm of meninges	M Ž	4 9	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 0	1 0	0 2	1 3	2 4	
D33	CZS, benigna neoplazma Benign neoplasm of brain and other parts of CNS	M Ž	1 1	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 0	1 0	0 0	0 0	0 0	0 0	0 0	0 1	
D43	CZS, neopredeljeno CNS, uncertain or unknown	M Ž	1 0	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 0	1 0	0 0	0 0	

* Vir: Nacionalni inštitut za javno zdravje
* Source: National Institute of Public Health

IZBOR PUBLIKACIJ, ki so jih sodelavci Epidemiologije in Registra raka objavili v zadnjih petih letih (tudi v sodelovanju z drugimi raziskovalci)

SELECTED PUBLICATIONS, published by the members of Epidemiology and Cancer Registry in the last five years (also in cooperation with other researchers)

2009

- Anttila A, Ronco G, Primic-Žakelj M, Pogačnik A, Uršič-Vrščaj M, Zadnik V, et al. Description of the national situation of cervical cancer screening in the member states of the European Union. *Eur J Cancer* 2009; 45: 2685–708.
- Berrino F, Verdecchia A, Lutz JM, Lombardo C, Micheli A, Primic-Žakelj M, et al. Comparative cancer survival information in Europe. *Eur J Cancer* 2009; 45: 901–8.
- Ciccolallo L, Licitra L, Cantu G, Gatta G, Pompe-Kirn V, Primic-Žakelj M, et al. Survival from salivary glands adenoid cystic carcinoma in European populations. *Oral Oncol* 2009; 45: 669–74.
- De Angelis R, Francisci S, Baili P, Marchesi F, Roazzi P, Primic-Žakelj M, et al. The EURO-CARE-4 database on cancer survival in Europe: data standardisation, quality control and methods of statistical analysis. *Eur J Cancer* 2009; 45: 909–30.
- Francisci S, Capocaccia R, Grande E, Santaquilani M, Simonetti A, Primic-Žakelj M, et al. The cure of cancer: a European perspective. *Eur J Cancer* 2009; 45: 1067–79.
- Gatta G, Zigon G, Capocaccia R, Coebergh JW, Desandes E, Primic-Žakelj M, et al. Survival of European children and young adults with cancer diagnosed 1995–2002. *Eur J Cancer* 2009; 45: 992–1005.
- Gondos A, Bray F, Hakulinen T, Brenner H, Usel M, Primic-Žakelj M, et al. Trends in cancer survival in 11 European populations from 1990 to 2009: a model-based analysis. *Ann Oncol* 2009; 20: 564–73.
- Lepage C, Ciccolallo L, De Angelis R, Bouvier AM, Pompe-Kirn V, Primic-Žakelj M, et al. European disparities in malignant digestive endocrine tumours survival. *Int J Cancer* 2009; available from: <http://www.ncbi.nlm.nih.gov/pubmed/19569047>.
- Nicula FA, Anttila A, Neamtiu L, Primic-Žakelj M, Tachezy R, Chil A, et al. Challenges in starting organised screening programmes for cervical cancer in the new member states of the European Union. *Eur J Cancer* 2009; 45: 2679–84.
- Pasanisi P, Hedelin G, Berrino J, Chang-Claude J, Primic-Žakelj M, Zadnik V, et al. Oral contraceptive use and BRCA penetrance: a case-only study. *Cancer Epidemiol Biomarkers Prev* 2009; 18: 2107–13.
- Primic-Žakelj M, Pogačnik A, Uršič-Vrščaj M, Ivanuš U. Presejalni program ZORA po petih letih delovanja že kaže pomembne javnozdravstvene rezultate. *Onkologija* 2009; 13: 4–6.
- Primic-Žakelj M, Zadnik V, Žagar T. Epidemiologija kožnega raka (Epidemiology of skin cancer). In: Luzar B, Jurčič V, Pižem J, Calonje E, eds. XL. memorialni sestanek profesorja Janeza Plečnika z mednarodnim simpozijem, 3.–4. december 2009, Ljubljana. Novosti v dermatopatologiji. Ljubljana: Inštitut za patologijo, Medicinska fakulteta; 2009.
- Primic-Žakelj M, Zadnik V, Žagar T, Zakotnik B. Preživetje bolnikov z rakom, zbolelih v letih 1991–2005 v Sloveniji (Survival of cancer patients, diagnosed in 1991–2005 in Slovenia). Ljubljana: Onkološki inštitut; 2009.
- Primic-Žakelj M, Krajc M, Zadnik V. Državni presejalni programi za raka (National cancer screening programs). *Farm vestn* 2009; 60: 90–4.
- Primic-Žakelj M, Zadnik V. Epidemiologija raka prostate (Epidemiology of prostate cancer). In: Kramer F, ed. Rak prostate: zbornik predavanj. Slovenj Gradec: Oddelek za urologijo, Splošna bolnišnica Slovenj Gradec; 2009.
- Primic-Žakelj M, Žgajnar J. Cervical and breast cancer screening in Slovenia. Public service review, European Union. 2009; 18: 272.
- Quaglia A, Tavilla A, Shack L, Brenner H, Janssen-Heijnen M, Primic-Žakelj M, et al. The cancer survival gap between elderly and middle-aged patients in Europe is widening. *Eur J Cancer* 2009; 45: 1006–16.
- Repše-Fokter A, Fležar M, Pogačnik A, Snoj V. Review of negative or low grade smears in women with invasive cervical cancer in Slovenia. *Virchows Arch* 2009; 455 Suppl,1: S6–S7.

- Ronco G, van Ballegooijen M, Becker N, Chil A, Fender M, Primic-Žakelj M, et al. Process performance of cervical screening programmes in Europe. *Eur J Cancer* 2009; 45: 2659–70.
- Rosso S, De Angelis R, Ciccolallo L, Carrani E, Soerjomataram I, Primic-Žakelj M, et al. Multiple tumours in survival estimates. *Eur J Cancer* 2009; 45: 1080–94.
- Sant M, Allemani C, Santaquilani M, Knijn A, Marchesi F, Primic-Žakelj M, et al. EURO-CARE-4. Survival of cancer patients diagnosed in 1995–1999. Results and commentary. *Eur J Cancer* 2009 Apr; 45(6): 931–91.
- Snoj Z, Primic-Žakelj M, Ličina M, Pregelj P. Psychosocial correlates of progesterone receptors in breast cancer. *Depress Anxiety* 2009; 26: 544–9.
- Trapido EJ, Primic-Žakelj M, Pogačnik A, Uršic-Vrsčaj M, Krajc M, Lešničar H, et al. Critical factors influencing the establishment, maintenance and sustainability of population-based cancer control programs. *Tumori* 2009; 95: 637–45.
- Verdecchia A, Guzzinati S, Francisci S, De Angelis R, Bray F, Primic-Žakelj M, et al. Survival trends in European cancer patients diagnosed from 1988 to 1999. *Eur J Cancer* 2009; 45: 1042–66.
- Zadnik V, Žagar T, Primic-Žakelj M. Pridobivanje in uporaba georeferenciranih podatkov v registru raka Republike Slovenije (Georeferenced data acquisition and usage in the cancer registry of Republic of Slovenia). *Bilt-ekon organ inform zdrav* 2009; 25 (izr. št.): 14.
- Zwitter M, Kovač V, Smrdel U, Vrankar M, Zadnik V. Gemcitabine in brief versus prolonged low-dose infusion, both combined with cisplatin, for advanced non-small cell lung cancer: a randomized phase II clinical trial. *J Thorac Oncol* 2009; 4: 1148–55.
- Žagar T, Zadnik V, Primic-Žakelj M. Register raka Republike Slovenije in pridobivanje informacij o bolnikih iz drugih državnih podatkovnih zbirk po elektronski poti (Cancer Registry of Slovenia obtains patient information from other state databases via electronic mediums). In: Orel M, ed. *Nova vizija tehnologij prihodnosti*. Ljubljana: Evropska hiša; 2009.

2010

- Bouvier A, Pompe-Kirn V. What reasons lie behind long-term survival differences for gastric cancer within Europe? *Eur J Cancer* 2010; 46: 1086–92.
- Chuang S, Pompe-Kirn V. Risks of second primary cancer among patients with major histological types of lung cancers in both men and women. *Br J Cancer* 2010; 102: 1190–5.
- EurocareWorking Group, Lepage C, Pompe-Kirn V, Primic-Žakelj M. European disparities in malignant digestive endocrine tumours survival. *Int J Cancer* 2010; 126: 2928–34.
- Kofol-Bric T, Zadnik V et al. Zdravje moških med 20. in 64. letom. In: *Zdravje v Sloveniji*. Ljubljana: Inštitut za varovanje zdravja RS; 2010, 80–6.
- Krajc M, Kadivec M, Hertl K, Primic-Žakelj M. V državnem presejalnem programu za raka dojke Dora do sedaj odkritih 86 rakov dojke. *Onkologija* 2010; 14: 104–10.
- Mihevc Ponikvar B, Zadnik V et al. Zdravje žensk med 20. in 64. letom. In: *Zdravje v Sloveniji*. Ljubljana: Inštitut za varovanje zdravja RS; 2010, 71–9.
- Primic-Žakelj M. Country-specific description: Slovenia. In: Obergainer W, Vittadello F eds. *Cancer mapping in Alpine regions: Austria, Italy, Slovenia, Switzerland: 2001–2005*. Innsbruck: Department of Clinical Epidemiology of TILAK; 2010, 47–9.
- Primic-Žakelj M, Ivanuš U. Državni program ZORA danes. In: Ivanuš U, Primic-Žakelj M, Florjančič M, Škulj P eds. *Prvi izobraževalni dan programa ZORA z mednarodno udeležbo*. Zbornik. Ljubljana: Onkološki inštitut; 2010, 9–15.
- Primic-Žakelj M, Zadnik V. Rak. In: *Zdravje v Sloveniji*. Ljubljana: Inštitut za varovanje zdravja RS; 2010: 96–100.
- Primic-Žakelj M, Zadnik V, Žagar T. Breme raka v Sloveniji. *Naša lekarna* 2010; 41: 22–8.
- Primic-Žakelj M, Zadnik V, Žagar T. Razširjenost raka v Sloveniji in Evropi. In: Rotar-Pavlič D. *Obravnava bolnika z rakom v osnovnem zdravstvenem varstvu: zbornik predavanj*, Bled, 24. april 2010. Ljubljana: Zavod za razvoj družinske medicine; 2010, 5–8.
- Rebolj M, Ivanuš U, Lynge E. Indicators of quality assurance in cancer screening - the case of cervical cancer = Kazalniki kakovosti presejalnih programov - primer presejalnega programa za raka na materničnem vratu. *Bilt-ekon. organ. inform. zdrav* 2010; 26(2): 44–51.
- Repše-Fokter A, Pogačnik A, Snoj V, Primic-Žakelj M, Strojman Fležar M. Review of negative and lowgrade cervical smears in women with invasive cervical cancer after the first 3 years of the national cervical screening programme in Slovenia. *Cytopathology* 2010; 22: 1–7.
- Rosso S, Gondos A, Zanetti R, Bray F, Primic-Žakelj M, Žagar T, Smailyte G, Ponti A, Brewster DH, Voogd AC, Crocetti E, Brenner H; EUNICE SurvivalWorking Group. Up-to-date estimates of breast cancer survival for the years 2000–2004 in 11 European countries: the role of screening and a comparison with data from the United States. *Eur J Cancer* 2010; 46: 3351–7.

- Strojman Fležar M, Snoj V, Ivanuš U, Primic-Žakelj M. Standardizacija izvidov patologije materničnega vratu. In: Ivanuš U, Primic-Žakelj M, Florjančič M, Škulj P eds. Prvi izobraževalni dan programa ZORA z mednarodno udeležbo. Zbornik. Ljubljana: Onkološki inštitut, 2010; 21-23, 61–72.
- Šelb-Šemerl J, Mihevc Ponikvar B, Primic-Žakelj M, Rok Simon M, Tomšič S, Zadnik V. Zdravje starejših. In: Zdravje v Sloveniji. Ljubljana: Inštitut za varovanje zdravja RS; 2010: 87–91.

2011

- Anttila A, Bielska-Lasota M, Davidson T, Van Delden JJ, Von Karsa L, Primic-Žakelj M, et al. Determinants for a successful implementation of population-based cancer screening programmes. Brussels: European Science Advisory Network for Health, 2012.
- Bosetti C, Scelo G, Chuang SC, Tonita JM, Tamaro S, Pompe-Kirn V, et al. High constant incidence rates of second primary cancers of the head and neck: a pooled analysis of 13 cancer registries. *Int J Cancer* 2012;129(1):173–9.
- Buzeti T, Djomba JK, Tomšič S, Gabrijelčič Blenkuš M, Ivanuša M, Zadnik V, et al. Neenakosti v zdravju v Sloveniji. Health inequalities in Slovenia. Ljubljana: Inštitut za varovanje zdravja, 2012.
- Gatta G, Van der Zwan JM, Casali PG, Siesling S, Dei Tos AP, Primic-Žakelj M, et al. Rare cancers are not so rare: the rare cancer burden in Europe. *Eur J Cancer* 2012; 47(17): 2493–511.
- Ivanuš U, Primic-Žakelj M, Uršič-Vrščaj M. Pomen triažnega testa HPV. In: Primic-Žakelj M, ed. XIX. seminar In memoriam dr. Dušana Reje. Državni presejalni programi za raka. Ljubljana: Zveza slovenskih društev za boj proti raku, 2012: 26–39.
- Kadivec M, Krajc M. Rezultati in kazalniki uspešnosti programa DORA. In: Primic-Žakelj M, ed. XIX. seminar In memoriam dr. Dušana Reje. Državni presejalni programi za raka. Ljubljana: Zveza slovenskih društev za boj proti raku, 2012: 40–8.
- Krajc M. Prednosti in omejitve mamografskega presejanja. In: Primic-Žakelj M, ed. XIX. seminar In memoriam dr. Dušana Reje. Državni presejalni programi za raka. Ljubljana: Zveza slovenskih društev za boj proti raku, 2012: 49–58.
- Krajc M. Epidemiologija raka dojk. In: Mamografska šola, 9. in 10. junij 2012. Ljubljana: Onkološki inštitut, SZD, Združenje radiologov Slovenije, 2012: 1–6.
- Krajc M. Kazalci kakovosti presejalnega programa za raka dojk. In: Farkaš-Lainščak J, ed. Z dokazi podprto javno zdravje: zbornik prispevkov. Ljubljana: Medicinska fakulteta, Katedra za javno zdravje, 2012: str 128.
- Maule M, Scélo G, Pastore G, Brennan P, Hemminki K, Pompe-Kirn V, et al. Second malignancies after childhood noncentral nervous system solid cancer: Results from 13 cancer registries. *Int J Cancer* 2012;129(8):1940–52.
- Primic-Žakelj M. Presejanje za raka kot javnozdravstveni ukrep. In: Primic-Žakelj M, ed. XIX. seminar In memoriam dr. Dušana Reje. Državni presejalni programi za raka. Ljubljana: Zveza slovenskih društev za boj proti raku, 2012: 7–12.
- Primic-Žakelj M. Epidemiologija raka in stopnja preživetja v Sloveniji v populaciji do 39 let. In: Ribič-Pucelj M, ed. Ohranjanje plodne sposobnosti pri onkoloških bolnicah in bolnikih: zbornik. Ljubljana: Slovensko društvo za reproduktivno medicino, 2012: 1–4.
- Primic-Žakelj M, Ivanuš U. Presejanje za raka pri ženskah. In: Čeh A, ed. Presejalni testi pri ženskah in otrocih: zbornik predavanj z recenzijo. Ljubljana: Zbornica zdravstvene in babiške nege Slovenije - Zveza strokovnih društev medicinskih sester, bobic in zdravstvenih tehnikov Slovenije, Sekcija medicinskih sester – bobic, 2012: 7–15.
- Primic-Žakelj M, Ivanuš U. Rezultati in kazalniki uspešnosti programa ZORA. In: Primic-Žakelj M, ed. XIX. seminar In memoriam dr. Dušana Reje. Državni presejalni programi za raka. Ljubljana: Zveza slovenskih društev za boj proti raku, 2012: 13–7.
- Primic-Žakelj M, Ivanuš U. Državni program ZORA v letih 2005-2010. In: Ivanuš U, Primic-Žakelj M, Florjančič M, Kuster M, eds. 2. izobraževalni dan programa ZORA, Brdo pri Kranju, 8. april 2012. Zbornik. Ljubljana: Onkološki inštitut Ljubljana, 2012: 9–12.
- Primic-Žakelj M, Zadnik V. Epidemiologija raka sečnega mehurja = Epidemiology of bladder cancer. In: Zupančič M, ed. Rak sečnega mehurja: zbornik predavanj. Slovenj Gradec: Oddelek za urologijo, Splošna bolnišnica Slovenj Gradec, 2010: 7–12.
- Rotovnik Kozjek N, Kompan L, Soeters P, Oblak I, Mlakar Mastnak D, Zadnik V, et al. Oral glutamine supplementation during preoperative radiochemotherapy in patients with rectal cancer: a randomised double blinded, placebo controlled pilot study. *Clin Nutr* 2012; 30(5): 567–70.
- Uršič-Vrščaj M, Primic-Žakelj M, Ivanuš U. Novosti v programu ZORA. In: Primic-Žakelj M, ed. XIX. seminar In memoriam dr. Dušana Reje. Državni presejalni programi za raka. Ljubljana: Zveza slovenskih društev za boj proti raku, 2012: 18–25.

- Velenik V, Štrbac D, Maučec Zakotnik J, Zadnik V. Oral glutamine supplementation during preoperative radiochemotherapy in patients with rectal cancer: a randomised double blinded, placebo controlled pilot study. *Eur J Cancer* 2012; 47(Supp1): S267.
- Zadnik V, Ivanuš U, Primic-Žakelj M. Geografska analiza incidence raka v Beli krajini in okolici: ugotavljanje morebitnega presežka incidence raka zaradi izpostavljenosti PCB-jem: zaključno poročilo. Ljubljana: Onkološki inštitut, 2012.
- Zadnik V, Ivanuš U, Primic-Žakelj M. Pojavljanje raka v upravnih enotah Celje in Šentjur pri Celju: zaključno poročilo. Ljubljana: Onkološki inštitut, 2012.
- Zadnik V, Kovše K, Tomšič S, Primic-Žakelj M. Breme raka v občini Dolenjske Toplice: zaključno poročilo. Ljubljana: Onkološki inštitut, 2012.
- Zadnik V, Primic-Žakelj M. SLORA - spletna stran z epidemiološkimi podatki o raku. *Onkologija* 2012; 15(1): 61–3.
- Zadnik V, Primic-Žakelj M. Breme raka uroloških in reproduktivnih organov v Sloveniji. *Slov 2000 in rak* 2012; 8–12.
- Žagar T, Zadnik V, Primic-Žakelj M. Local standardized incidence ratio estimates and comparison with other mapping methods for small geographical areas using Slovenian breast cancer data. *Journal of Applied Statistics* 2012; 38(12): 2751–61.

2012

- Čuić M, Zadnik V. Prekomerna telesna teža in debelost kot dejavnik tveganja raka = Overweight and obesity as cancer risk factor. In: Babnik K, Kocbek M, eds. Slovenski dan dietetike: prva znanstvena konferenca z mednarodno udeležbo, Izola, 25. oktober 2012. Zbornik prispevkov. Koper: Založba Univerze na Primorskem, 2012: 63–8.
- Glumac N, Hočevar M, Zadnik V, Snoj M. Inguinal or inguino-iliac/obturator lymph node dissection after positive inguinal sentinel lymph node in patients with cutaneous melanoma. *Radiol Oncol* 2012; 46(3): 258–64.
- Gregorič B, Zadnik V, Jezeršek Novaković B. The diffuse large B-cell lymphoma - where do we stand now in everyday clinical practice. *Radiol Oncol* 2012; 46(2): 153–9.
- Ivanuš U, Primic-Žakelj M. Interlaboratory variability in HPV-positive rates in ASC-US/LSIL smears in the cervical cancer screening programme ZORA = Razlike med citološkimi laboratoriji v deležu HPV-pozitivnih izvidov APC-N/PIL-NS v presejalnem programu za raka materničnega vratu ZORA. In: Strojman Fležar M, Luzar B, Gutnik H, Pižem J, Kocjan G, eds. Novosti v citopatologiji: most med kliniko in diagnostično patologijo: Bridge between clinics and diagnostic pathology. Ljubljana: Inštitut za patologijo, Medicinska fakulteta, 2012: 203–8.
- Ivanuš U, Primic-Žakelj M, Uršič-Vrščaj M. Aktivnosti DP ZORA v letu 2012. In: Ivanuš U, Primic-Žakelj M, Florjančič M, Kuster M. Zbornik. Ljubljana: Onkološki inštitut, 2012: 53–63.
- Ivanuš U, Primic-Žakelj M. Samoodvzem vaginalnega vzorca za test HPV pri neodzivnicah presejalnih programov raka materničnega vratu. *Onkologija* 2012; 16(2): 78–86.
- Ivanuš U, Primic-Žakelj M. Tretji izobraževalni dan programa ZORA. *Onkologija* 2012; 16(2): 98–100.
- Jarm K. Podrobna raziskava preživetja bolnikov z rakom danke v Sloveniji, zbolelih v letih 2003–2005: specialistična naloga s področja javnega zdravja. Ljubljana: Onkološki inštitut, 2012.
- Koivisto-Korander R, Scélo G, Ferro G, Mellempjaer L, Hemminki K, Pompe-Kirn V, et al. Second primary malignancies among women with uterine sarcoma. *Gynecol Oncol* 2012; 126(1): 30–5.
- Kovač V, Zwitter M, Žagar T. Improved survival after introduction of chemotherapy for malignant pleural mesothelioma in Slovenia: Population-based survey of 444 patients. *Radiol Oncol* 2012; 46(2): 136–44.
- Merlo DF, Ceppi M, Filiberti R, Bocchini V, Znaor A, Primic-Žakelj M, et al. Breast cancer incidence trends in European women aged 20–39 years at diagnosis. *Breast Cancer Res Treat* 2012; 134(1): 363–70.
- Primic-Žakelj M, Ivanuš U. Aktivnosti DP ZORA v letu 2012. In: Ivanuš U, Primic-Žakelj M, Florjančič M, Kuster M. Zbornik. Ljubljana: Onkološki inštitut, 2012: 9–14.
- Primic-Žakelj M, Zadnik V. Rak pri starejših. In: Rak pri starostniku. Ljubljana: Onkološki inštitut, 2012: 14–25.
- Primic-Žakelj M, Žagar T. Razširjenost, preprečevanje in zgodnje odkrivanje pljučnega raka. In: Matković M, ed. Pacienti in pljučni rak - trendi in novosti. Ljubljana: Sekcija medicinskih sester in zdravstvenih tehnikov v onkologiji pri Zbornici zdravstvene in babiške nege Slovenije - Zveza strokovnih društev medicinskih sester, babic in zdravstvenih tehnikov Slovenije, 2012: 19–31.
- Primic-Žakelj M. Presejanje za raka kot javnozdravstveni ukrep. *Slov 2000 Rak* 2012: 6–9.
- Primic-Žakelj M. Razširjenost in pomen redkih rakavih bolezni. In: Primic-Žakelj M, ed. Redki raki. Ljubljana: Zveza slovenskih društev za boj proti raku, 2012: 7–13.

- Repše-Fokter A, Pogačnik A, Snoj V, Primic-Žakelj M, Fležar MS. Review of negative and low-grade cervical smears in women with invasive cervical cancer after the first 3 years of the national cervical screening programme in Slovenia. *Cytopathol Off J Br Soc Clin Cytol* 2012; 23(1): 23–9.
- Uršič-Vrščaj M, Ivanuš U. HPV testiranje. In: Smrkolj Š, ed. Obnovitveni kolposkopski tečaj, Ljubljana, marec 2012. Zbornik. Ljubljana: Združenje za ginekološko onkologijo, kolposkopijo in cervikalno patologijo SZD, 2012: 63–9.
- Zadnik V, Primic-Žakelj M. Epidemiologic data on cervical cancer. In: Takač I, ed. Recent advances in cervical cancer. Kerala: Transworld Research Network, 2012: 1–7.
- Zadnik V, Primic-Žakelj M, Krajc M. Breme raka v Sloveniji v primerjavi z drugimi evropskimi državami = Cancer burden in Slovenia in comparison with the burden in other European countries. *Zdr Vestn* 2012; 81(5): 407–12.
- Zadnik V, Žagar T, Primic-Žakelj M. Analiza vpliva točkovnih virov onesnaženja na zbolevanje za rakom v Zasavju = Analysis of the impact of point source pollution on cancer in Zasavje. In: Kraigher A, ed. Zbornik predstavitev. Ljubljana: Sekcija za preventivno medicino Slovenskega zdravniškega društva, 2012: 1.
- Žagar T, Primic-Žakelj M, Zadnik V. Slovenian maps of local standardized incidence ratio. In: 34th International Association of Cancer Registries Conference, 17-19 September 2012. Cork: The National Cancer Registry, 2012: 42.
- Žagar T, Zadnik V, Primic-Žakelj M. Možnosti raziskovanja vpliva bivalnega okolja na pojavljanje raka. In: Kraigher A, ed. Zbornik predstavitev. Ljubljana: Sekcija za preventivno medicino Slovenskega zdravniškega društva, 2012: 1–15.
- Žist A, Milanez T, Škrbinc B, Zadnik V, Šeruga B. Spregledana korist neoadjuvantne kemoterapije v zdravljenju mišično invazivnega raka sečnega mehurja. *Onkologija* 2012; 16(2): 74–7.

2013

- Allemani C, Sant M, Weir HK, Richardson LC, Baili P, Primic-Žakelj M, et al. Breast cancer survival in the US and Europe: a CONCORD high-resolution study. *International journal of cancer* 2013; 132: 1170–81.
- Gašljević G, Lamovec J, Contreras JA, Zadnik V, Blas M, Gašparov S. HER2 in gastric cancer: an immunohistochemical study on tissue microarrays and the corresponding whole-tissue sections with a supplemental FISH study. *Pathol Oncol Res* 2013; 19: 855–65.
- Ivanuš U, Primic-Žakelj M, Žagar T, Florjančič M, Kuster M. Delovanje državnega presejalnega programa za raka materničnega vratu ZORA v osrednjeslovenski statistični regiji. In: Letnar Žbogar N, et al. Zdravje v ljubljanski zdravstveni regiji 2012. Ljubljana: Zavod za zdravstveno varstvo, 2013: 74–94.
- Ivanuš U, Primic-Žakelj M. Klinična uporaba in pomen testa za humani papilomski virus v Državnem presejalnem programu ZORA (Clinical use and value of human papillomavirus test in national cervical cancer screening programme ZORA). *Med Razgl* 2013; 52(3): 123–35.
- Ivanuš U, Primic-Žakelj M. Pomen izvida testa HPV v kolposkopski ambulanti. In: Smrkolj Š, ed. Zbornik. Ljubljana: Združenje za ginekološko onkologijo, kolposkopijo in cervikalno patologijo SZD: Onkološki inštitut, 2013: 78–101.
- Ivanuš U, Primic-Žakelj M. Uporaba triaznega testa HPV v programu ZORA v letu 2012. In: Ivanuš U, Primic-Žakelj M, Repše-Fokter A, eds. Zbornik predavanj. Ljubljana: Onkološki inštitut, 2013: 27–34.
- von Karsa L, Maučec-Zakotnik J, Primic-Žakelj M et al. European guidelines for quality assurance in colorectal cancer screening and diagnosis: overview and introduction to the full supplement publication. *Endoscopy* 2013; 45: 51–9.
- Koželj M, Zver S, Zadnik V. Long term follow-up report of cardiac toxicity in patients with multiple myeloma treated with tandem autologous hematopoietic stem cell transplantation. *Radiol Oncol* 2013; 47: 161–5.
- Krajc M, Šval C, Kadivec M, Hertl K, Primic-Žakelj M. Rezultati državnega presejalnega programa Dora v ljubljanski regiji. In: Letnar Žbogar N, et al. Zdravje v ljubljanski zdravstveni regiji 2012. Ljubljana: Zavod za zdravstveno varstvo, 2013: 66–73.
- Maver Vodičar P, Seme K, Korač T, Dimitrov G, Döbrössy L, Primic-Žakelj M, et al. Cervical cancer screening practices in central and eastern Europe in 2012. *Acta Dermatovenerol APA* 2013; 22: 7–19.
- Primic-Žakelj M, Ivanuš U. Deset let delovanja programa ZORA. In: Ivanuš U, Primic-Žakelj M, Repše-Fokter A, eds. Zbornik predavanj. Ljubljana: Onkološki inštitut, 2013: 7–11.
- Primic-Žakelj M, Zadnik V, Žagar T. Epidemiologija raka debelega črevesa in danke. In: Šola tumorjev prebavil, Ljubljana, 30. 11. 2012. Ljubljana: Onkološki inštitut, 2013: 17–20.
- Primic-Žakelj M, Zadnik V, Žagar T. Epidemiologija raka prostate, sečnega mehurja, ledvic in mod v Sloveniji. In: Novaković S, ed. Izzivi v multidisciplinarni obravnavi bolnikov z rakom sečnega mehurja, prostate, ledvic in mod. Zbornik. Ljubljana: Onkološki inštitut: Kancerološko združenje Slovenskega zdravniškega društva, 2013: 16–23.

- Primic-Žakelj M. Epidemiology of cancer diseases in different European regions and the importance of risk factors. In: Fourth International Medical Congress, 11-15 September 2013, Portorož, Slovenia, 2013: 49–51.
- Primic-Žakelj M, Ivanuš U, Žagar T. Neodzivnice DP DORA so bolj ogrožene z rakom materničnega vratu (Non-responders to the National Cervical Cancer Screening Programme Zora are at an increased risk of cervical cancer). In: Kraigher A, Skaza A, eds. Javno zdravje - priložnost za spreminjajočo se družbo (Public health - opportunity for changing society). Zbornik izvečkov. Ljubljana: Sekcija za preventivno medicino Slovenskega zdravniškega društva, 2013: 29.
- Primic-Žakelj M, Zadnik V, Žagar T. Rak dojke: zbolewnost, preživetje in dejavniki tveganja. In: Matković M, ed. Pacientke z rakom dojk - trendi in novosti. Ljubljana: Sekcija medicinskih sester in zdravstvenih tehnikov v onkologiji pri Zbornici zdravstvene in babiške nege - Zveza strokovnih društev medicinskih sester, babic in zdravstvenih tehnikov Slovenije, 2013: 5–13.
- Primic-Žakelj M, Zadnik V, Žagar T. Rak v Sloveniji. In: Novosti v diagnostiki in zdravljenju raka, Ljubljana, 13. decembra 2013: ob jubilejni, 20. obletnici delovanja združenja Fundacija doc. dr. Josip Cholewa v sodelovanju z Medicinsko fakulteto Ljubljana, Kliničnim centrom Ljubljana in Onkološkim inštitutom Ljubljana. Ljubljana: Fundacija doc. dr. Josip Cholewa, 2013: 5–6.
- Zadnik V, Žagar T, Jarm K, Primic-Žakelj M. The evaluation of the mesothelioma epidemic in Slovenia. In: 35th International Association of Cancer Registries Conference, 22-24 October 2013, Buenos Aires. Programme & abstracts. Buenos Aires: The National Cancer Institute, 2013: 109.
- Zadnik V, Ivanuš U, Žagar T, Primic-Žakelj M. Pojavljanje raka na območju upravnih enot Celje in Šentjur pri Celju (Cancer incidence in administrative units Celje and Šentjur pri Celju). In: Kraigher A, Skaza A, eds. Javno zdravje - priložnost za spreminjajočo se družbo (Public health - opportunity for changing society). Zbornik izvečkov. Ljubljana: Sekcija za preventivno medicino Slovenskega zdravniškega društva, 2013: 74.
- Znaor A, van den Hurk C, Primic-Žakelj M, Agius D, Coza D, Demetriou A, et al. Cancer incidence and mortality patterns in South Eastern Europe in the last decade : gaps persist compared with the rest of Europe. Eur J Cancer 2013; 49: 1683–91.
- Žagar T, Zadnik V, Primic-Žakelj M. Local estimation of standardized incidence ratio applied to Slovenian cancer data. V: International Conference Applied Statistics 2013, September 22-25, 2013, Ribno (Bled), Slovenia. Lusa L, Stare J, eds. Abstracts and program. Ljubljana: Statistical Society of Slovenia, 2013: 55.
- Žagar T, Primic-Žakelj M, Zadnik V. Zemljevidi raka, narejeni z metodo lokalno ocenjenega standardiziranega količnika (Cancer maps created with local standardized incidence ratio method). In: Kraigher A, Skaza A, eds. Javno zdravje - priložnost za spreminjajočo se družbo (Public health - opportunity for changing society). Zbornik izvečkov. Ljubljana: Sekcija za preventivno medicino Slovenskega zdravniškega društva, 2013: 71.

2014

- Arnold M, Holterhues C, Hollestein LM, Coebergh JW, Nijsten T, Primic-Žakelj M, et al. Trends in incidence and predictions of cutaneous melanoma across Europe up to 2015. J Eur Acad Dermatol Venereol 2014; 28: 1170–8.
- Gutnik H, Matičič JP, Primic-Žakelj M, Strojman Fležar M. Microinvasive cervical squamous cell carcinoma in Slovenia during the period 2001–2007. Radiol Oncol 2014; 48: 282–8.
- Ivanuš U, Primic-Žakelj M. Učinkovitost triažnega testa HPV pri ženskah s presejalno diagnozo APC-N in rezultati triažnega testiranja na HPV v 2013. In: 5. izobraževalni dan programa ZORA, Brdo pri Kranju, 15. oktober 2014. Ivanuš U, Primic-Žakelj M eds. Zbornik predavanj. Ljubljana: Onkološki inštitut, 2014: 45–52.
- Ivanuš U, Primic-Žakelj M. Obravnava žensk z indikacijo za triažni test HPV. In: Smrkolj Š ed. Obnovitveni kolposkopski tečaj. Zbornik. Ljubljana: Združenje za ginekološko onkologijo, kolposkopijo in cervikalno patologijo SZD: Onkološki inštitut, 2014: 48–69.
- Jarm K, Ivanuš U, Krajc M, Primic-Žakelj M. Državna presejalna programa za raka materničnega vratu in dojke. In: Grmek-Košnik I, Hvalič Touzery S, Skela-Savič B eds. Kronične bolezni sodobne družbe: od zgodnjega odkrivanja do paliativne oskrbe: zbornik prispevkov z recenzijo. Jesenice: Fakulteta za zdravstvo, 2014: 99–106.
- Kadivec M, Krajc M, Hertl K, Jarm K, Primic-Žakelj M, Šval C. Državni presejalni program za raka dojke Dora - program zgodnjega odkrivanja raka dojke = Slovenian breast cancer screening programme Dora - programme for early breast cancer detection. In: Završnik J ed. Bolezni dojke: [simpozij, Maribor 2014]. Maribor: Zdravstveni dom dr. Adolfa Drolca, 2014: 221–8.
- Kloboves-Prevodnik V, Uhan Kastelic S, Pohar-Marinšek Ž, Žagar T, Ivanuš U. Atipične žlezne celice, neopredeljene: rezultati revizije citoloških preparatov in tveganje CIN2+. In: 5. izobraževalni dan programa ZORA, Brdo pri Kranju, 15. oktober 2014. Ivanuš U, Primic-Žakelj M eds. Zbornik predavanj. Ljubljana: Onkološki inštitut, 2014: 64–72.

- Krajc M, Zadnik V, Novaković S, Stegel V, Teugels E, Bešić N et al. Geographical distribution of Slovenian BRCA1/2 families according to family origin: implications for genetic screening. *Clinical genetics* 2014; 85: 59–63.
- Pogačnik A, Kloboves-Prevodnik V, Nolde N, Novaković S, Prosenc U, Grgić M, Ivanuš U, Primic-Žakelj M. Nove triažne metode pri HPV-pozitivnih ženskah. In: 5. izobraževalni dan programa ZORA, Brdo pri Kranju, 15. oktober 2014. Ivanuš U, Primic-Žakelj M eds. Zbornik predavanj. Ljubljana: Onkološki inštitut, 2014: 36–40.
- Primic-Žakelj M. Current situation and prospects of cancer in the Balkan area: what can we do together?. In: Book of abstracts = international scientific conference. Tirana: Academy of Sciences of Albania, 2014: 6–7.
- Primic-Žakelj M, Ivanuš U. Državni presejalni program za raka materničnega vratu Zora: zgodba o uspehu. In: Petrovec M, Golle A eds. Okužbe spolovil in spolno prenosljive bolezni: [zbornik predavanj], (Medicinski razgledi, ISSN 0353-3484, Supplement, letn. 53, 6). Ljubljana: Medicinski razgledi, 2014: 249–55.
- Primic-Žakelj M, Ivanuš U. Pregled dela in novosti v DP ZORA - 2013/2014. In: 5. izobraževalni dan programa ZORA, Brdo pri Kranju, 15. oktober 2014. Ivanuš U, Primic-Žakelj M eds. Zbornik predavanj. Ljubljana: Onkološki inštitut, 2014: 7–11.
- Primic-Žakelj M, Ivanuš U. Presejalni programi za raka materničnega vratu - trenutno stanje in prihodnost. In: Smrkolj Š ed. Obnovitveni kolposkopski tečaj. Zbornik. Ljubljana: Združenje za ginekološko onkologijo, kolposkopijo in cervikalno patologijo SZD: Onkološki inštitut, 2014: 27–36.
- Primic-Žakelj M, Jarm K, Žagar T. Epidemiološke značilnosti raka prebavil v Sloveniji v zadnjem desetletju. In: Ivanecz A, Krebs B, Potrč S, eds. Simpozij z mednarodno udeležbo na temo Smernice in problemi zdravljenja malignomov želodca, trebušne slinavke in debelega črevesa ter danke. Zbornik predavanj. Maribor: Oddelek za abdominalno in splošno kirurgijo, Kirurška klinika UKC, 2014: 1–4.
- Primic-Žakelj M, Žagar T, Jarm K. Zbolevnost za rakom dojke in preživetje = Breast cancer incidence and survival rate. In: Završnik J ed. Bolezni dojke [simpozij, Maribor 2014]. Maribor: Zdravstveni dom dr. Adolfa Drolca, 2014: 115–24.
- Primic-Žakelj M, Žagar T, Zadnik V. Epidemiološke značilnosti malignomov krvotornega in limfatičnega tkiva. In: Primic-Žakelj M ed. XXII. seminar In memoriam dr. Dušana Reje. Malignomi krvotornega in limfatičnega tkiva. Ljubljana: Zveza slovenskih društev za boj proti raku, 2014: 7–34.
- Primic-Žakelj M, Žagar T, Zadnik V, Škrlec F. Linkage of the Slovenian Cancer Registry data to other state databases and to screening registries. In: Towards a harmonised cancer information system in Europe. European Union and European Network of Cancer Registries (ENCR), 2014: 71.
- Strojani P, Zadnik V, Šifrer R, Lanišnik B, Didanovič V, Jereb S et al. Incidence trends in head and neck squamous cell carcinoma in Slovenia, 1983–2009: role of human papillomavirus infection. *European archives of oto-rhino-laryngology* 2014: 1–7.
- Šeruga B, Zadnik V, Grašič-Kuhar C, Marinko T, Čufer T, Zakotnik B et al. Association of aromatase inhibitors with coronary heart disease in women with early breast cancer. *Cancer investigation* 2014; 32: 99–104.
- Škulj P, Babuder B, Zadnik V. Slora - Slovenija in rak, interaktivni spletni portal = Slora - Slovenia and cancer, an interactive web portal. In: Štemberger Kolnik T, et al eds. Zdravstvena nega v javnem zdravju = Nursing in public health : druga znanstvena konferenca z mednarodno udeležbo, Izola, 31. januar 2014 = Second scientific conference with international participation. Zbornik prispevkov = Proceedings. Koper: Založba Univerze na Primorskem, 2014: 67–73.
- Zadnik V. Rak debelega črevesa in danke: epidemiološke značilnosti in nevarnostni dejavniki. In: Ocvirk J et al. eds. Sodobna obravnava raka debelega črevesa in danke. Ljubljana: Europacoln Slovenija, združenje za boj proti raku debelega črevesa in danke, 2014: 22–4.
- Zadnik V, Žagar T, Primic-Žakelj M. Nizkofrekvenčna polja in rak. In: Strokovni seminar Daljnovidni in zdravje, Ljubljana, 25. 9. 2014. Zbornik predavanj. Ljubljana: Inštitut za neionizirano sevanje, 2014: 19–21.
- Zanetti R, Sacchetto L, Calvia M, Bordoni A, Hakulinen T, Primic-Žakelj M et al. Economic evaluation of cancer registration in Europe. *J Registry Manag* 2014; 41(1): 31–7.
- Žagar T, Primic-Žakelj M, Zadnik V, Škrlec F, Jarm K. Completeness of the cancer registry of the Republic of Slovenia using qualitative methods. In: International Association of Cancer Registries (IACR), Ottawa, Canada, 26-28 June 2014. 36th annual conference 2014. Ottawa: The National Cancer Institute, 2014: 109.



POROČILO RR št. 54
REPORT No. 54
Ljubljana 2016
ISSN 1318-5845